(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 June 2004 (03.06.2004)

PCT

(10) International Publication Number
WO 2004/046340 A2

(51) International Patent Classification[7]: C12N

(21) International Application Number:
PCT/US2003/037047

(22) International Filing Date:
14 November 2003 (14.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/426,095 14 November 2002 (14.11.2002) US

(71) Applicant *(for all designated States except US)*: GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: KRUMMEN, Lynne [US/US]; 3030 22nd Avenue, San Francisco, CA 94132 (US). SHEN, Amy [US/US]; 1828 Parrott Drive, San Mateo, CA 94402 (US).

(74) Agents: STEFFES, David et al.; Sidley Austin Brown & Wood LLP, 1501 K Street, N.W., Washington, D.C. 20005 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/046340 A2

(54) Title: INTRON FUSION CONSTRUCT AND METHOD OF USING FOR SELECTING HIGH-EXPRESSING PRODUCTION CELL LINES

(57) Abstract: This invention relates to a DNA construct, methods of selecting for high-expressing host cells, a method of producing a protein of interest in high yields and a method of producing eukaryotic cells having multiple copies of a sequence encoding a protein of interest. In one method, stable clones capable of producing a high level of a product of interest are generated from one step of a direct selection immediately after transfection.

INTRON FUSION CONSTRUCT AND METHOD OF USING FOR SELECTING HIGH-EXPRESSING PRODUCTION CELL LINES

This application claims priority under 35 U.S.C. § 119(e) from U.S. provisional application serial no. 60/426,095, filed November 14, 2002, which is herein incorporated by reference.

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to a DNA construct, a method of selecting for high-expressing host cells, a method of producing a protein of interest in high yields and a method of producing eukaryotic cells having multiple copies of a sequence encoding a protein of interest.

Description of Background and Related Art

The discovery of methods for introducing DNA into living host cells in a functional form has provided the key to understanding many fundamental biological processes, and has made possible the production of important proteins and other molecules in commercially useful quantities.

Despite the general success of such gene transfer methods, several common problems exist that may limit the efficiency with which a gene encoding a desired protein can be introduced into and expressed in a host cell. One problem is knowing when the gene has been successfully transferred into recipient cells. A second problem is distinguishing between those cells that contain the gene and those that have survived the transfer procedures but do not contain the gene. A third problem is identifying and isolating those cells that contain the gene and that are expressing high levels of the protein encoded by the gene.

In general, the known methods for introducing genes into eukaryotic cells tend to be highly inefficient. Of the cells in a given culture, only a small proportion take up and express exogenously added DNA, and an even smaller proportion stably maintain that DNA.

Identification of those cells that have incorporated a product gene encoding a desired protein typically is achieved by introducing into the same cells another gene, commonly referred to

as a selectable gene, that encodes a selectable marker. A selectable marker is a protein that is necessary for the growth or survival of a host cell under the particular culture conditions chosen, such as an enzyme that confers resistance to an antibiotic or other drug, or an enzyme that compensates for a metabolic or catabolic defect in the host cell. For example, selectable genes commonly used with eukaryotic cells include the genes for aminoglycoside phosphotransferase (APH), hygromycin phosphotransferase (hyg), dihydrofolate reductase (DHFR), thymidine kinase (tk), neomycin resistance, puromycin resistance, glutamine synthetase, and asparagine synthetase.

The method of identifying a host cell that has incorporated one gene on the basis of expression by the host cell of a second incorporated gene encoding a selectable marker is referred to as cotransfectation (or cotransfection). In that method, a gene encoding a desired polypeptide and a selection gene typically are introduced into the host cell simultaneously. In this case of simultaneous cotransfectation, the gene encoding the desired polypeptide and the selectable gene may be present on a single DNA molecule or on separate DNA molecules prior to being introduced into the host cells. Wigler *et al.*, Cell, **16**:777 (1979). Cells that have incorporated the gene encoding the desired polypeptide then are identified or isolated by culturing the cells under conditions that preferentially allow for the growth or survival of those cells that synthesize the selectable marker encoded by the selectable gene.

The level of expression of a gene introduced into a eukaryotic host cell depends on multiple factors, including gene copy number, efficiency of transcription, messenger RNA (mRNA) processing, stability, and translation efficiency. Accordingly, high level expression of a desired polypeptide typically will involve optimizing one or more of those factors.

For example, the level of protein production may be increased by covalently joining the coding sequence of the gene to a "strong" promoter or enhancer that will give high levels of transcription. Promoters and enhancers are nucleotide sequences that interact specifically with proteins in a host cell that are involved in transcription. Kriegler, Meth. Enzymol., **185**:512 (1990); Maniatis *et al.*, Science, **236**:1237 (1987). Promoters are located upstream of the coding sequence of a gene and facilitate transcription of the gene by RNA polymerase. Among the eukaryotic promoters that have been identified as strong promoters for high-level expression are the SV40 early promoter, adenovirus major late promoter, mouse metallothionein-I promoter, Rous sarcoma virus long terminal repeat, and human cytomegalovirus immediate early promoter (CMV).

Enhancers stimulate transcription from a linked promoter. Unlike promoters, enhancers are active when placed downstream from the transcription initiation site or at considerable distances from the promoter, although in practice enhancers may overlap physically and functionally with promoters. For example, all of the strong promoters listed above also contain strong enhancers. Bendig, Genetic Engineering, 7:91 (Academic Press, 1988).

The level of protein production also may be increased by increasing the gene copy number in the host cell. One method for obtaining high gene copy number is to directly introduce into the host cell multiple copies of the gene, for example, by using a large molar excess of the product gene relative to the selectable gene during cotransfectation. Kaufman, Meth. Enzymol., **185**:537 (1990). With this method, however, only a small proportion of the cotransfected cells will contain the product gene at high copy number. Furthermore, because no generally applicable, convenient method exists for distinguishing such cells from the majority of cells that contain fewer copies of the product gene, laborious and time-consuming screening methods typically are required to identify the desired high-copy number transfectants.

Another method for obtaining high gene copy number involves cloning the gene in a vector that is capable of replicating autonomously in the host cell. Examples of such vectors include mammalian expression vectors derived from Epstein-Barr virus or bovine papilloma virus, and yeast 2-micron plasmid vectors. Stephens & Hentschel, Biochem. J., **248**:1 (1987); Yates *et al.*, Nature, **313**:812 (1985); Beggs, Genetic Engineering, 2:175 (Academic Press, 1981).

Yet another method for obtaining high gene copy number involves gene amplification in the host cell. Gene amplification occurs naturally in eukaryotic cells at a relatively low frequency. Schimke, J. Biol. Chem., **263**:5989 (1988). However, gene amplification also may be induced, or at least selected for, by exposing host cells to appropriate selective pressure. For example, in many cases it is possible to introduce a product gene together with an amplifiable gene into a host cell and subsequently select for amplification of the marker gene by exposing the cotransfected cells to sequentially increasing concentrations of a selective agent. Typically the product gene will be coamplified with the marker gene under such conditions.

The most widely used amplifiable gene for that purpose is a DHFR gene, which encodes a dihydrofolate reductase enzyme. The selection conditions used in conjunction with a DHFR gene are the absence of glycine, hypoxanthine and thymidine (GHT) with or without the presence of methotrexate (Mtx). A host cell is cotransfected with a product gene encoding a desired protein

and a DHFR gene, and transfectants are identified by first culturing the cells in GHT –free culture medium that may contains Mtx. A suitable host cell when a wild-type DHFR gene is used is the Chinese Hamster Ovary (CHO) cell line deficient in DHFR activity, prepared and propagated as described by Urlaub & Chasin, Proc. Nat. Acad. Sci. USA, 77:4216 (1980). The transfected cells then are exposed to successively higher amounts of Mtx. This leads to the synthesis of multiple copies of the DHFR gene, and concomitantly, multiple copies of the product gene. Schimke, J. Biol. Chem., 263:5989 (1988); Axel *et al.*, U.S. Patent No. 4,399,216; Axel *et al.*, U.S. Patent No. 4,634,665. Other references directed to co-transfection of a gene together with a genetic marker that allows for selection and subsequent amplification include Kaufman in Genetic Engineering, ed. J. Setlow (Plenum Press, New York), Vol. 9 (1987); Kaufman and Sharp, J. Mol. Biol., 159:601 (1982); Ringold *et al.*, J. Mol. Appl. Genet., 1:165-175 (1981); Kaufman *et al.*, Mol. Cell Biol., 5:1750-1759 (1985); Kaetzel and Nilson, J. Biol. Chem., 263:6244-6251 (1988); Hung *et al.*, Proc. Natl. Acad. Sci. USA, 83:261-264 (1986); Kaufman *et al.*, EMBO J., 6:87-93 (1987); Johnston and Kucey, Science, 242:1551-1554 (1988); Urlaub *et al.*, Cell, 33:405-412 (1983).

To extend the DHFR amplification method to other cell types, a mutant DHFR gene that encodes a protein with reduced sensitivity to methotrexate may be used in conjunction with host cells that contain normal numbers of an endogenous wild-type DHFR gene. Simonsen and Levinson, Proc. Natl. Acad. Sci. USA, 80:2495 (1983); Wigler *et al.*, Proc. Natl. Acad. Sci. USA, 77:3567-3570 (1980); Haber and Schimke, Somatic Cell Genetics, 8:499-508 (1982).

Alternatively, host cells may be co-transfected with the product gene, a DHFR gene, and a dominant selectable gene, such as a neo^r gene. Kim and Wold, Cell, 42:129 (1985); Capon *et al.*, U.S. Pat. No. 4,965,199. Transfectants are identified by first culturing the cells in culture medium containing neomycin (or the related drug G418), and the transfectants so identified then are selected for amplification of the DHFR gene and the product gene by exposure to successively increasing amounts of Mtx.

As will be appreciated from this discussion, the selection of recombinant host cells that express high levels of a desired protein generally is a multi-step process. In the first step, initial transfectants are selected that have incorporated the product gene and the selectable gene. In subsequent steps, the initial transfectants are subject to further selection for high-level expression of the selectable gene and then random screening for high-level expression of the product gene. To identify cells expressing high levels of the desired protein, typically one must screen large numbers

of transfectants. The majority of transfectants produce less than maximal levels of the desired protein. Further, Mtx resistance in DHFR transformants is at least partially conferred by varying degrees of gene amplification. Schimke, Cell, 37:705-713 (1984). The inadequacies of co-expression of the non-selected gene have been reported by Wold *et al.*, Proc. Natl. Acad. Sci. USA, 76:5684-5688 (1979). Instability of the amplified DNA is reported by Kaufman and Schimke, Mol. Cell Biol., 1:1069-1076 (1981); Haber and Schimke, Cell, 26:355-362 (1981); and Fedespiel *et al.*, J. Biol. Chem., 259:9127-9140 (1984).

Several methods have been described for directly selecting such recombinant host cells in a single step. One strategy involves co-transfecting host cells with a product gene and a DHFR gene, and selecting those cells that express high levels of DHFR by directly culturing in medium containing a high concentration of Mtx. Many of the cells selected in that manner also express the co-transfected product gene at high levels Page and Sydenham, Bio/Technology, 9:64 (1991). This method for single-step selection suffers from certain drawbacks that limit its usefulness. High-expressing cells obtained by direct culturing in medium containing a high level of a selection agent may have poor growth and stability characteristics, thus limiting their usefulness for long-term production processes Page and Snyderman, Bio/Technology, 9:64 (1991). Single-step selection for high-level resistance to Mtx may produce cells with an altered, Mtx-resistant DHFR enzyme, or cells that have altered Mtx transport properties, rather than cells containing amplified genes. Haber *et al.*, J. Biol. Chem., 256:9501 (1981); Assaraf and Schimke, Proc. Natl. Acad. Sci. USA, 84:7154 (1987).

Another method involves the use of polycistronic mRNA expression vectors containing a product gene at the 5' end of the transcribed region and a selectable gene at the 3' end. Because translation of the selectable gene at the 3' end of the polycistronic mRNA is inefficient, such vectors exhibit preferential translation of the product gene and require high levels of polycistronic mRNA to survive selection. Kaufman, Meth. Enzymol., 185:487 (1990); Kaufman, Meth. Enzymol., 185:537 (1990); Kaufman *et al.*, EMBO J., 6:187 (1987). Accordingly, cells expressing high levels of the desired protein product may be obtained in a single step by culturing the initial transfectants in medium containing a selection agent appropriate for use with the particular selectable gene. However, the utility of these vectors is variable because of the unpredictable influence of the upstream product reading frame on selectable marker translation and because the upstream reading frame sometimes becomes deleted during methotrexate amplification (Kaufman

et al., J. Mol. Biol., **159**:601-621 (1982); Levinson, Methods in Enzymology, San Diego: Academic Press, Inc. (1990)). Later vectors incorporated an internal translation initiation site derived from members of the picornavirus family which is positioned between the product gene and the selectable gene (Pelletier *et al.*, Nature, **334**:320 (1988); Jang *et al.*, J. Virol., **63**:1651 (1989)).

A third method for single-step selection involves use of a DNA construct with a selectable gene containing an intron within which is located a gene encoding the protein of interest. See U.S. Patent No. 5,043,270 and Abrams *et al.*, J. Biol. Chem., **264(24)**: 14016-14021 (1989). In yet another single-step selection method, host cells are co-transfected with an intron-modified selectable gene and a gene encoding the protein of interest. See WO 92/17566, published October 15, 1992. The intron-modified gene is prepared by inserting into the transcribed region of a selectable gene an intron of such length that the intron is correctly spliced from the corresponding mRNA precursor at low efficiency, so that the amount of selectable marker produced from the intron-modified selectable gene is substantially less than that produced from the starting selectable gene. These vectors help to insure the integrity of the integrated DNA construct, but transcriptional linkage is not achieved as selectable gene and the protein gene are driven by separate promoters.

Other mammalian expression vectors that have single transcription units have been described. Retroviral vectors have been constructed (Cepko *et al.*, Cell, **37**:1053-1062 (1984)) in which a cDNA is inserted between the endogenous Moloney murine leukemia virus (M-MuLV) splice donor and splice acceptor sites which are followed by a neomycin resistance gene. This vector has been used to express a variety of gene products following retroviral infection of several cell types.

A method for selecting recombinant host cells expressing high levels of a desired protein was previously described by the applicants in Lucas *et al.*, Nucleic Acid Research, 24, No. 9: 1774-1779 and U.S. Patent No. 5,561,053. That method utilizes eukaryotic host cells harboring a DNA construct comprising a selectable gene (preferably an amplifiable gene) and a product gene provided 3' to the selectable gene. The selectable gene is positioned within an intron defined by a splice donor site and a splice acceptor site and the selectable gene and product gene are under the transcriptional control of a single transcriptional regulatory region. The splice donor site is generally an efficient splice donor site and thereby regulates expression of the product gene using the transcriptional regulatory region. The transfected cells are cultured so as to express the gene encoding the product in a selective medium which may contain an amplifying agent for sufficient

time to allow cells having multiple copies of the product gene, or cells with a single (or multiple) copy of the gene in a chromosomal loci with high transcriptional activity to be identified.

Other fusion expression constructs have been developed. For example, a fusion of green flourescent protein with the Zeocin-resistance marker construct has been created. Bennet, R.P. *et al.*, Biotechniques. 24(3):478-82, 1998 March. Such constructs were used to allow visual screening and drug selection of transfected eukaryotic cells.

In another example, human prothrombin was overexpressed in transformed eukaryotic cells using a dominant bifunctional selection and amplification marker. Herlitschka, Sabine E. *et al.*, Protein Expression and Purification. 8, 358-364, 1996 July. In this reference the marker consisted of the murine wild-type dihydrofolate reductase cDNA and the *E. coli* hygromycin phosphotransferase gene fused in frame. The gene of interest is connected, upstream, by the EMCV untranslated region to the fusion marker gene, forming a dicistronic transcription unit.

With the state of the art in mind, it is one object of the present invention to increase the level of homogeneity with regard to expression levels of stable clones transfected with a product gene of interest, by expressing fused selectable markers (i.e. DHFR and puromycin) and a protein of interest from a single promoter.

It is another object to provide a method for selecting stable, recombinant host cells that express high levels of a desired protein product, which method is rapid and convenient to perform, and reduces the numbers of transfected cells which need to be screened. Furthermore, it is an object to allow high levels of single and multiple unit polypeptides to be rapidly generated from clones or pools of stable host cell transfectants.

It is an additional object to provide expression vectors which bias for active integration events (*i.e.* have an increased tendency to generate transformants wherein the DNA construct is inserted into a region of the genome of the host cell which results in high level expression of the product gene) and can accommodate a variety of product genes without the need for modification.

SUMMARY OF THE INVENTION

Accordingly, the present invention is directed to a DNA construct (DNA molecule) comprising a 5' transcriptional initiation site and a 3' transcriptional termination site, two selectable genes that have been fused into one open reading frame (preferably amplifiable genes) and a product gene provided 3' to the fused selectable genes, a transcriptional regulatory region

regulating transcription of both the fused selectable genes and the product gene, the fused selectable genes positioned within an intron defined by a splice donor site and a splice acceptor site. The splice donor site preferably comprises an effective splice donor sequence as herein defined and thereby regulates expression of the product gene using the transcriptional regulatory region.

In another embodiment, the invention provides a method for producing a product of interest comprising culturing a eukaryotic cell which has been transfected with the DNA construct described above, so as to express the product gene and recovering the product.

In a further embodiment, the invention provides a method for producing eukaryotic cells having multiple copies of the product gene comprising transfecting eukaryotic cells with the DNA construct described above (where the selectable fused genes are amplifiable genes), growing the cells in a selective medium comprising an amplifying agent(s) for a sufficient time for amplification to occur, and selecting cells having multiple copies of the product gene. After transfection of the host cells, most of the transfectants fail to exhibit the selectable phenotype characteristic of the protein encoded by either of the selectable genes, but surprisingly a small proportion of the transfectants do exhibit one or both of the selectable phenotype, and among those transfectants, the majority are found to express high levels of the desired product encoded by the product gene. Thus, the invention provides an improved method for the selection of recombinant host cells expressing high levels of a desired product, which method is useful with a wide variety of eukaryotic host cells and avoids the problems inherent in, and improves upon, existing cell selection technology.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates schematically the construction of the pSV.IPD. The gene for the protein of interest would be inserted at the polylinker site.

Figures 2-1 to 2-4 depict the nucleotide sequence of the pSV.IPUR plasmid used in constructing pSV.IPD (SEQ ID NO 1).

Figures 3-1 to 3-4 depict the nucleotide sequence of the pSV.ID plasmid used in constructing pSV.IPD (SEQ ID NO 2).

Figures 4-1 to 4-4 depict the nucleotide sequence of the pSV.IPD (SEQ ID NO 3).

Figure 5 illustrates schematically the plasmid, pSV.ID.VEGF, used as a control in Example 1.

Figure 6 illustrates schematically the plasmid, pSV.IPD.2C4, used in Example 1 (SEQ ID NO 4).

Figures 7-1 to 7-8 depict the nucleotide sequence of the pSV.IPD.2C4 plasmid used in Example 1.

Figure 8 depicts a FACS analysis of transiently transfected CHO cells with a GTP plasmid in 250ml spinner transfection. FACS analysis was performed 24 hours after transfection.

Figure 9 depicts the expression level of clones from traditional 10nM MTX selection. Cells were transfected with commercial transfection reagent and directly selected in 10 nM MTX. Individual clones were grown in a 96-well plate. Product accumulated for 6 days prior to ELISA.

Figures 10-1 and 10-2 depict the expression level of clones from 25 and 50 nM MTX direct selections, respectively, of SV40-based constructs derived from spinner transfection. The assay was performed the same as in Figure 9.

Figure 11 depicts the expression level of clones from 25 nM MTX direct selection of CMV-based construct derived from spinner transfection. The assay was performed the same as in Figure 9.

Figure 12 depicts the titer evaluation in Miniferm. Samples were collected every day and submitted to an HPLC protein A assay for titer.

Figure 13-1 to 13-7 depict the nucleotide sequence of the pCMV.IPD.Heterologous polypeptide (HP) plasmid used in Example 3.

Figure 14-1 to 14-8 depicts the nucleotide sequence of the pSV40.IPD.HP plasmid used in Example 3.

Figure 15 illustrates schematically the plasmid, pCMV.IPD.HP, used in Example 3.

Figure 16 illustrates a time line and titer comparison between a traditional selection and direct selection method described in Example 3. Equivalent titers are indicated horizontally across the illustration. For example, the titers for a 200/300nM SV40-plasmid traditional selection, 100nM SV40-plasmid direct selection and 25nm CMV-plasmid direct selection are roughly equivalent.

DESCRIPTION OF THE PREFERRED EMBODIMENT

Definitions:

The "DNA construct" disclosed herein comprises a non-naturally occurring DNA molecule or chemical analog which can either be provided as an isolate or integrated in another DNA molecule *e.g.* in an expression vector or the chromosome of an eukaryotic host cell.

The term "selectable gene" as used herein refers to a DNA that encodes a selectable marker necessary for the growth or survival of a host cell under the particular cell culture conditions chosen. Accordingly, a host cell that is transformed with a selectable gene will be capable of growth or survival under certain cell culture conditions wherein a non-transfected host cell is not capable of growth or survival. Typically, a selectable gene will confer resistance to a drug or compensate for a metabolic or catabolic defect in the host cell. Examples of selectable genes are provided in the following table. See also Kaufman, Methods in Enzymology, **185**: 537-566 (1990), for a review of these.

"Fused selectable genes" as used herein refers to a DNA that encodes at least two selectable markers in the same open reading frame and inserted into an intron sequence.

TABLE 1

Examples of Selectable Genes and their Selection Agents

Selection Agent	Selectable Gene
Puromycin	Puromycin-N-acetyltransferase
Methotrexate	Dihydrofolate reductase
Cadmium	Metallothionein
PALA	CAD
Xyl-A-or adenosine and 2'-deoxycoformycin	Adenosine deaminase
Adenine, azaserine, and coformycin	Adenylate deaminase
6-Azauridine, pyrazofuran	UMP Synthetase
Mycophenolic acid	IMP 5'-dehydrogenase
Mycophenolic acid with limiting xanthine	Xanthine-guanine phosphoribosyltransferase
Hypoxanthine, aminopterin, and thymidine (HAT)	Mutant HGPRTase or mutant thymidine kinase
5-Fluorodeoxyuridine	Thymidylate synthetase
Multiple drugs *e.g.* adriamycin, vincristine or colchicine	P-glycoprotein 170
Aphidicolin	Ribonucleotide reductase
Methionine sulfoximine	Glutamine synthetase

β-Aspartyl hydroxamate or Albizziin	Asparagine synthetase
Canavanine	Arginosuccinate synthetase
α-Difluoromethylornithine	Ornithine decarboxylase
Compactin	HMG-CoA reductase
Tunicamycin	*N*-Acetylglucosaminyl transferase
Borrelidin	Threonyl-tRNA synthetase
Ouabain	Na^+K^+-ATPase

The preferred selectable genes are amplifiable genes. As used herein, the term "amplifiable gene" refers to a gene which is amplified (*i.e.* additional copies of the gene are generated which survive in intrachromosomal or extrachromosomal form) under certain conditions. The amplifiable gene(s) usually encodes an enzyme (*i.e.* an amplifiable marker) which is required for growth of eukaryotic cells under those conditions. For example, the gene may encode DHFR which is amplified when a host cell transformed therewith is grown in Mtx. According to Kaufman, the selectable genes in Table 1 above can also be considered amplifiable genes. An example of a selectable gene which is generally not considered to be an amplifiable gene is the neomycin resistance gene (Cepko *et al.*, *supra*).

As used herein, "selective medium" refers to nutrient solution used for growing eukaryotic cells which have the selectable gene(s) and therefore is deficient in components supplied by the selectable gene or includes a "selection agent". Commercially available media based on formulations such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are exemplary nutrient solutions. In addition, any of the media described in Ham and Wallace, Meth. Enz., **58**:44 (1979), Barnes and Sato, Anal. Biochem., **102**:255 (1980), U.S. Patent Nos. 4,767,704; 4,657,866; 4,927,762; or 4,560,655; WO 90/03430; WO 87/00195; U.S. Patent Re. 30,985; or U.S. Patent No. 5,122,469, the disclosures of all of which are incorporated herein by reference, may be used as culture media. Any of these media may be supplemented as necessary with hormones and/or other

growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as Gentamycin™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The preferred nutrient solution comprises fetal bovine serum.

The term "selection agent" refers to a substance that interferes with the growth or survival of a host cell possibly because the cell is deficient in a particular selectable gene. Examples of selection agents are presented in Table 1 above. The selection agent preferably comprises an "amplifying agent" which is defined for purposes herein as an agent for amplifying copies of the amplifiable gene or causing integration of multiple copies of the amplifiable gene into the genome, such as Mtx if the amplifiable gene is DHFR. See Table 1 for examples of amplifying agents.

As used herein, the terms "direct selection" or "direct culturing" means the first exposure to selective conditions either without MTX or GHT or with MTX, and production of a heterologous polypeptide in an amount of about 250mg/l, 400mg/l, 600mg/l or 800mg/l up to about 1g/l or more.

As used herein, the term "transcriptional initiation site" refers to the nucleic acid in the DNA construct corresponding to the first nucleic acid incorporated into the primary transcript, *i.e.*, the mRNA precursor, which site is generally provided at, or adjacent to, the 5' end of the DNA construct.

The term "transcriptional termination site" refers to a sequence of DNA, normally represented at the 3' end of the DNA construct, that causes RNA polymerase to terminate transcription.

As used herein, "transcriptional regulatory region" refers to a region of the DNA construct that regulates transcription of the selectable gene and the product gene. The transcriptional regulatory region normally refers to a promoter sequence (*i.e.* a region of DNA involved in binding of RNA polymerase to initiate transcription) which can be constitutive or inducible and, optionally, an enhancer (*i.e.* a *cis*-acting DNA element, usually from about 10-300 bp, that acts on a promoter to increase its transcription).

As used herein, "product gene" refers to DNA that encodes a desired protein or polypeptide product. Any product gene that is capable of expression in a host cell may be used, although the methods of the invention are particularly suited for obtaining high-level expression of a product gene that is not also a selectable or amplifiable gene. Accordingly, the protein or polypeptide encoded by a product gene typically will be one that is not necessary for the growth or survival of a host cell under the particular cell culture conditions chosen. For example, product genes suitably encode a peptide, or may encode a polypeptide sequence of amino acids for which the chain length is sufficient to produce higher levels of tertiary and/or quaternary structure.

Examples of bacterial polypeptides or proteins include, *e.g.*, alkaline phosphatase and β-lactamase. Examples of mammalian polypeptides or proteins include molecules such as renin; a growth hormone, including human growth hormone, and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha-1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIC, factor IX, tissue factor, and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1-alpha); a serum albumin such as human serum albumin; mullerian-inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-associated peptide; a microbial protein, such as beta-lactamase; DNase; inhibin; activin; vascular endothelial growth factor (VEGF); receptors for hormones or growth factors; integrin; protein A or D; rheumatoid factors; a neurotrophic factor such as bone-derived neurotrophic factor (BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6), or a nerve growth factor such as NGF-β; platelet-derived growth factor (PDGF); fibroblast growth factor such as aFGF and bFGF; epidermal growth factor (EGF); transforming growth factor (TGF) such as TGF-alpha and TGF-beta, including TGF-β1, TGF-β2, TGF-β3, TGF-β4, or TGF-β5; insulin-like growth factor-I and -II (IGF-I and IGF-II); des(1-3)-IGF-I (brain IGF-I), insulin-like growth factor binding proteins; CD proteins such as CD-3, CD-4, CD-8, and CD-19; erythropoietin; osteoinductive factors; immunotoxins; a bone morphogenetic protein (BMP); an interferon such as interferon-alpha, -beta, and -gamma; colony stimulating factors (CSFs), *e.g.*, M-CSF, GM-CSF,

and G-CSF; interleukins (ILs), *e.g.*, IL-1 to IL-10; superoxide dismutase; T-cell receptors; surface membrane proteins; decay accelerating factor; viral antigen such as, for example, a portion of the AIDS envelope; transport proteins; homing receptors; addressins; regulatory proteins; antibodies; chimeric proteins such as immunoadhesins and fragments of any of the above-listed polypeptides.

The product gene preferably does not consist of an anti-sense sequence for inhibiting the expression of a gene present in the host. Preferred proteins herein are therapeutic proteins such as TGF-β, TGF-α, PDGF, EGF, FGF, IGF-I, DNase, plasminogen activators such as t-PA, clotting factors such as tissue factor and factor VIII, hormones such as relaxin and insulin, cytokines such as IFN-γ, chimeric proteins such as TNF receptor IgG immunoadhesin (TNFr-IgG) or antibodies such as anti-IgE. An example of an antibody that can be produced with the pSV.IDP plasmid (Figure 4) is anti-HER2 Neu antibody, 2C4, as provided in Example 1, *supra*.

The term "intron" as used herein refers to a nucleotide sequence present within the transcribed region of a gene or within a messenger RNA precursor, which nucleotide sequence is capable of being excised, or spliced, from the messenger RNA precursor by a host cell prior to translation. Introns suitable for use in the present invention are suitably prepared by any of several methods that are well known in the art, such as purification from a naturally occurring nucleic acid or *de novo* synthesis. The introns present in many naturally occurring eukaryotic genes have been identified and characterized. Mount, Nuc. Acids Res., **10**:459 (1982). Artificial introns comprising functional splice sites also have been described. Winey *et al.*, Mol. Cell Biol., **9**:329 (1989); Gatermann *et al.*, Mol. Cell Biol., **9**:1526 (1989). Introns may be obtained from naturally occurring nucleic acids, for example, by digestion of a naturally occurring nucleic acid with a suitable restriction endonuclease, or by PCR cloning using primers complementary to sequences at the 5' and 3' ends of the intron. Alternatively, introns of defined sequence and length may be prepared synthetically using various methods in organic chemistry. Narang *et al.*, Meth. Enzymol., **68**:90 (1979); Caruthers *et al.*, Meth. Enzymol., **154**:287 (1985); Froehler *et al.*, Nuc. Acids Res., **14**:5399 (1986).

As used herein "splice donor site" or "SD" refers to the DNA sequence immediately surrounding the exon-intron boundary at the 5' end of the intron, where the "exon" comprises the nucleic acid 5' to the intron. Many splice donor sites have been characterized and Ohshima *et al.*, J. Mol. Biol., **195**:247-259 (1987) provides a review of these. An "efficient splice donor sequence" refers to a nucleic acid sequence encoding a splice donor site wherein the efficiency of splicing of

messenger RNA precursors having the splice donor sequence is between about 80 to 99% and preferably 90 to 95% as determined by quantitative PCR. Examples of efficient splice donor sequences include the wild type (WT) ras splice donor sequence and the GAC:GTAAGT sequence of Example 3. Other efficient splice donor sequences can be readily selected using the techniques for measuring the efficiency of splicing disclosed herein.

The terms "PCR" and "polymerase chain reaction" as used herein refer to the *in vitro* amplification method described in US Patent No. 4,683,195 (issued July 28, 1987). In general, the PCR method involves repeated cycles of primer extension synthesis, using two DNA primers capable of hybridizing preferentially to a template nucleic acid comprising the nucleotide sequence to be amplified. The PCR method can be used to clone specific DNA sequences from total genomic DNA, cDNA transcribed from cellular RNA, viral or plasmid DNAs. Wang & Mark, in PCR Protocols, pp.70-75 (Academic Press, 1990); Scharf, in PCR Protocols, pp. 84-98; Kawasaki & Wang, in PCR Technology, pp. 89-97 (Stockton Press, 1989). Reverse transcription-polymerase chain reaction (RT-PCR) can be used to analyze RNA samples containing mixtures of spliced and unspliced mRNA transcripts. Fluorescently tagged primers designed to span the intron are used to amplify both spliced and unspliced targets. The resultant amplification products are then separated by gel electrophoresis and quantitated by measuring the fluorescent emission of the appropriate band(s). A comparison is made to determine the amount of spliced and unspliced transcripts present in the RNA sample.

One preferred splice donor sequence is a "consensus splice donor sequence". The nucleotide sequences surrounding intron splice sites, which sequences are evolutionarily highly conserved, are referred to as "consensus splice donor sequences". In the mRNAs of higher eukaryotes, the 5' splice site occurs within the consensus sequence AG:GUAAGU (wherein the colon denotes the site of cleavage and ligation). In the mRNAs of yeast, the 5' splice site is bounded by the consensus sequence :GUAUGU. Padgett, *et al.*, Ann. Rev. Biochem., 55:1119 (1986).

The expression "splice acceptor site" or "SA" refers to the sequence immediately surrounding the intron-exon boundary at the 3' end of the intron, where the "exon" comprises the nucleic acid 3' to the intron. Many splice acceptor sites have been characterized and Ohshima *et al.*, J. Mol. Biol., **195**:247-259 (1987) provides a review of these. The preferred splice acceptor site is an efficient splice acceptor site which refers to a nucleic acid sequence encoding a splice

acceptor site wherein the efficiency of splicing of messenger RNA precursors having the splice acceptor site is between about 80 to 99% and preferably 90 to 95% as determined by quantitative PCR. The splice acceptor site may comprise a consensus sequence. In the mRNAs of higher eukaryotes, the 3' splice acceptor site occurs within the consensus sequence $(U/C)_{11}NCAG:G$. In the mRNAs of yeast, the 3' acceptor splice site is bounded by the consensus sequence (C/U)AG:. Padgett, *et al., supra.*

As used herein "culturing for sufficient time to allow amplification to occur" refers to the act of physically culturing the eukaryotic host cells which have been transformed with the DNA construct in cell culture media containing the amplifying agent, until the copy number of the amplifiable gene (and preferably also the copy number of the product gene) in the host cells has increased relative to the transformed cells prior to this culturing.

The term "expression" as used herein refers to transcription or translation occurring within a host cell. The level of expression of a product gene in a host cell may be determined on the basis of either the amount of corresponding mRNA that is present in the cell or the amount of the protein encoded by the product gene that is produced by the cell. For example, mRNA transcribed from a product gene is desirably quantitated by northern hybridization or quantitative real-time PCR. Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, pp. 7.3-7.57 (Cold Spring Harbor Laboratory Press, 1989). Protein encoded by a product gene can be quantitated either by assaying for the biological activity of the protein or by employing assays that are independent of such activity, such as western blotting or radioimmunoassay using antibodies that are capable of reacting with the protein. Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, pp. 18.1-18.88 (Cold Spring Harbor Laboratory Press, 1989).

Modes for Carrying Out the Invention

Methods and compositions are provided for enhancing the stability and/or copy number of a transcribed sequence in order to allow for elevated levels of a RNA sequence of interest. In general, the methods of the present invention involve transfecting a eukaryotic host cell with an expression vector comprising both a product gene encoding a desired polypeptide and fused selectable genes.

Selectable genes and product genes may be obtained from genomic DNA, cDNA transcribed from cellular RNA, or by *in vitro* synthesis. For example, libraries are screened with

probes (such as antibodies or oligonucleotides of about 20-80 bases) designed to identify the selectable gene or the product gene (or the protein(s) encoded thereby). Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures as described in chapters 10-12 of Sambrook *et al.*, Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the selectable gene or product gene is to use PCR methodology as described in section 14 of Sambrook *et al.*, *supra*.

A preferred method of practicing this invention is to use carefully selected oligonucleotide sequences to screen cDNA libraries from various tissues known to contain the selectable gene or product gene. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized.

The oligonucleotide generally is labeled such that it can be detected upon hybridization to DNA in the library being screened. The preferred method of labeling is to use ^{32}P- labeled ATP with polynucleotide kinase, as is well known in the art, to radiolabel the oligonucleotide. However, other methods may be used to label the oligonucleotide, including, but not limited to, biotinylation or enzyme labeling.

Sometimes, the DNA encoding the fused selectable genes and product gene is preceded by DNA encoding a signal sequence having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the expression vector, or it may be a part of the selectable gene or product gene that is inserted into the expression vector. If a heterologous signal sequence is used, it preferably is one that is recognized and processed (*i.e.*, cleaved by a signal peptidase) by the host cell. For yeast secretion the native signal sequence may be substituted by, *e.g.*, the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces* α-factor leaders, the latter described in U.S. Pat. No. 5,010,182 issued 23 April 1991), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression the native signal sequence of the protein of interest is satisfactory, although other mammalian signal sequences may be suitable, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders, for example, the herpes simplex gD signal. The DNA for such precursor region is ligated in reading frame to the fused selectable genes or product gene.

As shown in Figure 1, the fused selectable genes are generally provided at the 5' end of the DNA construct and are followed by the product gene (which would be inserted into the linker site). Therefore, the full-length (non-spiced) message will contain, for example, the PURO-DHFR fusion as the first open reading frame and will therefore generate PURO-DHFR protein to allow selection of stable transfectants. The full length message is not expected to generate appreciable amounts of the protein of interest as the second AUG in a dicistronic message is an inefficient initiator of translation in mammalian cells (Kozak, J. Cell Biol., **115**: 887-903 (1991)).

The fused selectable genes are positioned within an intron. Introns are noncoding nucleotide sequences, normally present within many eukaryotic genes, which are removed from newly transcribed mRNA precursors in a multiple-step process collectively referred to as splicing.

A single mechanism is thought to be responsible for the splicing of mRNA precursors in mammalian, plant, and yeast cells. In general, the process of splicing requires that the 5' and 3' ends of the intron be correctly cleaved and the resulting ends of the mRNA be accurately joined, such that a mature mRNA having the proper reading frame for protein synthesis is produced. Analysis of a variety of naturally occurring and synthetically constructed mutant genes has shown that nucleotide changes at many of the positions within the consensus sequences at the 5' and 3' splice sites have the effect of reducing or abolishing the synthesis of mature mRNA. Sharp, Science, 235:766 (1987); Padgett, *et al.*, Ann. Rev. Biochem., 55:1119 (1986); Green, Ann. Rev. Genet., 20:671 (1986). Mutational studies also have shown that RNA secondary structures involving splicing sites can affect the efficiency of splicing. Solnick, Cell, 43:667 (1985); Konarska, *et al.*, Cell, 42:165 (1985).

The length of the intron may also affect the efficiency of splicing. By making deletion mutations of different sizes within the large intron of the rabbit beta-globin gene, Wieringa, *et al.* determined that the minimum intron length necessary for correct splicing is about 69 nucleotides. Cell, 37:915 (1984). Similar studies of the intron of the adenovirus E1A region have shown that an intron length of about 78 nucleotides allows correct splicing to occur, but at reduced efficiency. Increasing the length of the intron to 91 nucleotides restores normal splicing efficiency, whereas truncating the intron to 63 nucleotides abolishes correct splicing. Ulfendahl, *et al.*, Nuc. Acids Res., 13:6299 (1985).

To be useful in the invention, the intron must have a length such that splicing of the intron from the mRNA is efficient. The preparation of introns of differing lengths is a routine matter,

involving methods well known in the art, such as *de novo* synthesis or *in vitro* deletion mutagenesis of an existing intron. Typically, the intron will have a length of at least about 150 nucleotides, since introns which are shorter than this tend to be spliced less efficiently. The upper limit for the length of the intron can be up to 30 kB or more. However, as a general proposition, the intron is generally less than about 10 kB in length.

The intron is modified to contain the fused selectable genes not normally present within the intron using any of the various known methods for modifying a nucleic acid *in vitro*. Typically, the fused selectable genes will be introduced into an intron by first cleaving the intron with a restriction endonuclease, and then covalently joining the resulting restriction fragments to the fused selectable genes in the correct orientation for host cell expression, for example by ligation with a DNA ligase enzyme.

The DNA construct is dicistronic, *i.e.* the fused selectable genes and product gene are both under the transcriptional control of a single transcriptional regulatory region. As mentioned above, the transcriptional regulatory region comprises a promoter. Suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman *et al.*, J. Biol. Chem., 255:2073 (1980)) or other glycolytic enzymes (Hess *et al.*, J. Adv. Enzyme Reg., 7:149 (1968); and Holland, Biochemistry, 17:4900 (1978)), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in Hitzeman *et al.*, EP 73,657A. Yeast enhancers also are advantageously used with yeast promoters.

Expression control sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CXCAAT region where X may be any nucleotide.

Product gene transcription from vectors in mammalian host cells is controlled by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40) or cytomegalovirus (CMV), from heterologous mammalian promoters, e.g. the actin promoter or an immunoglobulin promoter, from heat-shock promoters, and from the promoter normally associated with the product gene, provided such promoters are compatible with the host cell systems. Promoters endogenous to the host cell system, such as the CHO Elongation Factor 1 alpha promoter may also be used.

The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication. Fiers *et al.*, Nature, **273**:113 (1978); Mulligan and Berg, Science, **209**:1422-1427 (1980); Pavlakis *et al.*, Proc. Natl. Acad. Sci. USA, **78**:7398-7402 (1981). The immediate early promoter of the human cytomegalovirus (CMV) is conveniently obtained as a *Hin*dIII E restriction fragment. Greenaway *et al.*, Gene, **18**:355-360 (1982). A system for expressing DNA in mammalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. 4,419,446. A modification of this system is described in U.S. 4,601,978. See also Gray *et al.*, Nature, **295**:503-508 (1982) on expressing cDNA encoding immune interferon in monkey cells; , Reyes *et al.*, Nature, **297**:598-601 (1982) on expression of human β-interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus, Canaani and Berg, Proc. Natl. Acad. Sci. USA, **79**:5166-5170 (1982) on expression of the human interferon β1 gene in cultured mouse and rabbit cells, and Gorman *et al.*, Proc. Natl. Acad. Sci. USA, **79**:6777-6781 (1982) on expression of bacterial CAT sequences in CV-1 monkey kidney cells, chicken embryo fibroblasts, Chinese hamster ovary cells, HeLa cells, and mouse NIH-3T3 cells using the Rous sarcoma virus long terminal repeat as a promoter.

Preferably the transcriptional regulatory region in higher eukaryotes comprises an enhancer sequence. Enhancers are relatively orientation and position independent having been found 5' (Lainins *et al.*, Proc. Natl. Acad. Sci. USA, **78**:993 (1981)) and 3' (Lusky *et al.*, Mol. Cell Bio., **3**:1108 (1983)) to the transcription unit, within an intron (Banerji *et al.*, Cell, **33**:729 (1983)) as well as within the coding sequence itself (Osborne *et al.*, Mol. Cell Bio., **4**:1293 (1984)). Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α-

fetoprotein and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer (CMV), the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, Nature, 297:17-18 (1982) on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into the vector at a position 5' or 3' to the product gene, but is preferably located at a site 5' from the promoter.

The DNA construct of the present invention has a transcriptional initiation site following the transcriptional regulatory region and a transcriptional termination region following the product gene (see, e.g., Figure 1). These sequences are provided in the DNA construct using techniques which are well known in the art.

The DNA construct normally forms part of an expression vector which may have other components such as an origin of replication (*i.e.*, a nucleic acid sequence that enables the vector to replicate in one or more selected host cells) and, if desired, one or more additional selectable gene(s). Construction of suitable vectors containing the desired coding and control sequences employs standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required.

Generally, in cloning vectors the origin of replication is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known. The 2μ plasmid origin of replication is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).

Most expression vectors are "shuttle" vectors, *i.e.*, they are capable of replication in at least one class of organisms but can be transfected into another organism for expression. For example, a vector is cloned in *E. coli* and then the same vector is transfected into yeast or mammalian cells for expression even though it is not capable of replicating independently of the host cell chromosome.

For analysis to confirm correct sequences in plasmids constructed, plasmids from the transformants are prepared, analyzed by restriction, and/or sequenced by the method of Messing *et*

al., Nucleic Acids Res., **9**:309 (1981) or by the method of Maxam *et al.*, Methods in Enzymology, **65**:499 (1980).

The expression vector having the DNA construct prepared as discussed above is transformed into a eukaryotic host cell. Suitable host cells for cloning or expressing the vectors herein are yeast or higher eukaryote cells.

Eukaryotic microbes such as filamentous fungi or yeast are suitable hosts for vectors containing the product gene. *Saccharomyces cerevisiae*, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly available and useful herein, such as *S. pombe* (Beach and Nurse, Nature, **290**:140 (1981)), *Kluyveromyces lactis* (Louvencourt *et al.*, J. Bacteriol., 737 (1983)), k*yarrowia* (EP 402,226), *Pichia pastoris* (EP 183,070), *Trichoderma reesia* (EP 244,234), *Neurospora crassa* (Case *et al.*, Proc. Natl. Acad. Sci. USA, **76**:5259-5263 (1979)), and *Aspergillus* hosts such as *A. nidulans* (Ballance *et al.*, Biochem. Biophys. Res. Commun., **112**:284-289 (1983); Tilburn *et al.*, Gene, **26**:205-221 (1983); Yelton *et al.*, Proc. Natl. Acad. Sci. USA, **81**:1470-1474 (1984)) and *A. niger* (Kelly and Hynes, EMBO J., **4**:475-479 (1985)).

Suitable host cells for the expression of the product gene are derived from multicellular organisms. Such host cells are capable of complex processing and glycosylation activities. In principle, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes aegypti* (mosquito), *Aedes albopictus* (mosquito), *Drosphila melanogaster* (fruitfly), and *Bombyx mori* host cells have been identified. See, e.g., Luckow *et al.*, Bio/Technology, **6**:47-55 (1988); Miller *et al.*, in Genetic Engineering, Setlow, J.K. *et al.*, eds., Vol. 8 (Plenum Publishing, 1986), pp. 277-279; and Maeda *et al.*, Nature, **315**:592-594 (1985). A variety of such viral strains are publicly available, e.g., the L-1 variant of *Autographa californica* NPV and the Bm-5 strain of *Bombyx mori* NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of *Spodoptera frugiperda* cells.

Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can be utilized as hosts. Typically, plant cells are transfected by incubation with certain strains of the bacterium *Agrobacterium tumefaciens*, which has been previously manipulated to contain the product gene. During incubation of the plant cell culture with *A. tumefaciens*, the product gene is

transferred to the plant cell host such that it is transfected, and will, under appropriate conditions, express the product gene. In addition, regulatory and signal sequences compatible with plant cells are available, such as the nopaline synthase promoter and polyadenylation signal sequences. Depicker *et al.*, J. Mol. Appl. Gen., 1:561 (1982). In addition, DNA segments isolated from the upstream region of the T-DNA *780* gene are capable of activating or increasing transcription levels of plant-expressible genes in recombinant DNA-containing plant tissue. EP 321,196 published 21 June 1989.

However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure in recent years (Tissue Culture, Academic Press, Kruse and Patterson, editors (1973)). Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham *et al.*, J. Gen Virol., **36**:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, **77**:4216 (1980)); dp12.CHO cells (EP 307,247 published 15 March 1989); mouse sertoli cells (TM4, Mather, Biol. Reprod., **23**:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather *et al.*, Annals N.Y. Acad. Sci., **383**:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).

Host cells are transformed with the above-described expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw *et al.*, Gene, **23**:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, **52**:456-457 (1978) may be used. General aspects of mammalian cell host system transformations have been described by Axel in U.S. 4,399,216 issued 16 August 1983. Transformations into yeast are typically carried out according to the method of Van Solingen *et al.*, J. Bact., **130**:946 (1977) and Hsiao *et al.*, Proc. Natl. Acad. Sci. (USA), **76**:3829

(1979). However, other methods for introducing DNA into cells such as by nuclear injection or by protoplast fusion may also be used.

In preferred embodiments the DNA is introduced into the host cells using electroporation, lipofection or polyfection techniques. In a particularly preferred embodiment, the transfection is performed in a spinner vessel as illustrated by Example 3 or in some other form of suspension culture. Transfection performed in a spinner vessel is also referred to as "spinner transfection". Culturing the cells in suspension allows them to reach a cell density of at least about $5x10^5$/ml and more preferrably at least about $1.5x10^6$/ml prior to transfection. See Andreason, J. Tiss. Cult. Meth., 15:56-62 (1993), for a review of electroporation techniques useful for practicing the claimed invention. It was discovered that these techniques for introducing the DNA construct into the host cells are preferable over calcium phosphate precipitation techniques insofar as the latter could cause the DNA to break up and form concatemers.

The mammalian host cells used to express the product gene herein may be cultured in a variety of media as discussed in the definitions section above. The media is formulated to provide selective nutrient conditions or a selection agent to select transformed host cells which have taken up the DNA construct (either as an intra- or extra-chromosomal element). To achieve selection of the transformed eukaryotic cells, the host cells may be grown in cell culture plates and individual colonies expressing one or both of the selectable genes (and thus the product gene) can be isolated and grown in growth medium under defined conditions. The host cells are then analyzed for transcription and/or transformation as discussed below. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA (Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)), dot blotting (DNA or mRNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Various labels may be employed, most commonly radioisotopes, particularly ^{32}P. However, other techniques may also be employed, such as using biotin-modified nucleotides for introduction into a polynucleotide. The biotin then serves as the site for binding to avidin or antibodies, which may be labeled with a wide variety of labels, such as radionuclides, fluorescence, enzymes, or the like. Alternatively, antibodies may be employed that can recognize specific

duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. With immunohistochemical staining techniques, a cell sample is prepared, typically by dehydration and fixation, followed by reaction with labeled antibodies specific for the gene product coupled, where the labels are usually visually detectable, such as enzymatic labels, fluorescent labels, luminescent labels, and the like. A particularly sensitive staining technique suitable for use in the present invention is described by Hsu *et al.*, Am. J. Clin. Path., 75:734-738 (1980).

In the preferred embodiment protein expression is measured using ELISA as described in Example 1 herein.

The product of interest preferably is recovered from the culture medium as a secreted polypeptide, although it also may be recovered from host cell lysates when directly expressed without a secretory signal. When the product gene is expressed in a recombinant cell other than one of human origin, the product of interest is completely free of proteins or polypeptides of human origin. However, it is necessary to purify the product of interest from recombinant cell proteins or polypeptides to obtain preparations that are substantially homogeneous as to the product of interest. As a first step, the culture medium or lysate is centrifuged to remove particulate cell debris. The product of interest thereafter is purified from contaminant soluble proteins and polypeptides, for example, by fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel electrophoresis using, for example, Sephadex G-75; chromatography on plasminogen columns to bind the product of interest and protein A Sepharose columns to remove contaminants such as IgG.

The following examples are offered by way of illustration only and are not intended to limit the invention in any manner. All patent and literature references cited herein are expressly incorporated by reference.

EXAMPLE 1

2C4 production using the fusion construct expression vector

Vectors related to those described by Lucas et al (Lucas BK, Giere LM, DeMarco RA, Shen A, Chisholm V and Crowley C. High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector. (1996) Nucleic Acids Res. 24(9), 1774-1779.), which contain an intron between the SV40 promoter and enhancer and the cDNA that encodes the polypeptide of interest, were constructed. The intron is boardered on its 3' and 5' ends, respectively, by a splice donor site derived from cytomegalovirus immediate early gene (CMVIE), and a splice acceptor site from an IgG heavy chain variable region (V_H) gene (Eaton *et al.*; Biochem., 25:8343 (1986)). The splice sites selected provide slightly inefficient splicing such that only about 90% of the transcripts produced are intron free. Previous studies have demonstrated that when a selectable marker such as DHFR is integrated within this intron,as in the plasmid pSV.ID, marker gene transcription proceeds from any unspliced transcripts, providing a highly efficient means of maintaining linkage between the expression of the marker gene and the cDNA of interest as well as enhanced product expression relative to expression of the marker gene.

Vectors containing a murine puromycin/DHFR fusion sequence in the intron following the SV40 promoter elements were constructed by linearizing a pSV.IPUR plasmid, which contained the puromycin resistance gene in an intron following the SV40 promoter/enhancer (pSV.IPUR, Figures 1 and 2), with Hpa I immediately following the end of the puromycin ORF. A 564 bp PCR fragment containing the entire coding region for the murine DHFR gene was subsequently ligated into this linearized vector 3' of the puromycin resistance gene. The stop codon TAG between the puromycin resistance gene and the DHFR gene was deleted by site-directed mutagenesis resulting in a pSV.I plasmid containing a Puro/DHFR fusion gene within the intron of the expression cassette (pSV.IPD, Figures 1 and 4).

The cDNA of the Heavy chain (HC) and light chain (LC) sequences of an anti-HER2 Neu antibody, 2C4, were inserted into pSV.IPD as shown in Figure 6. The sequence of the resulting pSV.IPD.2C4 vector is shown in Figure 7. Data collected using the pSV.IPD.2C4 vector are shown in Table 2.

Additionally, a vector containing only a murine DHFR sequence within the intron (pSV.ID) was prepared. The DNA sequence for the pSV.ID vector is shown in Figure 3. The preparation of such vectors is disclosed in U.S. Patent No. 5,561,053, which is herein incorporated by reference. Into that vector, the HC and LC sequences of monoclonal antibodies to VEGF were inserted. The sequence of the resulting pSV.IPD.VEGF vector is shown in Figure 5.

Plasmid DNA's that contained either the Puro/DHFR fusion sequences in the intron or murine DHFR alone preceding cDNA sequences for HC and LC of 2C4 and anti-VEGF, respectively were introduced into CHO DHFR minus cells by lipofection. Briefly, for transfection, 4 million CHO DUX-B11 (DHFR minus) were seeded in 10 cm plates the day before transfection. On the day of transfection, 4 ug DNA was mixed with 300 ul of serum free medium and 25 ul of polyfect from Qiagen. The mixture was incubated at room temperature for 5 to 10 minutes and added to the cells. Cells were fed with fresh glycine, hypoxanthine and thymidine-free (GHT-free) medium and twenty-four hours later, were trypsinzed and selected in fresh GHT- free medium with 0 – 5 nM of methotrexate (MTX) in order to select for stable DHFR+ clones. Approximately 300 – 400 individual clones were selected in this first round of screening for measurement of protein expression levels. Clones from each vector which expressed the highest levels of antibody were then re-exposed to higher levels of methotrexate to affect a second round of gene amplification and selection. The screening process was repeated on all available clones, the highest of which were exposed to a third round of amplification. The methotrexate concentrations used during amplification using the pSV.ID-derived vector was 50 to 1000 nM in the 2nd round and 200 to 1000 nM in the 3rd round. These concentrations are typically required to achieve growth-limiting toxicity, which is required to achieve sufficient selective pressure for gene amplification. Concentrations required to reach this same degree of toxicity using the pSV.IPD-derived vectors were remarkably lower.

The level of antibody expression was determined by seeding cells in 1 ml of serum-free F12:DMEM-based media supplemented with protein hydrolysate and amino acids in 24 well dishes at 3 X 10^6 cells/ml or in 100 ul of similar media in individual wells of a 96 well plate. Growth media was collected after 3-4 days and titers were assayed by an ELISA directed towards the intact IgG molecule. In experiments where cells were not seeded at equal cell densities, a fluorescent measure of viable cell number was performed on each well in order to normalize expression data. An Intact IgG ELISA was performed on microtiter plates which used a capture

antisera directed to framework Fab residues common in both antibodies. Media samples were added to the wells followed by washing and a horseradish peroxidase labeled second antibody directed towards common framework Fc residues was used for detection.

Table 2 presents expression level distributions of clones isolated during each round of screening of anti VEGF clones, which resulted from transfection with the plasmid containing only the DHFR sequence in the intron (pSV.ID.aVEGF), and 2C4 clones that were created using the Puro/DHFR fusion sequence in the same intron (pSV.IPD.2C4). The distribution of expression levels seen in the case of anti VEGF is typical of the performance of the vector containing only the murine DHFR gene in the intron (pSV.ID). All isolates identified in the first and second rounds of screening have relatively low expression levels. In the intial selection round, no clones with expression above 5 were isolated. At least three rounds of amplification are required to identify clones capable of specific productivity greater than 50. The 2C4 clones were screened after the first exposure to methotrexate (0-2.5 nM) and the most productive of these were exposed to a second round of amplification in 10–25 nM MTX. Cells surviving this amplification were pooled and exposed to 3rd round amplification prior to selection for further screening. In contrast to the pSV.ID vetor, using the pSV.IPD vector, clones with an expression level of up to 25 were identified even in the first round of screening. Clones with an expression level greater than 25 represented 95% of the population after their third round of amplification and screening.

The data from Example 1 indicates that use of the Puro/DHFR fusion protein as the selectable marker allows for faster, more efficient isolation of highly productive CHO clones using significantly lower levels of methotrexate. The data suggests that exposure to low concentrations and stepwise increments in methotrexate allow for the efficient initial selection of highly expressing clones and subsequent gene amplification. Exposure to excessively high concentrations of methotrexate or large incremental increases in exposure often does not yield increases in gene expression since cells rapidly acquire methotrexate resistance through non-gene amplification mechanisms. Importantly, the data also shows that the Puro/DHFR fusion protein provides an unexpectedly impaired activity of the DHFR gene product or an enhanced sensitivity to methotrexate, which results in a highly stringent initial selection step, and allows efficient gene amplification at concentrations of methotrexate not frequently associated with the acquisition of drug resistance through alternative mechanisms. The ability to select cells which have incorporated the plasmid either in the presence of puromycin or methotrexate, prior to initiating exposure to

methotrexate also provides a means of transferring this efficient system to DHFR (positive) host cells.

For Example 1 the structure of the expressed antibody has been extensively characterized. The proteins generated from the pSV.IPD are indistinguishable from the antibody produced by the pSV.ID vector, with no apparent increase of free heavy or light chain expressed by the pool.

TABLE 2. PERCENTAGES OF pSV.IPD.2C4 CLONES ISOLATED AT VARIOUS EXPRESSION LEVELS AFTER MTX EXPOSURE[1]

Expression Level[2]	pSV.ID.aVEGF 1st Rd	pSV.IPD.2C4 1st Rd	pSV.ID.aVEGF 3rd Rd	pSV.IPD.2C4 3rd Rd
<1	71	16	0	0
1-5	29	67	0	0
5-10	0	14	2	3
10-25	0	3	15	4
25-50	0	0	35	21
50-100	0	0	46	61
100-150	0	0	2	3

[1] MTX concentration for Control SD vector = 0-10 nM 1st round, 50 –1000 nM 2nd round, 200-1000 nM, 3rd round. SD- Puro/DHFR vector = 2.5 nM 1st round, 25 nM 2nd round, 100 nM 3rd round.

[2] Expression levels are in mg/ml or (mg/ml)/Fluorescent Unit

This example demonstrate the general applicability of the Puro/DHFR fusion sequence for selection of highly productive recombinant cell lines following minimal exposure to MTX.

EXAMPLE 2

Recombinant protein production using a pSV.I construct containing DHFR and a fusion gene other than Puro

Constructs can also be produced that contain a fusion sequence of an alternative selectable marker and DHFR within an intron region as described in Example 1. For instance

starting with the vector pSVID, the coding sequences for the neomycin resistance gene (Neo), hygromycin resistance gene (Hygro), glutamine synthase (GS), thymidine kinase (TK) or zeocin (Zeo) could be inserted in frame with the start site of the murine DHFR sequence contained within the intron. The stop codon of this inserted gene would then be removed using site dirtected mutagenesis according to example 1. Depending upon the phenotype of the host cell selected, cells incorporating the plasmid could then be selected using either GHT-free or MTX containing media as described in examples 1-3 or using an appropriate quantity of the alternative selective agent. Gene expression by the resulting clones could then be amplified in the presence of increased levels of methotrexate.

EXAMPLE 3

Direct Selection with plasmids SV.IPD.HP and CMV.IPD.HP after spinner transfection

DP12 CHO cells were grown in growth medium with 5% FBS (fetal bovine serum) and 1X GHT (glycine, hypoxanthine and thymidine). The process typically took about 4 days. On day 1, cells were seeded at 4X10^5/ml in 400 ml growth medium in a 500 ml spinner vessel and grown for 2 days at 37 ^{0}C. On day 3, the exponentially grown cells were seeded at 1.5X10^6 cells/ml in a 250 ml spinner vessel containing 200 ml of growth medium plus 5% FBS and 1X GHT. The cells were grown for 1 to 2 hours at 37 ^{0}C before transfection. During that time, serum-free growth medium and 1X GHT was warmed to 37 ^{0}C. 400 µg plasmid construct DNA and 1 ml of Lipofectamine 2000® (Qiagen) were separately diluted into 25 ml of warm serum-free medium in 50 ml Falcon tubes. The solutions in the tubes were combined and incubated at room temperature for 30 minutes. The cells were then transfected with plasmid constructs pSV.IPD.HP and pCMV.IPD.HP, which constructs are illustrated in Figures 13 and 14, respectively. At the end of incubation, the cells were transfected by adding all 50 ml of the mixture of diluted plasmid construct and Lipofectamine 2000® to the 250 ml spinner vessel containing cells in serum-free medium, and the cells continued to grow at 37 ^{0}C for about 24 hours. On day 4, 250 ml of transfected cells were centrifuged at 1000 rpm for 5 minutes to collect the pellet. The transfection efficiency was monitored by transfecting cells with a GFP plasmid followed by FACS analysis 24 hours after transfection. The transfection efficiency with this protocol was typically approximately 55 to 70 % in CHO cells as shown in Figure 8.

After the transfection, cells were centrifuged to collect the pellet. The pellet was then resuspended in growth medium containing methotrexate (MTX) ranging from 10 to 100 nM for either SV40 or CMV based constructs. Approximately 100 clones survived the direct selection. Cell growth medium was changed every 3 to 4 days. At approximately 2 weeks after transfection, individual clones were picked and grown in 96-well plates in growth medium containing MTX. Heterologous polypeptide expression levels were evaluated by ELISA. Figures 10-1, 10-2, and 11 show the results from 25 nM and 50 nM MTX selection. Figure 9 shows heterologous polypeptide expression levels of clones from a traditional 10 nM MTX selection where the cells were not transfected in a spinner flask.

It took about 1 week for cells to grow confluent in a 96-well plate. When they were confluent, the growth medium was removed and commercially available enriched cell culture medium (which includes 1x GHT but no MTX) was added into each well. On the day after adding the commercially available enriched cell culture medium, the plate was incubated at 33 ^{0}C for 5-6 days before performing an ELISA assay to quantitate the amount of humanized monoclonal antibody produced by the cells. ELISA was typically performed with serial dilutions of the commercially available enriched cell culture medium. Results from a humanized monoclonal antibody production were shown in Figures 9, 10-1, 10-2 and 11.

The four clones producing the greatest amount over 100 μg/ml of intact IgG based on direct selection at 25 nM MTX using a CMV-based construct were scaled up from a 96-well plate to a 6-well plate and then to a 10 cm plate. Cells were seeded at 3X10^5/ml in 200 ml volume in a 250 ml spinner vessel in serum-free growth medium with 2 μg/ml human insulin and 1X Trace Elements (TE). Cells were initially passaged at either two- or three-day intervals with medium exchange. Then they were passaged at either three- or four-day intervals for about 6 weeks before bioreactor evaluation. At each passage time, cell viability and count number were monitored. To determine the cell growth after serum-free adaptation, a spinner vessel growth experiment was performed. Cells were seeded at 3X10^5 cells/ml into 400 ml of growth medium with 2 μg/ml recombinant human insulin and 1X TE in a 500 ml spinner vessel on day 1. On each day, packed cell volume (PCV) was monitored until day 5. PCVs reached between 0.4 % to 0.6% by day 4. Two serum-free adapted clones from 25 nM MTX selection with CMV-based construct were evaluated in bioreactors. Two liter bioreactors with commercially available

enriched cell culture medium were run for a total of 14 days. The data from the titer evaluation is shown in Figure 12.

An ELISA assay of clones surviving the direct selection shows that the best clones coming out of the method described in this example produce as much product of interest as highly amplified clones from a traditional method. See Figure 16. Evaluations of 2 clones from the direct selection shows that those clones produce about 1g/L of a product of interest in a bioreactor process. Since those clones were generated from one step of a direct selection immediately after transfection, it only takes about 5 to 6 weeks to generate a stable cell line producing 1g/L of a product of interest in a bioreactor leading to significant timeline reduction, about 3 months, which is critical for efficiency of product development.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the examples presented herein, since the exemplified embodiments are intended as illustrations of certain aspects of the invention and any functionally equivalent embodiments are within the scope of this invention. The examples presented herein are not intended as limiting the scope of the claims to the specific illustrations. Indeed, various modifications of the invention, in addition to those shown and described herein and which fall within the scope of the appended claims, may become apparent to those skilled in the art from the foregoing description.

CLAIMS
What is claimed is:

1. A method of producing a host cell capable of producing a product of interest, comprising:

transfecting a host cell culture with a DNA construct comprising a transcriptional regulatory region, a fused selectable gene sequence and a gene encoding a product of interest;

directly culturing the transfected host cells in a selective medium;

allowing the host cells to grow in the selective medium for a sufficient time to allow amplification of gene encoding the product of interest to occur; and

selecting a host cell clone that is capable of producing at least about 250mg/l of the product of interest.

2. A method of claim 1 wherein the selective medium contains at least about 25nM methotrexate.

3. A method of claim 1 wherein the selective medium contains at least about 50nM methotrexate.

4. A method of claim 1 wherein the host cell is a CHO cell.

5. A method of claim 1 wherein the product of interest is a protein selected from the group consisting of an antibody, enzyme, hormone, lipoprotein, clotting factor, anti-clotting factor, cytokine, viral antigen, chimeric protein, transport protein, regulatory protein, homing receptor, and addressin; or a fragment of said protein.

6. A method of claim 1 wherein said product of interest is a humanized antibody.

7. A host cell produced according to the method of claim 1.

8. A method of producing a product of interest, comprising culturing a host cell produced according to the method of claim 1 under conditions suitable to cause expression of the product of interest in an amount at least about 250mg/l.

9. A method of claim 1 wherein the DNA construct comprises, in order 5' to 3':

a) a transcriptional regulatory region capable of regulating transcription of both the selectable gene and the product gene;

b) a transcriptional initiation site;

c) a fused selectable gene sequence positioned within an intron defined by a 5' splice donor site comprising a splice donor sequence such that the efficiency of splicing messenger RNA having said splice donor sequence is between about 80% and 99% as determined by PCR, and a 3' splice acceptor cite;

d) a product gene encoding a product of interest; and

e) a transcriptional termination site.

10. The method of claim 9 further comprising recovering the product of interest from the culture.

11. A method of claim 9 wherein the transcriptional regulatory region capable of regulating transcription of both the selectable gene and the product gene is driven by a SV40 promoter.

12. A method of claim 9 wherein the transcriptional regulatory region capable of regulating transcription of both the selectable gene and the product gene is driven by a CMV promoter.

13. A cell culture composition comprising a host cell according to claim 9 and at least about 250mg/l of the product of interest.

14. A method of producing a host cell capable of producing at least about 250mg/ml of a product of interest comprising transfecting a host cell with a DNA construct comprising in order from 5' to 3':

a) a transcriptional regulatory region capable of regulating transcription of both the selectable gene and the product gene;

b) a transcriptional initiation site;

c) a fused selectable gene sequence positioned within an intron defined by a 5' splice donor site comprising a splice donor sequence such that the efficiency of splicing messenger RNA having said splice donor sequence is between about 80% and 99% as determined by PCR, and a 3' splice acceptor cite;

d) a product gene encoding a product of interest; and

e) a transcriptional termination site;

wherein the transfection is performed in suspension culture.

15. A method of claim 14, wherein the DNA construct is introduced into the host cells by lipofection.

16. A method of claim 14 wherein said transfection is performed in a spinner vessel.

17. The method of claim 14 wherein the suspension culture has cell density of at least about $5x10^5$/ml at the time of transfection.

18. The method of claim 14 wherein the suspension culture has a cell density of at least about $1.5x10^5$/ml at the time of transfection

19. A method of claim 15 wherein the product of interest is selected from the group consisting of an antibody, enzyme, hormone, lipoprotein, clotting factor, anti-clotting factor, cytokine, viral antigen, chimeric protein, transport protein, regulatory protein, homing receptor, and addressin and a fragment of any of said product of interest.

20. A method of rapidly selecting a host cell producing a product of interest, comprising:

transfecting a host cell culture with a DNA construct comprising a transcriptional regulatory region, a fused selectable gene sequence and a gene encoding a product of interest;

directly culturing the transfected host cells in a selective medium; and

allowing the host cells to grow in the selective medium for a sufficient time to allow amplification of gene encoding the product of interest to occur.



Figure 1. Construction of pSV.IPD Plasmid

Figure 2
pSV.IPUR
length: 5147 (circular)

Figure 2-1

```
1401 CATCACAAAT TTCACAAATA AAGCATTTTT TTCACTGCAT TCTAGTTGTG GTTTGTCCAA ACTCATCAAT GTATCTTATC ATGTCTGGAT CGATCCGGAA
     GTAGTGTTTA AAGTGTTTAT TTCGTAAAAA AAGTGACGTA AGATCAACAC CAAACAGGTT TGAGTAGTTA CATAGAATAG TACAGACCTA GCTAGCCCTT

1501 TTAATTCGGC GCAGCACCAT GGCCTGAAAT AACCTCTGAA AGAGGAACTT GGTTAGGTAC CTTCTGAGGC GGAAAGAACC AGCTGTGGAA TGTGTGTCAG
     AATTAAGCCG CGTCGTGGTA CCGGACTTTA TTGGAGACTT TCTCCTTGAA CCAATCCATG GAAGACTCCG CCTTTCTTGG TCGACACCTT ACACACAGTC

1601 TTAGGGTGTG GAAAGTCCCC AGGCTCCCCA GCAGGCAGAA GTATGCAAAG CATGCATCTC AATTAGTCAG CAACCAGGTG TGGAAAGTCC CCAGGCTCCC
     AATCCCACAC CTTTCAGGGG TCCGAGGGGT CGTCCGTCTT CATACGTTTC GTACGTAGAG TTAATCAGTC GTTGGTCCAC ACCTTTCAGG GGTCCGAGGG

1701 CAGCAGGCAG AAGTATGCAA AGCATGCATC TCAATTAGTC AGCAACCATA GTCCCGCCCC TAACTCCGCC CATCCCGCCC CTAACTCCGC CCAGTTCCGC
     GTCGTCCGTC TTCATACGTT TCGTACGTAG AGTTAATCAG TCGTTGGTAT CAGGGCGGGG ATTGAGGCGG GTAGGGCGGG GATTGAGGCG GGTCAAGGCG

1801 CCATTCTCCG CCCCATGGCT GACTAATTTT TTTTATTTAT GCAGAGGCCG AGGCCGCCTC GGCCTCTGAG CTATTCCAGA AGTAGTGAGG AGGCTTTTTT
     GGTAAGAGGC GGGGTACCGA CTGATTAAAA AAAATAAATA CGTCTCCGGC TCCGGCGGAG CCGGAGACTC GATAAGGTCT TCATCACTCC TCCGAAAAAA

1901 GGAGGCCTAG GCTTTTGCAA AAAGCTGTTA CCTCGAGCGG CCGCTTAATT AAGGCGCGCC ATTTAAATCC TGCAGGTAAC AGCTTGGCAC TGGCCGTCGT
     CCTCCGGATC CGAAAACGTT TTTCGACAAT GGAGCTCGCC GGCGAATTAA TTCCGCGCGG TAAATTTAGG ACGTCCATTG TCGAACCGTG ACCGGCAGCA

2001 TTTACAACGT CGTGACTGGG AAAACCCTGG CGTTACCCAA CTTAATCGCC TTGCAGCACA TCCCCCCTTC GCCAGCTGGC GTAATAGCGA ACAGGCCCGC
     AAATGTTGCA GCACTGACCC TTTTGGGACC GCAATGGGTT GAATTAGCGG AACGTCGTGT AGGGGGGAAG CGGTCGACCG CATTATCGCT TCTCCGGGCG

2101 ACCGATCGCC CTTCCCAACA GTTGCGTAGC CTGAATGGCG AATGGCGCCT GATGCGGTAT TTTCTCCTTA CGCATCTGTG CGGTATTTCA CACCGCATAC
     TGGCTAGCGG GAAGGGTTGT CAACGCATCG GACTTACCGC TTACCGCGGA CTACGCCATA AAAGAGGAAT GCGTAGACAC GCCATAAAGT GTGGCGTATG

2201 GTCAAAGCAA CCATAGTACG CGCCCTGTAG CGGCGCATTA AGCGCGGCGG GTGTGGTGGT TACGCGCAGC GTGACCGCTA CACTTGCCAG CGCCCTAGCG
     CAGTTTCGTT GGTATCATGC GCGGGACATC GCCGCGTAAT TCGCGCCGCC CACACCACCA ATGCGCGTCG CACTGGCGAT GTGAACGGTC GCGGGATCGC

2301 CCCGCTCCTT TCGCTTTCTT CCCTTCCTTT CTCGCCACGT TCGCCGGCTT TCCCCGTCAA GCTCTAAATC GGGGGCTCCC TTTAGGGTTC CGATTTAGTG
     GGGCGAGGAA AGCGAAAGAA GGGAAGGAAA GAGCGGTGCA AGCGGCCGAA AGGGGCAGTT CGAGATTTAG CCCCCGAGGG AAATCCCAAG GCTAAATCAC

2401 CTTTACGGCA CCTCGACCCC AAAAAACTTG ATTTGGGTGA TGGTTCACGT AGTGGGCCAT CGCCCTGATA GACGGTTTTT CGCCCTTTGA CGTTGGAGTC
     GAAATGCCGT GGAGCTGGGG TTTTTTGAAC TAAACCCACT ACCAAGTGCA TCACCCGGTA GCGGGACTAT CTGCCAAAAA GCGGGAAACT GCAACCTCAG

2501 CACGTTCTTT AATAGTGGAC TCTTGTTCCA AACTGGAACA ACACTCAACC CTATCTCGGG CTATTCTTTT GATTTATAAG GGATTTTGCC GATTTCGGCC
     GTGCAAGAAA TTATCACCTG AGAACAAGGT TTGACCTTGT TGTGAGTTGG GATAGAGCCC GATAAGAAAA CTAAATATTC CCTAAAACGG CTAAAGCCGG

2601 TATTGGTTAA AAAATGAGCT GATTTAACAA AAATTTAACG CGAATTTTAA CAAAATATTA ACGTTTACAA TTTTATGGTG CACTCTCAGT ACAATCTGCT
     ATAACCAATT TTTTACTCGA CTAAATTGTT TTTAAATTGC GCTTAAAATT GTTTTATAAT TGCAAATGTT AAAATACCAC GTGAGAGTCA TGTTAGACGA

2701 CTGATGCCGC ATAGTTAAGC CAACTCCGCT ATCGCTACGT GACTGGGTCA TGGCTGCGCC CCGACACCCG CCAACACCCG CTGACGCGCC CTGACGGGCT
     GACTACGGCG TATCAATTCG GTTGAGGCGA TAGCGATGCA CTGACCCAGT ACCGACGCGG GGCTGTGGGC GGTTGTGGGC GACTGCGCGG GACTGCCCGA

2801 TGTCTGCTCC CGGCATCCGC TTACAGACAA GCTGTGACCG TCTCCGGGAG CTGCATGTGT CAGAGGTTTT CACCGTCATC ACCGAAACGC GCGAGGCAGT
     ACAGACGAGG GCCGTAGGCG AATGTCTGTT CGACACTGGC AGAGGCCCTC GACGTACACA GTCTCCAAAA GTGGCAGTAG TGGCTTTGCG CGCTCCGTCA

2901 ATTCTTGAAG ACGAAAGGGC CTCGTGATAC GCCTATTTTT ATAGGTTAAT GTCATGATAA TAATGGTTTC TTAGACGTCA GGTGGCACTT TTCGGGGAAA
     TAAGAACTTC TGCTTTCCCG GAGCACTATG CGGATAAAAA TATCCAATTA CAGTACTATT ATTACCAAAG AATCTGCAGT CCACCGTGAA AAGCCCCTTT

3001 TGTGCGCGGA ACCCCTATTT GTTTATTTTT CTAAATACAT TCAAATATGT ATCCGCTCAT GAGACAATAA CCCTGATAAA TGCTTCAATA ATATTGAAAA
```

Figure 2-2



Figure 2-3

```
4801 GTTATCCCCT GATTCTGTGG ATAACCGTAT TACCGCCTTT GAGTGAGCTG ATACCGCTCG CCGCAGCCGA ACGACCGAGC GCAGCGAGTC AGTGAGCGAG
     CAATAGGGGA CTAAGACACC TATTGGCATA ATGGCGGAAA CTCACTCGAC TATGGCGAGC GGCGTCGGCT TGCTGGCTCG CGTCGCTCAG TCACTCGCTC

4901 GAAGCGGAAG AGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TCCAGCTGGC ACGACAGGTT TCCCGACTGG AAAGCGGGCA
     CTTCGCCTTC TCGCGGGTTA TGCGTTTGGC GGAGAGGGGC GCGCAACCGG CTAAGTAATT AGGTCGACCG TGCTGTCCAA AGGGCTGACC TTTCGCCCGT

5001 GTGAGCGCAA CGCAATTAAT GTGAGTTACC TCACTCATTA GGCACCCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA TTGTGAGCGG
     CACTCGCGTT GCGTTAATTA CACTCAATGG AGTGAGTAAT CCGTGGGGTC CGAAATGTGA AATACGAAGG CCGAGCATAC AACACACCTT AACACTCGCC

     TATTGTTAAA GTGTGTCCTT TGTCGATACT GGTACTAATG CTTAATT

>length: 5147
```

Figure 2-4

Figure 3
pSV.ID
length: 5171 (circular)

```
   1 TTCGAGCTCG CCCGACATTG ATTATTGACT AGAGTCGATC GACAGCTGTG GAATGTGTGT CAGTTAGGGT GTGGAAAGTC CCCAGGCTCC CCAGCAGGCA
     AAGCTCGAGC GGGCTGTAAC TAATAACTGA TCTCAGCTAG CTGTCGACAC CTTACACACA GTCAATCCCA CACCTTTCAG GGGTCCGAGG GGTCGTCCGT

 101 GAAGTATGCA AAGCATGCAT CTCAATTAGT CAGCAACCAG GTGTGGAAAG TCCCCAGGCT CCCCAGCAGG CAGAAGTATG CAAAGCATGC ATCTCAATTA
     CTTCATACGT TTCGTACGTA GAGTTAATCA GTCGTTGGTC CACACCTTTC AGGGGTCCGA GGGGTCGTCC GTCTTCATAC GTTTCGTACG TAGAGTTAAT

 201 GTCAGCAACC ATAGTCCCGC CCCTAACTCC GCCCATCCCG CCCCTAACTC CGCCCAGTTC CGCCCATTCT CCGCCCCATG GCTGACTAAT TTTTTTTATT
     CAGTCGTTGG TATCAGGGCG GGGATTGAGG CGGGTAGGGC GGGGATTGAG GCGGGTCAAG GCGGGTAAGA GGCGGGGTAC CGACTGATTA AAAAAAATAA


 301 TATGCAGAGG CCGAGGCCGC CTCGGCCTCT GAGCTATTCC AGAAGTAGTG AGGAGGCTTT TTTGGAGGCC TAGGCTTTTG CAAAAAGCTA GCTTATCCGG
     ATACGTCTCC GGCTCCGGCG GAGCCGGAGA CTCGATAAGG TCTTCATCAC TCCTCCGAAA AAACCTCCGG ATCCGAAAAC GTTTTTCGAT CGAATAGGCC


 401 CCGGGAACGG TGCATTGGAA CGCGGATTCC CCGTGCCAAG AGTGACGTAA GTACCGCCTA TAGAGTCTAT AGGCCCACCC CTTGGCTCTA GAGAGATATA
     GGCCCTTGCC ACGTAACCTT GCGCCTAAGG GGCACGGTTC TCACTGCATT CATGGCGGAT ATCTCAGATA TCCGGGTGGG GAACCGAGAT CTCTCTATAT
                                                ^splice donor

 501 AGCCTAGGAT TTTATCCCCG GTGCCATCAT GGTTCGACCA TTGAACTGCA TCGTCGCCGT GTCCCAAAAT ATGGGGATTG GCAAGAACGG AGACCTACCC
     TCGGATCCTA AAATAGGGGC CACGGTAGTA CCAAGCTGGT AACTTGACGT AGCAGCGGCA CAGGGTTTTA TACCCCTAAC CGTTCTTGCC TCTGGATGGG
                                  ^DHFR ATG
 601 TGCCCTCCGC TCAGGAACGC GTTCAAGTAC TTCCAAAGAA TGACCACAAC CTCTTCAGTG GAAGGTAAAC AGAATCTGGT GATTATGGGT AGGAAAACCT
     ACGGGAGGCG AGTCCTTGCG CAAGTTCATG AAGGTTTCTT ACTGGTGTTG GAGAAGTCAC CTTCCATTTG TCTTAGACCA CTAATACCCA TCCTTTTGGA

 701 GGTTCTCCAT TCCTGAGAAG AATCGACCTT TAAAGGACAG AATTAATATA GTTCTCAGTA GAGAACTCAA AGAACCACCA CGAGGAGCTC ATTTTCTTGC
     CCAAGAGGTA AGGACTCTTC TTAGCTGGAA ATTTCCTGTC TTAATTATAT CAAGAGTCAT CTCTTGAGTT TCTTGGTGGT GCTCCTCGAG TAAAAGAACG

 801 CAAAAGTTTG GATGATGCCT TAAGACTTAT TGAACAACCG GAATTGGCAA GTAAAGTAGA CATGGTTTGG ATAGTCGGAG GCAGTTCTGT TTACCAGGAA
     GTTTTCAAAC CTACTACGGA ATTCTGAATA ACTTGTTGGC CTTAACCGTT CATTTCATCT GTACCAAACC TATCAGCCTC CGTCAAGACA AATGGTCCTT

 901 GCCATGAATC AACCAGGCCA CCTTAGACTC TTTGTGACAA GGATCATGCA GGAATTTGAA AGTGACACGT TTTTCCCAGA AATTGATTTG GGGAAATATA
     CGGTACTTAG TTGGTCCGGT GGAATCTGAG AAACACTGTT CCTAGTACGT CCTTAAACTT TCACTGTGCA AAAAGGGTCT TTAACTAAAC CCCTTTATAT

1001 AACCTCTCCC AGAATACCCA GGCGTCCTCT CTGAGGTCCA GGAGGAAAAA GGCATCAAGT ATAAGTTTGA AGTCTACGAG AAGAAAGACT AACAGGAAGA
     TTGGAGAGGG TCTTATGGGT CCGCAGGAGA GACTCCAGGT CCTCCTTTTT CCGTAGTTCA TATTCAAACT TCAGATGCTC TTCTTTCTGA TTGTCCTTCT
                                                                                ^END DHFR
1101 TGCTTTCAAG TTCTCTGCTC CCCTCCTAAA GCTATGCATT TTTATAAGAC CATGGGACTT TTGCTGGCTT TAGACCCCCT TGGCTTCGTT AGAACGCGGC
     ACGAAAGTTC AAGAGACGAG GGGAGGATTT CGATACGTAA AAATATTCTG GTACCCTGAA AACGACCGAA ATCTGGGGGA ACCGAAGCAA TCTTGCGCCG

1201 TACAATTAAT ACATAACCTT ATGTATCATA CACATAGATT TAGGTGACAC TATAGAATAA CATCCACTTT GCCTTTCTCT CCACAGGTGT CACTCCAGGT
     ATGTTAATTA TGTATTGGAA TACATAGTAT GTGTATCTAA ATCCACTGTG ATATCTTATT GTAGGTGAAA CGGAAAGAGA GGTGTCCACA GTGAGGTCCA

1301 CAACTGCACC TCGGTTCTAT CGATTGAATT CCCCGGGGAT CCTCTAGAGT CGACCTGCAG AAGCTTGGCC GCCATGGCCC AACTTGTTTA TTGCAGCTTA
     GTTGACGTGG AGCCAAGATA GCTAACTTAA GGGGCCCCTA GGAGATCTCA GCTGGACGTC TTCGAACCGG CGGTACCGGG TTGAACAAAT AACGTCGAAT

1401 TAATGGTTAC AAATAAAGCA ATAGCATCAC AAATTTCACA AATAAAGCAT TTTTTTCACT GCATTCTAGT TGTGGTTTGT CCAAACTCAT CAATGTATCT
```

Figure 3-1

```
     ATTACCAATG TTTATTTCGT TATCGTAGTG TTTAAAGTGT TTATTTCGTA AAAAAAGTGA CGTAAGATCA ACACCAAACA GGTTTGAGTA GTTACATAGA

1501 TATCATGTCT GGATCGATCG GGAATTAATT CGGCGCAGCA CCATGGCCTG AAATAACCTC TGAAAGAGGA ACTTGGTTAG GTACCTTCTG AGGCGGAAAG
     ATAGTACAGA CCTAGCTAGC CCTTAATTAA GCCGCGTCGT GGTACCGGAC TTTATTGGAG ACTTTCTCCT TGAACCAATC CATGGAAGAC TCCGCCTTTC
                              ^sv40 origin
1601 AACCAGCTGT GGAATGTGTG TCAGTTAGGG TGTGGAAAGT CCCCAGGCTC CCCAGCAGGC AGAAGTATGC AAAGCATGCA TCTCAATTAG TCACCAACCA
     TTGGTCGACA CCTTACACAC AGTCAATCCC ACACCTTTCA GGGGTCCGAG GGGTCGTCCG TCTTCATACG TTTCGTACGT AGAGTTAATC AGTCGTTGGT

1701 GGTGTGGAAA GTCCCCAGGC TCCCCAGCAG GCAGAAGTAT GCAAAGCATG CATCTCAATT AGTCAGCAAC CATAGTCCCG CCCCTAACTC CGCCCATCCC
     CCACACCTTT CAGGGGTCCG AGGGGTCGTC CGTCTTCATA CGTTTCGTAC GTAGAGTTAA TCAGTCGTTG GTATCAGGGC GGGGATTGAG GCGGGTAGGG

1801 GCCCCTAACT CCGCCCAGTT CCGCCCATTC TCCGCCCCAT GGCTGACTAA TTTTTTTTAT TTATGCAGAG GCCGAGGCCG CCTCGGCCTC TGAGCTATTC
     CGGGGATTGA GGCGGGTCAA GGCGGGTAAG AGGCGGGGTA CCGACTGATT AAAAAAAATA AATACGTCTC CGGCTCCGGC GGACCCGGAG ACTCGATAAG

1901 CAGAAGTAGT GAGGAGGCTT TTTTGGAGGC CTAGGCTTTT GCAAAAAGCT GTTACCTCGA GCGGCCGCTT AATTAAGGCG CGCCATTTAA ATCCTGCAGG
     GTCTTCATCA CTCCTCCGAA AAAACCTCCG GATCCGAAAA CGTTTTTCGA CAATGGAGCT CGCCGGCGAA TTAATTCCGC GCGGTAAATT TAGGACGTCC
                                                  ^start pUC118
                                                                ^linearization linker inserted into HpaI site
2001 TAACAGCTTG GCACTGGCCG TCGTTTTACA ACGTCGTGAC TGGGAAAACC CTGGCGTTAC CCAACTTAAT CGCCTTGCAG CACATCCCCC CTTCGCCAGC
     ATTGTCGAAC CGTGACCGGC AGCAAAATGT TGCAGCACTG ACCCTTTTGG GACCGCAATG GGTTGAATTA GCGGAACGTC GTGTAGGGGG GAAGCGGTCG

2101 TGGCGTAATA GCGAAGAGGC CCGCACCGAT CGCCCTTCCC AACAGTTGCG TAGCCTGAAT GGCGAATGGC GCCTGATGCG GTATTTTCTC CTTACGCATC
     ACCGCATTAT CGCTTCTCCG GGCGTGGCTA GCGGGAAGGG TTGTCAACGC ATCGGACTTA CCGCTTACCG CGGACTACGC CATAAAAGAG GAATGCGTAG

2201 TGTGCGGTAT TTCACACCGC ATACGTCAAA GCAACCATAG TACGCGCCCT GTAGCGGCGC ATTAAGCGCG GCGGGTGTGG TGGTTACGCG CAGCGTGACT
     ACACGCCATA AAGTGTGGCG TATGCAGTTT CGTTGGTATC ATGCGCGGGA CATCGCCGCG TAATTCGCGC CGCCCACACC ACCAATGCGC GTCGCACTGG

2301 GCTACACTTG CCAGCGCCCT AGCGCCCGCT CCTTTCGCTT TCTTCCCTTC CTTTCTCGCC ACGTTCGCCG GCTTTCCCCG TCAAGCTCTA AATCGGGGGC
     CGATGTGAAC GGTCGCGGGA TCGCGGGCGA GGAAAGCGAA AGAAGGGAAG GAAAGAGCGG TGCAAGCGGC CGAAAGGGGC AGTTCGAGAT TTAGCCCCCG

2401 TCCCTTTAGG GTTCCGATTT AGTGCTTTAC GGCACCTCGA CCCCAAAAAA CTTGATTTGG GTGATGGTTC ACGTAGTGGG CCATCGCCCT GATAGACGGT
     AGGGAAATCC CAAGGCTAAA TCACGAAATG CCGTGGAGCT GGGGTTTTTT GAACTAAACC CACTACCAAG TGCATCACCC GGTAGCGGGA CTATCTGCCA

2501 TTTTCGCCCT TTGACGTTGG AGTCCACGTT CTTTAATAGT GGACTCTTGT TCCAAACTGG AACAACACTC AACCCTATCT CGGGCTATTC TTTTGATTTA
     AAAAGCGGGA AACTGCAACC TCAGGTGCAA GAAATTATCA CCTGAGAACA AGGTTTGACC TTGTTGTGAG TTGGGATAGA GCCCGATAAG AAAACTAAAT

2601 TAAGGGATTT TGCCGATTTC GGCCTATTGG TTAAAAAATG AGCTGATTTA ACAAAAATTT AACGCGAATT TTAACAAAAT ATTAACGTTT ACAATTTTAT
     ATTCCCTAAA ACGGCTAAAG CCGGATAACC AATTTTTTAC TCGACTAAAT TGTTTTTAAA TTGCGCTTAA AATTGTTTTA TAATTGCAAA TGTTAAAATA

2701 GGTGCACTCT CAGTACAATC TGCTCTGATG CCGCATAGTT AAGCCAACTC CGCTATCGCT ACGTGACTGG GTCATGGCTG CGCCCCGACA CCCGCCAACA
     CCACGTGAGA GTCATGTTAG ACGAGACTAC GGCGTATCAA TTCGGTTGAG GCGATAGCGA TGCACTGACC CAGTACCGAC GCGGGGCTGT GGGCGGTTGT

2801 CCCGCTGACG CGCCCTGACG GGCTTGTCTG CTCCCGGCAT CCGCTTACAG ACAAGCTGTG ACCGTCTCCG GGAGCTGCAT GTGTCAGAGG TTTTCACCGT
     GGGCGACTGC GCGGGACTGC CCGAACAGAC GAGGGCCGTA GGCGAATGTC TGTTCGACAC TGGCAGAGGC CCTCGACGTA CACAGTCTCC AAAAGTGGCA

2901 CATCACCGAA ACGCGCGAGG CAGTATTCTT GAAGACGAAA GGGCCTCGTG ATACGCCTAT TTTTATAGGT TAATGTCATG ATAATAATGG TTTCTTAGAC
     GTAGTGGCTT TGCGCGCTCC GTCATAAGAA CTTCTGCTTT CCCGGAGCAC TATGCGGATA AAAATATCCA ATTACAGTAC TATTATTACC AAAGAATCTG

3001 GTCAGGTGGC ACTTTTCGGG GAAATGTGCG CGGAACCCCT ATTTGTTTAT TTTTCTAAAT ACATTCAAAT ATGTATCCGC TCATGAGACA ATAACCCTGA
     CAGTCCACCG TGAAAAGCCC CTTTACACGC GCCTTGGGGA TAAACAAATA AAAAGATTTA TGTAAGTTTA TACATAGGCG AGTACTCTGT TATTGGGACT

3101 TAAATGCTTC AATAATATTG AAAAAGGAAG AGTATGAGTA TTCAACATTT CCGTGTCGCC CTTATTCCCT TTTTTGCGGC ATTTTGCCTT CCTGTTTTTG
     ATTTACGAAG TTATTATAAC TTTTTCCTTC TCATACTCAT AAGTTGTAAA GGCACAGCGG GAATAAGGGA AAAAACGCCG TAAAACGGAA GGACAAAAAC
```

Figure 3-2

```
3201 CTCACCCAGA AACGCTGGTG AAAGTAAAAG ATGCTGAAGA TCAGTTGGGT GCACGAGTGG GTTACATCGA ACTGGATCTC AACAGCGGTA AGATCCTTGA
     GAGTGGGTCT TTGCGACCAC TTTCATTTTC TACGACTTCT AGTCAACCCA CGTGCTCACC CAATGTAGCT TGACCTAGAG TTGTCGCCAT TCTAGGAACT

3301 GAGTTTTCGC CCCGAAGAAC GTTTTCCAAT GATGAGCACT TTTAAAGTTC TGCTATGTGG CGCGGTATTA TCCCGTGATG ACGCTGGGCA AGAGCAACTC
     CTCAAAAGCG GGGCTTCTTG CAAAAGGTTA CTACTCGTGA AAATTTCAAG ACGATACACC GCGCCATAAT AGGGCACTAC TGCGGCCCGT TCTCGTTGAG

3401 GGTCGCCGCA TACACTATTC TCAGAATGAC TTGGTTGAGT ACTCACCAGT CACAGAAAAG CATCTTACGG ATGGCATGAC AGTAAGAGAA TTATGCAGTG
     CCAGCGGCGT ATGTGATAAG AGTCTTACTG AACCAACTCA TGAGTGGTCA GTGTCTTTTC GTAGAATGCC TACCGTACTG TCATTCTCTT AATACGTCAC

3501 CTGCCATAAC CATGAGTGAT AACACTGCGG CCAACTTACT TCTGACAACG ATCGGAGGAC CGAAGGAGCT AACCGCTTTT TTGCACAACA TGGGGGATCA
     GACGGTATTG GTACTCACTA TTGTGACGCC GGTTGAATGA AGACTGTTGC TAGCCTCCTG GCTTCCTCGA TTGGCGAAAA AACGTGTTGT ACCCCGTAGT

3601 TGTAACTCGC CTTGATCGTT GGGAACCGGA GCTGAATGAA GCCATACCAA ACGACGAGCG TGACACCACG ATGCCAGCAG CAATGGCAAC AACGTTGCGC
     ACATTGAGCG GAACTAGCAA CCCTTGGCCT CGACTTACTT CGGTATGGTT TGCTGCTCGC ACTGTGGTGC TACGGTCGTC GTTACCGTTG TTGCAACGCG

3701 AAACTATTAA CTGGCGAACT ACTTACTCTA GCTTCCCGGC AACAATTAAT AGACTGGATG GAGGCGGATA AAGTTGCAGG ACCACTTCTG CGCTCGGCCC
     TTTGATAATT GACCGCTTGA TGAATGAGAT CGAAGGGCCG TTGTTAATTA TCTGACCTAC CTCCGCCTAT TTCAACGTCC TGGTGAAGAC GCGAGCCGGG

3801 TTCCGGCTGG CTGGTTTATT GCTGATAAAT CTGGAGCCGG TGAGCGTGGG TCTCGCGGTA TCATTGCAGC ACTGGGGCCA GATGGTAAGC CCTCCCGTAT
     AAGGCCGACC GACCAAATAA CGACTATTTA GACCTCGGCC ACTCGCACCC AGAGCGCCAT AGTAACGTCG TGACCCCGGT CTACCATTCG GGAGGGCATA

3901 CGTAGTTATC TACACGACGG GGAGTCAGGC AACTATGGAT GAACGAAATA GACAGATCGC TGAGATAGGT GCCTCACTGA TTAAGCATTG GTAACTGTCA
     GCATCAATAG ATGTGCTGCC CCTCAGTCCG TTGATACCTA CTTGCTTTAT CTGTCTAGCG ACTCTATCCA CGGAGTGACT AATTCGTAAC CATTGACAGT

4001 GACCAAGTTT ACTCATATAT ACTTTAGATT GATTTAAAAC TTCATTTTTA ATTTAAAAGG ATCTAGGTGA AGATCCTTTT TGATAATCTC ATGACCAAAA
     CTGGTTCAAA TGAGTATATA TGAAATCTAA CTAAATTTTG AAGTAAAAAT TAAATTTTCC TAGATCCACT TCTAGGAAAA ACTATTAGAG TACTGGTTTT

4101 TCCCTTAACG TGAGTTTTCG TTCCACTGAG CGTCAGACCC CGTAGAAAAG ATCAAAGGAT CTTCTTGAGA TCCTTTTTTT CTGCGCGTAA TCTGCTGCTT
     AGGGAATTGC ACTCAAAAGC AAGGTGACTC GCAGTCTGGG GCATCTTTTC TAGTTTCCTA GAAGAACTCT AGGAAAAAAA GACGCGCATT AGACGACGAA

4201 GCAAACAAAA AAACCACCGC TACCAGCGGT GGTTTGTTTG CCGGATCAAG AGCTACCAAC TCTTTTTCCG AAGGTAACTG GCTTCAGCAG AGCGCAGATA
     CGTTTGTTTT TTTGGTGGCG ATGGTCGCCA CCAAACAAAC GGCCTAGTTC TCGATGGTTG AGAAAAAGGC TTCCATTGAC CGAAGTCGTC TCGCGTCTAT

4301 CCAAATACTG TCCTTCTAGT GTAGCCGTAG TTAGGCCACC ACTTCAAGAA CTCTGTAGCA CCGCCTACAT ACCTCGCTCT GCTAATCCTG TTACCAGTGG
     GGTTTATGAC AGGAAGATCA CATCGGCATC AATCCGGTGG TGAAGTTCTT GAGACATCGT GGCGGATGTA TGGAGCGAGA CGATTAGGAC AATGGTCACC

4401 CTGCTGCCAG TGGCGATAAG TCGTGTCTTA CCGGGTTGGA CTCAAGACGA TAGTTACCGG ATAAGGCGCA GCGGTCGGGC TGAACGGGGG GTTCGTGCAC
     GACGACGGTC ACCGCTATTC AGCACAGAAT GGCCCAACCT GAGTTCTGCT ATCAATGGCC TATTCCGCGT CGCCAGCCCG ACTTGCCCCC CAAGCACGTG

4501 ACAGCCCAGC TTGGAGCGAA CGACCTACAC CGAACTGAGA TACCTACAGC GTGAGCATTG AGAAAGCGCC ACGCTTCCCG AAGGGAGAAA GGCGGACAGG
     TGTCGGGTCG AACCTCGCTT GCTGGATGTG GCTTGACTCT ATGGATGTCG CACTCGTAAC TCTTTCGCGG TGCGAAGGGC TTCCCTCTTT CCGCCTGTCC

4601 TATCCGGTAA GCGGCAGGGT CGGAACAGGA GAGCGCACGA GGGAGCTTCC AGGGGGAAAC GCCTGGTATC TTTATAGTCC TGTCGGGTTT CGCCACCTCT
     ATAGGCCATT CGCCGTCCCA GCCTTGTCCT CTCGCGTGCT CCCTCGAAGG TCCCCCTTTG CGGACCATAG AAATATCAGG ACAGCCCAAA GCGGTGGAGA

4701 GACTTGAGCG TCGATTTTTG TGATGCTCGT CAGGGGGGCG GAGCCTATGG AAAAACGCCA GCAACGCGGC CTTTTTACGG TTCCTGGCCT TTTGCTGGCC
     CTGAACTCGC AGCTAAAAAC ACTACGAGCA GTCCCCCCGC CTCGGATACC TTTTTGCGGT CGTTGCGCCG GAAAAATGCC AAGGACCGGA AAACGACCGG

4801 TTTTGCTCAC ATGTTCTTTC CTGCGTTATC CCCTGATTCT GTGGATAACC GTATTACCGC CTTTGAGTGA GCTGATACCG CTCGCCGCAG CCGAACGACC
     AAAACGAGTG TACAAGAAAG GACGCAATAG GGGACTAAGA CACCTATTGG CATAATGGCG GAAACTCACT CGACTATGGC GAGCGGCGTC GGCTTGCTGG

4901 GAGCGCAGCG AGTCAGTGAG CGAGGAAGCG GAAGAGCGCC CAATACGCAA ACCGCCTCTC CCCGCGCGTT GGCCGATTCA TTAATCCAGC TGGCACGACA
```

Figure 3-3

```
      CTCGCGTCGC TCAGTCACTC GCTCCTTCGC CTTCTCGCGG GTTATGCGTT TGGCGGAGAG GGGCGCGCAA CCGGCTAAGT AATTAGGTCG ACCGTGCTC

 5001 GGTTTCCCGA CTGGAAAGCG GGCAGTGAGC GCAACGCAAT TAATGTGAGT TACCTCACTC ATTAGGCACC CCAGGCTTTA CACTTTATGC TTCCGGCTC
      CCAAAGGGCT GACCTTTCGC CCGTCACTCG CGTTGCGTTA ATTACACTCA ATGGAGTGAG TAATCCGTGG GGTCCGAAAT GTGAAATACG AAGGCCGAG

 5101 TATGTTGTGT GGAATTGTGA GCGGATAACA ATTTCACACA GGAAACAGCT ATGACCATGA TTACGAATTA A
      ATACAACACA CCTTAACACT CGCCTATTGT TAAAGTGTGT CCTTTGTCGA TACTGGTACT AATGCTTAAT T

>length: 5171
```

Figure 3-4

Figure 4
pSV.IPD
length: 5712 (circular)

```
   1 TTCGAGCTCG CCCGACATTG ATTATTGACT AGAGTCGATC GACAGCTGTG GAATGTGTGT CAGTTAGGGT GTGGAAAGTC CCCAGGCTCC CCAGCAGGCA
     AAGCTCGAGC GGGCTGTAAC TAATAACTGA TCTCAGCTAG CTGTCGACAC CTTACACACA GTCAATCCCA CACCTTTCAG GGGTCCGAGG GGTCGTCCGT

 101 GAAGTATGCA AAGCATGCAT CTCAATTAGT CAGCAACCAG GTGTGGAAAG TCCCCAGGCT CCCCAGCAGG CAGAAGTATG CAAAGCATGC ATCTCAATTA
     CTTCATACGT TTCGTACGTA GAGTTAATCA GTCGTTGGTC CACACCTTTC AGGGGTCCGA GGGGTCGTCC GTCTTCATAC GTTTCGTACG TAGAGTTAAT

 201 GTCAGCAACC ATAGTCCCGC CCCTAACTCC GCCCATCCCG CCCCTAACTC CGCCCAGTTC CGCCCATTCT CCGCCCCATG GCTGACTAAT TTTTTTTATT
     CAGTCGTTGG TATCAGGGCG GGGATTGAGG CGGGTAGGGC GGGGATTGAG GCGGGTCAAG GCGGGTAAGA GGCGGGGTAC CGACTGATTA AAAAAAATAA

 301 TATGCAGAGG CCGAGGCCGC CTCGGCCTCT GAGCTATTCC AGAAGTAGTG AGGAGGCTTT TTTGGAGGCC TAGGCTTTTG CAAAAAGCTA GCTTATCCGG
     ATACGTCTCC GGCTCCGGCG GAGCCGGAGA CTCGATAAGG TCTTCATCAC TCCTCCGAAA AAACCTCCGG ATCCGAAAAC GTTTTTCGAT CGAATAGGCC

 401 CCGGGAACGG TGCATTGGAA CGCGGATTCC CCGTGCCAAG AGTGACGTAA GTACCGCCTA TAGAGCGACT AGTCCACCAT GACCGAGTAC AAGCCCACGC
     GGCCCTTGCC ACGTAACCTT GCGCCTAAGG GGCACGGTTC TCACTGCATT CATGGCGGAT ATCTCGCTGA TCAGGTGGTA CTGGCTCATG TTCGGGTGCG
                                          ^splice donor                                ^PUR
 501 TGCGCCTCGC CACCCGCGAC GACGTCCCGC GGGCCGTACG CACCCTCGCC GCCGCGTTCG CCGACTACCC CGCCACGCGC CACACCGTAG ACCCGGACCG
     ACGCGGAGCG GTGGGCGCTG CTGCAGGGCG CCCGGCATGC GTGGGAGCGG CGGCGCAAGC GGCTGATGGG GCGGTGCGCG GTGTGGCATC TGGGCCTGGC

 601 CCACATCGAG CGGGTCACCG AGCTGCAAGA ACTCTTCCTC ACGCGCGTCG GGCTCGACAT CGGCAAGGTG TGGGTCGCGG ACGACGGCGC CGCGGTGGCG
     GGTGTAGCTC GCCCAGTGGC TCGACGTTCT TGAGAAGGAG TGCGCGCAGC CCGAGCTGTA GCCGTTCCAC ACCCAGCGCC TGCTGCCGCG GCGCCACCGC

 701 GTCTGGACCA CGCCGGAGAG CGTCGAAGCG GGGGCGGTGT TCGCCGAGAT CGGCCCGCGC ATGGCCGAGT TGAGCGGTTC CCGGCTGGCC GCGCAGCAAC
     CAGACCTGGT GCGGCCTCTC GCAGCTTCGC CCCCGCCACA AGCGGCTCTA GCCGGGCGCG TACCGGCTCA ACTCGCCAAG GGCCGACCGG CGCGTCGTTG

 801 AGATGGAAGG CCTCCTGGCG CCGCACCGGC CCAAGGAGCC CGCGTGGTTC CTGGCCACCG TCGGCGTCTC GCCCGACCAC CAGGGCAAGG GTCTGGGCAG
     TCTACCTTCC GGAGGACCGC GGCGTGGCCG GGTTCCTCGG GCGCACCAAG GACCGGTGGC AGCCGCAGAG CGGGCTGGTG GTCCCGTTCC CAGACCCGTC

 901 CGCCGTCGTG CTCCCCGGAG TGGAGGCGGC CGAGCGCGCC GGGGTGCCCG CCTTCCTGGA GACCTCCGCG CCCCGCAACC TCCCCTTCTA CGAGCGGCTC
     GCGGCAGCAC GAGGGGCCTC ACCTCCGCCG GCTCGCGCGG CCCCACGGGC GGAAGGACCT CTGGAGGCGC GGGGCGTTGG AGGGGAAGAT GCTCGCCGAG

1001 GGCTTCACCG TCACCGCCGA CGTCGAGTGC CCGAAGGACC GCGCGACCTG GTGCATGACC CGCAAGCCCG GTGCCAACAT GGTTCGACCA TTGAACTGCA
     CCGAAGTGGC AGTGGCGGCT GCAGCTCACG GGCTTCCTGG CGCGCTGGAC CACGTACTGG GCGTTCGGGC CACGGTTGTA CCAAGCTGGT AACTTGACGT
                                                                                  ^DHFR ATG
1101 TCGTCGCCGT GTCCCAAAAT ATGGGGATTG GCAAGAACGG AGACCTACCC TGCCCTCCGC TCAGGAACGC GTTCAAGTAC TTCCAAAGAA TGACCACAAC
     AGCAGCGGCA CAGGGTTTTA TACCCCTAAC CGTTCTTGCC TCTGGATGGG ACGGGAGGCG AGTCCTTGCG CAAGTTCATG AAGGTTTCTT ACTGGTGTTG

1201 CTCTTCAGTG GAAGGTAAAC AGAATCTGGT GATTATGGGT AGGAAAACCT GGTTCTCCAT TCCTGAGAAG AATCGACCTT TAAAGGACAG AATTAATATA
     GAGAAGTCAC CTTCCATTTG TCTTAGACCA CTAATACCCA TCCTTTTGGA CCAAGAGGTA AGGACTCTTC TTAGCTGGAA ATTTCCTGTC TTAATTATAT

1301 GTTCTCAGTA GAGAACTCAA AGAACCACCA CGAGGAGCTC ATTTTCTTGC CAAAAGTTTG GATGATGCCT TAAGACTTAT TGAACAACCG GAATTGGTAA
     CAAGAGTCAT CTCTTGAGTT TCTTGGTGGT GCTCCTCGAG TAAAAGAACG GTTTTCAAAC CTACTACGGA ATTCTGAATA ACTTGTTGGC CTTAACCGTT

1401 GTAAAGTAGA CATGGTTTGG ATAGTCGGAG GCAGTTCTGT TTACCAGGAA GCCATGAATC AACCAGGCCA CCTTAGACTC TTTGTGACAA GGATCATGCA
     CATTTCATCT GTACCAAACC TATCAGCCTC CGTCAAGACA AATGGTCCTT CGGTACTTAG TTGGTCCGGT GGAATCTGAG AAACACTGTT CCTAGTACGT

1501 GGAATTTGAA AGTGACACGT TTTTCCCAGA AATTGATTTG GGGAAATATA AACCTCTCCC AGAATACCCA GGCGTCCTCT CTGAGGTCCA GGAGGAAAAA
```

Figure 4-1

```
      CCTTAAACTT TCACTGTGCA AAAAGGGTCT TTAACTAAAC CCCTTTATAT TTGGAGAGGG TCTTATGGGT CCGCAGGAGA GACTCCAGGT CCTCCTTTTT

1601  GGCATCAAGT ATAAGTTTGA AGTCTACGAG AAGAAAGACT AACGTTAACT GCTCCCCTCC TAAAGCTATG CATTTTTATA AGACCATGGG ACTTTTGCTG
      CCGTAGTTCA TATTCAAACT TCAGATGCTC TTCTTTCTGA TTGCAATTGA CGAGGGGAGG ATTTCGATAC GTAAAAATAT TCTGGTACCC TGAAAACGAC
                                                  ^End DHFR
1701  GCTTTAGATC CCCTTGGCTT CGTTAGAACG CAGCTACAAT TAATACATAA CCTTATGTAT CATACACATA CGATTTAGGT GACACTATAG ATAACATCCA
      CGAAATCTAG GGGAACCGAA GCAATCTTGC GTCGATGTTA ATTATGTATT GGAATACATA GTATGTGTAT GCTAAATCCA CTGTGATATC TATTGTAGGT

1801  CTTTGCCTTT CTCTCCACAG GTGTCCACTC CCAGGTCCAA CTGCACCTCG GTTCTATCGA TTGAATTCCC CGGGGATCCT CTAGACTCGA CCTGCAGAAG
      GAAACGGAAA GAGAGGTGTC CACAGGTGAG GGTCCAGGTT GACGTGGAGC CAAGATAGCT AACTTAAGGG GCCCCTAGGA GATCTGAGCT GGACGTCTTC

1901  CTTCGATGGC CGCCATGGCC CAACTTGTTT ATTGCAGCTT ATAATGGTTA CAAATAAAGC AATAGCATCA CAAATTTCAC AAATAAAGCA TTTTTTTCAC
      GAAGCTACCG GCGGTACCGG GTTGAACAAA TAACGTCGAA TATTACCAAT GTTTATTTCG TTATCGTAGT GTTTAAAGTG TTTATTTCGT AAAAAAAGTG

2001  TGCATTCTAG TTGTGGTTTG TCCAAACTCA TCAATGTATC TTATCATGTC TGGATCGATC GGGAATTAAT TCGGCGCAGC ACCATGGCCT GAAATAACCT
      ACGTAAGATC AACACCAAAC AGGTTTGAGT AGTTACATAG AATAGTACAG ACCTAGCTAG CCCTTAATTA AGCCGCGTCG TGGTACCGGA CTTTATTGGA

2101  CTGAAAGAGG AACTTGGTTA GGTACCTTCT GAGGCGGAAA GAACCAGCTG TGGAATGTGT GTCAGTTAGG GTGTGGAAAG TCCCCAGGCT CCCCAGCAGG
      GACTTTCTCC TTGAACCAAT CCATGGAAGA CTCCGCCTTT CTTGGTCGAC ACCTTACACA CAGTCAATCC CACACCTTTC AGGCGTCCGA GGGGTCGTCC

2201  CAGAAGTATG CAAAGCATGC ATCTCAATTA GTCAGCAACC AGGTGTGGAA AGTCCCCAGG CTCCCCAGCA GGCAGAAGTA TGCAAAGCAT GCATCTCAAT
      GTCTTCATAC GTTTCGTACG TAGAGTTAAT CAGTCGTTGG TCCACACCTT TCAGGGGTCC GAGGGGTCGT CCGTCTTCAT ACGTTTCGTA CGTAGAGTTA

2301  TAGTCAGCAA CCATAGTCCC GCCCCTAACT CCGCCCATCC CGCCCCTAAC TCCGCCCAGT TCCGCCCATT CTCCGCCCCA TGGCTGACTA ATTTTTTTTA
      ATCAGTCGTT GGTATCAGGG CGGGGATTGA GGCGGGTAGG GCGGGGATTG AGGCGGGTCA AGGCGGGTAA GAGGCGGGGT ACCGACTGAT TAAAAAAAAT

2401  TTTATGCAGA GGCCGAGGCC GCCTCGGCCT CTGAGCTATT CCAGAAGTAG TGAGGAGGCT TTTTTGGAGG CCTAGGCTTT TGCAAAAAGC TGTTACCTCG
      AAATACGTCT CCGGCTCCGG CGGAGCCGGA GACTCGATAA GGTCTTCATC ACTCCTCCGA AAAAACCTCC GGATCCGAAA ACGTTTTTCG ACAATGGAGC

2501  AGCGGCCGCT TAATTAAGGC GCGCCATTTA AATCCTGCAG GTAACAGCTT GGCACTGGCC GTCGTTTTAC AACGTCGTGA CTGGGAAAAC CCTGGCGTTA
      TCGCCGGCGA ATTAATTCCG CGCGGTAAAT TTAGGACGTC CATTGTCGAA CCGTGACCGG CAGCAAAATG TTGCAGCACT GACCCTTTTG GGACCGCAAT

2601  CCCAACTTAA TCGCCTTGCA GCACATCCCC CCTTCGCCAG CTGGCGTAAT AGCGAAGAGG CCCGCACCGA TCGCCCTTCC CAACAGTTGC GTAGCCTGAA
      GGGTTGAATT AGCGGAACGT CGTGTAGGGG GGAAGCGGTC GACCGCATTA TCGCTTCTCC GGGCGTGGCT AGCGGGAAGG GTTGTCAACG CATCGGACTT

2701  TGGCGAATGG CGCCTGATGC GGTATTTTCT CCTTACGCAT CTGTGCGGTA TTTCACACCG CATACGTCAA AGCAACCATA GTACGCGCCC TGTAGCGGCG
      ACCGCTTACC GCGGACTACG CCATAAAAGA GGAATGCGTA GACACGCCAT AAAGTGTGGC GTATGCAGTT TCGTTGGTAT CATGCGCGGG ACATCGCCGC

2801  CATTAAGCGC GGCGGGTGTG GTGGTTACGC GCAGCGTGAC CGCTACACTT GCCAGCGCCC TAGCGCCCGC TCCTTTCGCT TTCTTCCCTT CCTTTCTCGC
      GTAATTCGCG CCGCCCACAC CACCAATGCG CGTCGCACTG GCGATGTGAA CGGTCGCGGG ATCGCGGGCG AGGAAAGCGA AAGAAGGGAA GGAAAGAGCG

2901  CACGTTCGCC GGCTTTCCCC GTCAAGCTCT AAATCGGGGG CTCCCTTTAG GGTTCCGATT TAGTGCTTTA CGGCACCTCG ACCCCAAAAA ACTTGATTTG
      GTGCAAGCGG CCGAAAGGGG CAGTTCGAGA TTTAGCCCCC GAGGGAAATC CCAAGGCTAA ATCACGAAAT GCCGTGGAGC TGGGGTTTTT TGAACTAAAC

3001  GGTGATGGTT CACGTAGTGG GCCATCGCCC TGATAGACGG TTTTTCGCCC TTTGACGTTG GAGTCCACGT TCTTTAATAG TGGACTCTTG TTCCAAACTG
      CCACTACCAA GTGCATCACC CGGTAGCGGG ACTATCTGCC AAAAAGCGGG AAACTGCAAC CTCAGGTGCA AGAAATTATC ACCTGAGAAC AAGGTTTGAC

3101  GAACAACACT CAACCCTATC TCGGGCTATT CTTTTGATTT ATAAGGGATT TTGCCGATTT CGGCCTATTG GTTAAAAAAT GAGCTGATTT AACAAAAATT
      CTTGTTGTGA GTTGGGATAG AGCCCGATAA GAAAACTAAA TATTCCCTAA AACGGCTAAA GCCGGATAAC CAATTTTTTA CTCGACTAAA TTGTTTTTAA

3201  TAACGCGAAT TTTAACAAAA TATTAACGTT TACAATTTTA TGGTGCACTC TCAGTACAAT CTGCTCTGAT GCCGCATAGT TAAGCCAACT CCGCTATCGC
      ATTGCGCTTA AAATTGTTTT ATAATTGCAA ATGTTAAAAT ACCACGTGAG AGTCATGTTA GACGAGACTA CGGCGTATCA ATTCGGTTGA GGCGATAGCG
```

Figure 4-2

```
3301 TACGTGACTG GGTCATGGCT GCGCCCCGAC ACCCGCCAAC ACCCGCTGAC GCGCCCTGAC GCGCTTGTCT GCTCCCCGCA TCCGCTTACA GACAAGCTGT
     ATGCACTGAC CCAGTACCGA CGCGGGGCTG TGGGCGGTTG TGGGCGACTG CGCGGGACTG CCCGAACAGA CGAGGGCCGT AGGCGAATGT CTGTTCGACA

3401 GACCGTCTCC GGGAGCTGCA TGTGTCAGAG GTTTTCACCG TCATCACCGA AACGCGCGAG GCAGTATTCT TGAAGACGAA AGGGCCTCGT GATACGCCTA
     CTGGCAGAGG CCCTCGACGT ACACAGTCTC CAAAAGTGGC AGTAGTGGCT TTGCGCGCTC CGTCATAAGA ACTTCTGCTT TCCCGGAGCA CTATGCGGAT

3501 TTTTTATAGG TTAATGTCAT GATAATAATG GTTTCTTAGA CGTCAGGTGG CACTTTTCGG GGAAATGTGC GCGGAACCCC TATTTGTTTA TTTTTCTAAA
     AAAAATATCC AATTACAGTA CTATTATTAC CAAAGAATCT GCAGTCCACC GTGAAAAGCC CCTTTACACG CGCCTTGGGG ATAAACAAAT AAAAAGATTT


3601 TACATTCAAA TATGTATCCG CTCATGAGAC AATAACCCTG ATAAATGCTT CAATAATATT GAAAAAGGAA GAGTATGAGT ATTCAACATT TCCGTGTCGC
     ATGTAAGTTT ATACATAGGC GAGTACTCTG TTATTGGGAC TATTTACGAA GTTATTATAA CTTTTTCCTT CTCATACTCA TAAGTTGTAA AGGCACAGCG

3701 CCTTATTCCC TTTTTTGCGG CATTTTGCCT TCCTGTTTTT GCTCACCCAG AAACGCTGGT GAAAGTAAAA GATGCTGAAG ATCAGTTGGG TGCACGAGTG
     GGAATAAGGG AAAAAACGCC GTAAAACGGA AGGACAAAAA CGAGTGGGTC TTTGCGACCA CTTTCATTTT CTACGACTTC TAGTCAACCC ACGTGCTCAC

3801 GGTTACATCG AACTGGATCT CAACAGCGGT AAGATCCTTG AGAGTTTTCG CCCCGAAGAA CGTTTTCCAA TGATGAGCAC TTTTAAAGTT CTGCTATGTG
     CCAATGTAGC TTGACCTAGA GTTGTCGCCA TTCTAGGAAC TCTCAAAAGC GGGGCTTCTT GCAAAAGGTT ACTACTCGTG AAAATTTCAA GACGATACAC

3901 GCGCGGTATT ATCCCGTGAT GACGCCGGGC AAGAGCAACT CGGTCGCCGC ATACACTATT CTCAGAATGA CTTGGTTGAG TACTCACCAG TCACAGAAAA
     CGCGCCATAA TAGGGCACTA CTGCGGCCCG TTCTCGTTGA GCCAGCGGCG TATGTGATAA GAGTCTTACT GAACCAACTC ATGAGTGGTC AGTGTCTTTT

4001 GCATCTTACG GATGGCATGA CAGTAAGAGA ATTATGCAGT GCTGCCATAA CCATGAGTGA TAACACTGCG GCCAACTTAC TTCTGACAAC GATCGGAGGA
     CGTAGAATGC CTACCGTACT GTCATTCTCT TAATACGTCA CGACGGTATT GGTACTCACT ATTGTGACGC CGGTTGAATG AAGACTGTTG CTAGCCTCCT

4101 CCGAAGGAGC TAACCGCTTT TTTGCACAAC ATGGGGGATC ATGTAACTCG CCTTGATCGT TGGGAACCGG AGCTGAATGA AGCCATACCA AACGACGAGC
     GGCTTCCTCG ATTGGCGAAA AAACGTGTTG TACCCCCTAG TACATTGAGC GGAACTAGCA ACCCTTGGCC TCGACTTACT TCGGTATGGT TTGCTGCTCG

4201 GTGACACCAC GATGCCAGCA GCAATGGCAA CAACGTTGCG CAAACTATTA ACTGGCGAAC TACTTACTCT AGCTTCCCGG CAACAATTAA TAGACTGGAT
     CACTGTGGTG CTACGGTCGT CGTTACCGTT GTTGCAACGC GTTTGATAAT TGACCGCTTG ATGAATGAGA TCGAAGGGCC GTTGTTAATT ATCTGACCTA

4301 GGAGGCGGAT AAAGTTGCAG GACCACTTCT GCGCTCGGCC CTTCCGGCTG GCTGGTTTAT TGCTGATAAA TCTGGAGCCG GTGAGCGTGG GTCTCGCGGT
     CCTCCGCCTA TTTCAACGTC CTGGTGAAGA CGCGAGCCGG GAAGGCCGAC CGACCAAATA ACGACTATTT AGACCTCGGC CACTCGCACC CAGAGCGCCA

4401 ATCATTGCAG CACTGGGGCC AGATGGTAAG CCCTCCCGTA TCGTAGTTAT CTACACGACG GGGAGTCAGG CAACTATGGA TGAACGAAAT AGACAGATCG
     TAGTAACGTC GTGACCCCGG TCTACCATTC GGGAGGGCAT AGCATCAATA GATGTGCTGC CCCTCAGTCC GTTGATACCT ACTTGCTTTA TCTGTCTAGC

4501 CTGAGATAGG TGCCTCACTG ATTAAGCATT GGTAACTGTC AGACCAAGTT TACTCATATA TACTTTAGAT TCATTTAAAA CTTCATTTTT AATTTAAAAG
     GACTCTATCC ACGGAGTGAC TAATTCGTAA CCATTGACAG TCTGGTTCAA ATGAGTATAT ATGAAATCTA ACTAAATTTT GAAGTAAAAA TTAAATTTTC

4601 GATCTAGGTG AAGATCCTTT TTGATAATCT CATGACCAAA ATCCCTTAAC GTGAGTTTTC GTTCCACTGA GCGTCAGACC CCGTAGAAAA GATCAAAGGA
     CTAGATCCAC TTCTAGGAAA AACTATTAGA GTACTGGTTT TAGGGAATTG CACTCAAAAG CAAGGTGACT CGCAGTCTGG GGCATCTTTT CTAGTTTCCT

4701 TCTTCTTGAG ATCCTTTTTT TCTGCGCGTA ATCTGCTGCT TGCAAACAAA AAAACCACCG CTACCAGCGG TGGTTTGTTT GCCGGATCAA GAGCTACCAA
     AGAAGAACTC TAGGAAAAAA AGACGCGCAT TAGACGACGA ACGTTTGTTT TTTTGGTGGC GATGGTCGCC ACCAAACAAA CGGCCTAGTT CTCGATGGTT

4801 CTCTTTTTCC GAAGGTAACT GGCTTCAGCA GAGCGCAGAT ACCAAATACT GTCCTTCTAG TGTAGCCGTA GTTAGGCCAC CACTTCAAGA ACTCTGTAGC
     GAGAAAAAGG CTTCCATTGA CCGAAGTCGT CTCGCGTCTA TGGTTTATGA CAGGAAGATC ACATCGGCAT CAATCCGGTG GTGAAGTTCT TGAGACATCG

4901 ACCGCCTACA TACCTCGCTC TGCTAATCCT GTTACCAGTG GCTGCTGCCA GTGGCGATAA GTCGTGTCTT ACCGGGTTGG ACTCAAGACG ATAGTTACCG
     TGGCGGATGT ATGGAGCGAG ACGATTAGGA CAATGGTCAC CGACGACGGT CACCGCTATT CAGCACAGAA TGGCCCAACC TGAGTTCTGC TATCAATGGC

5001 GATAAGGCGC AGCGGTCGGG CTGAACGGGG GGTTCGTGCA CACAGCCCAG CTTGGAGCGA ACGACCTACA CCGAACTGAG ATACCTACAG CGTGAGCATT
```

Figure 4-3

```
     CTATTCCGCG TCGCCAGCCC GACTTGCCCC CCAAGCACGT GTGTCGGGTC GAACCTCGCT TGCTGGATGT GGCTTGACTC TATGGATGTC GCACTCGTAA

5101 GAGAAAGCGC CACGCTTCCC GAAGGGAGAA AGGCGGACAG GTATCCGGTA AGCGGCAGGG TCGGAACAGG AGAGCGCACG AGGGAGCTTC CAGGGGGAAA
     CTCTTTCGCG GTGCGAAGGG CTTCCCTCTT TCCGCCTGTC CATAGGCCAT TCGCCGTCCC AGCCTTGTCC TCTCGCGTGC TCCCTCGAAG GTCCCCCTTT

5201 CGCCTGGTAT CTTTATAGTC CTGTCGGGTT TCGCCACCTC TGACTTGAGC GTCGATTTTT GTGATGCTCG TCAGGGGGGC GGAGCCTATG GAAAAACGCC
     GCGGACCATA GAAATATCAG GACAGCCCAA AGCGGTGGAG ACTGAACTCG CAGCTAAAAA CACTACGAGC AGTCCCCCCG CCTCGGATAC CTTTTTGCGG

5301 AGCAACGCGG CCTTTTTACG GTTCCTGGCC TTTTGCTGGC CTTTTGCTCA CATGTTCTTT CCTGCGTTAT CCCCTGATTC TGTGGATAAC CGTATTACCG
     TCGTTGCGCC GGAAAAATGC CAAGGACCGG AAAACGACCG GAAAACGAGT GTACAAGAAA GGACGCAATA GGGGACTAAG ACACCTATTG GCATAATGGC

5401 CCTTTGAGTG AGCTGATACC GCTCGCCGCA GCCGAACGAC CGAGCGCAGC GAGTCAGTGA GCGAGGAAGC GGAAGAGCGC CCAATACGCA AACCGCCTCT
     GGAAACTCAC TCGACTATGG CGAGCGGCGT CGGCTTGCTG GCTCGCGTCG CTCAGTCACT CGCTCCTTCG CCTTCTCGCG GGTTATGCGT TTGGCGGAGA

5501 CCCCGCGCGT TGGCCGATTC ATTAATCCAG CTGGCACGAC AGGTTTCCCG ACTGGAAAGC GGGCAGTGAG CGCAACGCAA TTAATGTGAG TTACCTCACT
     GGGGCGCGCA ACCGGCTAAG TAATTAGGTC GACCGTGCTG TCCAAAGGGC TGACCTTTCG CCCGTCACTC GCGTTGCGTT AATTACACTC AATGGAGTGA

5601 CATTAGGCAC CCCAGGCTTT ACACTTTATG CTTCCGGCTC GTATGTTGTG TGGAATTGTG AGCGGATAAC AATTTCACAC AGGAAACAGC TATGACCATG
     GTAATCCGTG GGGTCCGAAA TGTGAAATAC GAAGGCCGAG CATACAACAC ACCTTAACAC TCGCCTATTG TTAAAGTGTG TCCTTTGTCG ATACTGGTAC

5701 ATTACGAATT AA
     TAATGCTTAA TT

>length: 5712
```

Figure 4-4



Figure 5. pSV.ID.aVEGF control plasmid



Figure 6. pSV.IPD.2C4

Figure 7
pSV.IPD.2C4
length: 12514 (circular)

```
   1 TTCGAGCTCG CCCGACATTG ATTATTGACT AGAGTCGATC GACAGCTGTG GAATGTGTGT CAGTTAGGGT GTGGAAAGTC CCCAGGCTCC CCAGCAGGCA
     AAGCTCGAGC GGGCTGTAAC TAATAACTGA TCTCAGCTAG CTGTCGACAC CTTACACACA GTCAATCCCA CACCTTTCAG GGGTCCGAGG GGTCGTCCGT

 101 GAAGTATGCA AAGCATGCAT CTCAATTAGT CAGCAACCAG GTGTGGAAAG TCCCCAGGCT CCCCAGCAGG CAGAAGTATG CAAAGCATGC ATCTCAATTA
     CTTCATACGT TTCGTACGTA GAGTTAATCA GTCGTTGGTC CACACCTTTC AGGGGTCCGA GGGGTCGTCC GTCTTCATAC GTTTCGTACG TAGAGTTAAT

 201 GTCAGCAACC ATAGTCCCGC CCCTAACTCC GCCCATCCCG CCCCTAACTC CGCCCAGTTC CGCCCATTCT CCGCCCCATG GCTGACTAAT TTTTTTTATT
     CAGTCGTTGG TATCAGGGCG GGGATTGAGG CGGGTAGGGC GGGGATTGAG GCGGGTCAAG GCGGGTAAGA GGCGGGGTAC CGACTGATTA AAAAAAATAA

 301 TATGCAGAGG CCGAGGCCGC CTCGGCCTCT GAGCTATTCC AGAAGTAGTG AGGAGGCTTT TTTGGAGGCC TAGGCTTTTG CAAAAAGCTA GCTTATCCGG
     ATACGTCTCC GGCTCCGGCG GAGCCGGAGA CTCGATAAGG TCTTCATCAC TCCTCCGAAA AAACCTCCGG ATCCGAAAAC GTTTTTCGAT CGAATAGGCC

 401 CCGGGAACGG TGCATTGGAA CGCGGATTCC CCGTGCCAAG AGTGACGTAA GTACCGCCTA TAGAGCGACT AGTCCACCAT GACCGAGTAC AAGCCCACGG
     GGCCCTTGCC ACGTAACCTT GCGCCTAAGG GGCACGGTTC TCACTGCATT CATGGCGGAT ATCTCGCTGA TCAGGTGGTA CTGGCTCATG TTCGGGTGCC
                                                ^splice donor                                  ^Start PUR coding
 501 TGCGCCTCGC CACCCGCGAC GACGTCCCGC GGGCCGTACG CACCCTCGCC GCCGCGTTCG CCGACTACCC CGCCACGCGC CACACCGTAG ACCCGGACCG
     ACGCGGAGCG GTGGGCGCTG CTGCAGGGCG CCCGGCATGC GTGGGAGCGG CGGCGCAAGC GGCTGATGGG GCGGTGCGCG GTGTGGCATC TGGGCCTGGC

 601 CCACATCGAG CGGGTCACCG AGCTGCAAGA ACTCTTCCTC ACGCGCGTCG GGCTCGACAT CGGCAAGGTG TGGGTCGCGG ACGACGGCGC CGCGGTGGCG
     GGTGTAGCTC GCCCAGTGGC TCGACGTTCT TGAGAAGGAG TGCGCGCAGC CCGAGCTGTA GCCGTTCCAC ACCCAGCGCC TGCTGCCGCG GCGCCACCGC

 701 GTCTGGACCA CGCCGGAGAG CGTCGAAGCG GGGGCGGTGT TCGCCGAGAT CGGCCCGCGC ATGGCCGAGT TGAGCGGTTC CCGGCTGGCC GCGCAGCAAC
     CAGACCTGGT GCGGCCTCTC GCAGCTTCGC CCCCGCCACA AGCGGCTCTA GCCGGGCGCG TACCGGCTCA ACTCGCCAAG GGCCGACCGG CGCGTCGTTG

 801 AGATGGAAGG CCTCCTGGCG CCGCACCGGC CCAAGGAGCC CGCGTGGTTC CTGGCCACCG TCGGCGTCTC GCCCGACCAC CAGGGCAAGG GTCTGGGCAG
     TCTACCTTCC GGAGGACCGC GGCGTGGCCG GGTTCCTCGG GCGCACCAAG GACCGGTGGC AGCCGCAGAG CGGGCTGGTG GTCCCGTTCC CAGACCCGTC

 901 CGCCGTCGTG CTCCCCGGAG TGGAGGCGGC CGAGCGCGCC GGGGTGCCCG CCTTCCTGGA GACCTCCGCG CCCCGCAACC TCCCCTTCTA CGAGCGGCTC
     GCGGCAGCAC GAGGGGCCTC ACCTCCGCCG GCTCGCGCGG CCCCACGGGC GGAAGGACCT CTGGAGGCGC GGGGCGTTGG AGGGGAAGAT GCTCGCCGAG

1001 GGCTTCACCG TCACCGCCGA CGTCGAGTGC CCGAAGGACC GCGCGACCTG GTGCATGACC CGCAAGCCCG GTGCCAACAT GGTTCGACCA TTGAACTGCA
     CCGAAGTGGC AGTGGCGGCT GCAGCTCACG GGCTTCCTGG CGCGCTGGAC CACGTACTGG CGGTTCGGGC CACGGTTGTA CCAAGCTGGT AACTTGACGT
                                                                                    ^Start DHFR coding
1101 TCGTCGCCGT GTCCCAAAAT ATGGGGATTG GCAAGAACGG AGACCTACCC TGCCCTCCGC TCAGGAACGC GTTCAAGTAC TTCCAAAGAA TGACCACAAG
     AGCAGCGGCA CAGGGTTTTA TACCCCTAAC CGTTCTTGCC TCTGGATGGG ACGGGAGGCG AGTCCTTGCG CAAGTTCATG AAGGTTTCTT ACTGGTGTTC

1201 CTCTTCAGTG GAAGGTAAAC AGAATCTGGT GATTATGGGT AGGAAAACCT GGTTCTCCAT TCCTGAGAAG AATCGACCTT TAAAGGACAG AATTAATATA
     GAGAAGTCAC CTTCCATTTG TCTTAGACCA CTAATACCCA TCCTTTTGGA CCAAGAGGTA AGGACTCTTC TTAGCTGGAA ATTTCCTGTC TTAATTATAT

1301 GTTCTCAGTA GAGAACTCAA AGAACCACCA CGAGGAGCTC ATTTTCTTGC CAAAAGTTTG GATGATGCCT TAAGACTTAT TGAACAACCG GAATTGGCAA
     CAAGAGTCAT CTCTTGAGTT TCTTGGTGGT GCTCCTCGAG TAAAAGAACG GTTTTCAAAC CTACTACGGA ATTCTGAATA ACTTGTTGGC CTTAACCGTT

1401 GTAAAGTAGA CATGGTTTGG ATAGTCGGAG GCAGTTCTGT TTACCAGGAA GCCATGAATC AACCAGGCCA CCTTAGACTC TTTGTGACAA GGATCATGTA
     CATTTCATCT GTACCAAACC TATCAGCCTC CGTCAAGACA AATGGTCCTT CGGTACTTAG TTGGTCCGGT GGAATCTGAG AAACACTGTT CCTAGTACGT

1501 GGAATTTGAA AGTGACACGT TTTTCCCAGA AATTGATTTG GGGAAATATA AACCTCTCCC AGAATACCCA GGCGTCCTCT CTGAGGTCCA GGAGGAAAAA
```

Figure 7-1

```
      CCTTAAACTT TCACTGTGCA AAAAGGGTCT TTAACTAAAC CCCTTTATAT TTGGAGAGGG TCTTATGGGT CCGCAGGAGA GACTCCAGGT CCTCCTTTTT

1601  GGCATCAAGT ATAAGTTTGA AGTCTACGAG AAGAAAGACT AACGTTAACT GCTCCCCTCC TAAAGCTATG CATTTTTATA AGACCATGGG ACTTTTGCTG
      CCGTAGTTCA TATTCAAACT TCAGATGCTC TTCTTTCTGA TTGCAATTGA CGAGGGGAGG ATTTCGATAC GTAAAAATAT TCTGGTACCC TGAAAACGAC
                                                 ^End DHFR
1701  GCTTTAGATC CCCTTGGCTT CGTTAGAACG CAGCTACAAT TAATACATAA CCTTATGTAT CATACACATA CGATTTAGGT GACACTATAG AATAACATCC
      CGAAATCTAG GGGAACCGAA GCAATCTTGC GTCGATGTTA ATTATGTATT GGAATACATA GTATGTGTAT GCTAAATCCA CTGTGATATC TTATTGTAGG

1801  ACTTTGCCTT TCTCTCCACA GGTGTCCACT CCCAGGTCCA ACTGCACCTC GGTTCTATCG ATTGAATTCC ACCATGGGAT GGTCATGTAT CATCCTTTTT
      TGAAACGGAA AGAGAGGTGT CCACAGGTGA GGGTCCAGGT TGACGTGGAG CCAAGATAGC TAACTTAAGG TGGTACCCTA CCAGTACATA GTAGGAAAAA
                                                                                          ^Start 2C4 HCcoding
1901  CTAGTAGCAA CTGCAACTGG AGTACATTCA GAAGTTCAGC TGGTGGAGTC TGGCGGTGGC CTGGTGCAGC CAGGGGGCTC ACTCCGTTTG TCCTGTGCAG
      GATCATCGTT GACGTTGACC TCATGTAAGT CTTCAAGTCG ACCACCTCAG ACCGCCACCG GACCACGTCG GTCCCCCGAG TGAGGCAAAC AGGACACGTC

2001  CTTCTGGCTT CACCTTCACC GACTATACCA TGGACTGGGT CCGTCAGGCC CCGGGTAAGG GCCTGGAATG GGTTGCAGAT GTTAATCCTA ACAGTGGCGG
      GAAGACCGAA GTGGAAGTGG CTGATATGGT ACCTGACCCA GGCAGTCCGG GGCCCATTCC CGGACCTTAC CCAACGTCTA CAATTAGGAT TGTCACCGCC

2101  CTCTATCTAT AACCAGCGCT TCAAGGGCCG TTTCACTCTG AGTGTTGACA GATCTAAAAA CACATTATAC CTGCAGATGA ACAGCCTGCG TGCTGAGGAC
      GAGATAGATA TTGGTCGCGA AGTTCCCGGC AAAGTGAGAC TCACAACTGT CTAGATTTTT GTGTAATATG GACGTCTACT TGTCGGACGC ACGACTCCTG

2201  ACTGCCGTCT ATTATTGTGC TCGTAACCTG GGACCCTCTT TCTACTTTGA CTACTGGGGT CAAGGAACCC TGGTCACCGT CTCCTCGGCC TCCACCAAGG
      TGACGGCAGA TAATAACACG AGCATTGGAC CCTGGGAGAA AGATGAAACT GATGACCCCA GTTCCTTGGG ACCAGTGGCA GAGGAGCCGG AGGTGGTTCC

2301  GCCCATCGGT CTTCCCCCTG GCACCCTCCT CCAAGAGCAC CTCTGGGGGC ACAGCGGCCC TGGGCTGCCT GGTCAAGGAC TACTTCCCCG AACCGGTGAC
      CGGGTAGCCA GAAGGGGGAC CGTGGGAGGA GGTTCTCGTG GAGACCCCCG TGTCGCCGGG ACCCGACGGA CCAGTTCCTG ATGAAGGGGC TTGGCCACTG

2401  GGTGTCGTGG AACTCAGGCG CCCTGACCAG CGGCGTGCAC ACCTTCCCGG CTGTCCTACA GTCCTCAGGA CTCTACTCCC TCAGCAGCGT GGTGACTGTG
      CCACAGCACC TTGAGTCCGC GGGACTGGTC GCCGCACGTG TGGAAGGGCC GACAGGATGT CAGGAGTCCT GAGATGAGGG AGTCGTCGCA CCACTGACAC

2501  CCCTCTAGCA GCTTGGGCAC CCAGACCTAC ATCTGCAACG TGAATCACAA GCCCAGCAAC ACCAAGGTGG ACAAGAAAGT TGAGCCCAAA TCTTGTGACA
      GGGAGATCGT CGAACCCGTG GGTCTGGATG TAGACGTTGC ACTTAGTGTT CGGGTCGTTG TGGTTCCACC TGTTCTTTCA ACTCGGGTTT AGAACACTGT

2601  AAACTCACAC ATGCCCACCG TGCCCAGCAC CTGAACTCCT GGGGGGACCG TCAGTCTTCC TCTTCCCCCC AAAACCCAAG GACACCCTCA TGATCTCCCG
      TTTGAGTGTG TACGGGTGGC ACGGGTCGTG GACTTGAGGA CCCCCCTGGC AGTCAGAAGG AGAAGGGGGG TTTTGGGTTC CTGTGGGAGT ACTAGAGGGC

2701  GACCCCTGAG GTCACATGCG TGGTGGTGGA CGTGAGCCAC GAAGACCCTG AGGTCAAGTT CAACTGGTAC GTGGACGGCG TGGAGGTGCA TAATGCCAAG
      CTGGGGACTC CAGTGTACGC ACCACCACCT GCACTCGGTG CTTCTGGGAC TCCAGTTCAA GTTGACCATG CACCTGCCGC ACCTCCACGT ATTACGGTTC

2801  ACAAAGCCGC GGGAGGAGCA GTACAACAGC ACGTACCGGG TGGTCAGCGT CCTCACCGTC CTGCACCAGG ACTGGCTGAA TGGCAAGGAG TACAAGTGCA
      TGTTTCGGCG CCCTCCTCGT CATGTTGTCG TGCATGGCCC ACCAGTCGCA GGAGTGGCAG GACGTGGTCC TGACCGACTT ACCGTTCCTC ATGTTCACGT

2901  AGGTCTCCAA CAAAGCCCTC CCAGCCCCCA TCGAGAAAAC CATCTCCAAA GCCAAAGGGC AGCCCCGAGA ACCACAGGTG TACACCCTGC CCCCATCCCG
      TCCAGAGGTT GTTTCGGGAG GGTCGGGGGT AGCTCTTTTG GTAGAGGTTT CGGTTTCCCG TCGGGGCTCT TGGTGTCCAC ATGTGGGACG GGGGTAGGGC

3001  GGAAGAGATG ACCAAGAACC AGGTCAGCCT GACCTGCCTG GTCAAAGGCT TCTATCCCAG CGACATCGCC GTGGAGTGGG AGAGCAATGG GCAGCCGGAG
      CCTTCTCTAC TGGTTCTTGG TCCAGTCGGA CTGGACGGAC CAGTTTCCGA AGATAGGGTC GCTGTAGCGG CACCTCACCC TCTCGTTACC CGTCGGCCTC

3101  AACAACTACA AGACCACGCC TCCCGTGCTG GACTCCGACG GCTCCTTCTT CCTCTACAGC AAGCTCACCG TGGACAAGAG CAGGTGGCAG CAGGGGAACG
      TTGTTGATGT TCTGGTGCGG AGGGCACGAC CTGAGGCTGC CGAGGAAGAA GGAGATGTCG TTCGAGTGGC ACCTGTTCTC GTCCACCGTC GTCCCCTTGC

3201  TCTTCTCATG CTCCGTGATG CATGAGGCTC TGCACAACCA CTACACGCAG AAGAGCCTCT CCCTGTCTCC GGGTAAATGA GTGCGACGGC CCTAGAGTCG
      AGAAGAGTAC GAGGCACTAC GTACTCCGAG ACGTGTTGGT GATGTGCGTC TTCTCGGAGA GGGACAGAGG CCCATTTACT CACGCTGCCG GGATCTCAGC
```

Figure 7-2

```
3301 ACCTGCAGAA GCTTCGATGG CCGCCATGGC CCAACTTGTT TATTGCAGCT TATAATGGTT ACAAATAAAG CAATAGCATC ACAAATTTCA CAAATAAAGC
     TGGACGTCTT CGAAGCTACC GGCGGTACCG GGTTGAACAA ATAACGTCGA ATATTACCAA TGTTTATTTC GTTATCGTAG TGTTTAAAGT GTTTATTTCG

3401 ATTTTTTTCA CTGCATTCTA GTTGTGGTTT GTCCAAACTC ATCAATGTAT CTTATCATGT CTGGATCGGG AATTAATTCG GCGCAGCACC ATGGCCTGAA
     TAAAAAAAGT GACGTAAGAT CAACACCAAA CAGGTTTGAG TAGTTACATA GAATAGTACA GACCTAGCCC TTAATTAAGC CGCGTCGTGG TACCGGACTT

3501 ATAACCTCTG AAAGAGGAAC TTGGTTAGGT ACCTTCTGAG GCGGAAAGAA CCAGCTGTGG AATGTGTGTC AGTTAGGGTG TGGAAAGTCC CCAGGCTCCC
     TATTGGAGAC TTTCTCCTTG AACCAATCCA TGGAAGACTC CGCCTTTCTT GGTCGACACC TTACACACAG TCAATCCCAC ACCTTTCAGG GGTCCGAGGG

3601 CAGCAGGCAG AAGTATGCAA AGCATGCATC TCAATTAGTC AGCAACCAGG TGTGGAAAGT CCCCAGGCTC CCCAGCAGGC AGAAGTATGC AAAGCATGCA
     GTCGTCCGTC TTCATACGTT TCGTACGTAG AGTTAATCAG TCGTTGGTCC ACACCTTTCA GGGGTCCGAG GGGTCGTCCG TCTTCATACG TTTCGTACGT

3701 TCTCAATTAG TCAGCAACCA TAGTCCCGCC CCTAACTCCG CCCATCCCGC CCCTAACTCC GCCCAGTTCC GCCCATTCTC CGCCCCATGG CTGACTAATT
     AGAGTTAATC AGTCGTTGGT ATCAGGGCGG GGATTGAGGC GGGTAGGGCG GGGATTGAGG CGGGTCAAGG CGGGTAAGAG GCGGGGTACC GACTGATTAA

3801 TTTTTTATTT ATGCAGAGGC CGAGGCCGCC TCGGCCTCTG AGCTATTCCA GAAGTAGTGA GGAGGCTTTT TTGGAGGACT AGGCTTTTGC AAAAAGCTAG
     AAAAAATAAA TACGTCTCCG GCTCCGGCGG AGCCGGAGAC TCGATAAGGT CTTCATCACT CCTCCGAAAA AACCTCCTGA TCCGAAAACG TTTTTCGATC

3901 CTTATCCGGC CGGGAACGGT GCATTGGAAC GCGGATTCCC CGTGCCAAGA GTCAGGTAAG TACCGCCTAT AGAGTCTATA GGCCCACCCC CTTGGCTTCG
     GAATAGGCCG GCCCTTGCCA CGTAACCTTG CGCCTAAGGG GCACGGTTCT CAGTCCATTC ATGGCGGATA TCTCAGATAT CCGGGTGGGG GAACCGAAGC

4001 TTAGAACGCG GCTACAATTA ATACATAACC TTTTGGATCG ATCCTACTGA CACTGACATC CACTTTTTCT TTTTCTCCAC AGGTGTCCAC TCCCAGGTCC
     AATCTTGCGC CGATGTTAAT TATGTATTGG AAAACCTAGC TAGGATGACT GTGACTGTAG GTGAAAAAGA AAAAGAGGTG TCCACAGGTG AGGGTCCAGG

4101 AACTGCACCT CGGTTCGCGA AGCTAGCTTG GGCTGCATCG ATTGAATTCC ACCATGGGAT GGTCATGTAT CATCCTTTTT CTAGTAGCAA CTGCAACTGG
     TTGACGTGGA GCCAAGCGCT TCGATCGAAC CCGACGTAGC TAACTTAAGG TGGTACCCTA CCAGTACATA GTAGGAAAAA GATCATCGTT GACGTTGACC
                                                          ^Start LC coding
4201 AGTACATTCA GATATCCAGA TGACCCAGTC CCCGAGCTCC CTGTCCGCCT CTGTGGGCGA TAGGGTCACC ATCACCTGCA AGGCCAGTCA GGATGTGTCT
     TCATGTAAGT CTATAGGTCT ACTGGGTCAG GGGCTCGAGG GACAGGCGGA GACACCCGCT ATCCCAGTGG TAGTGGACGT TCCGGTCAGT CCTACACAGA

4301 ATTGGTGTCG CCTGGTATCA ACAGAAACCA GGAAAAGCTC CGAAACTACT GATTTACTCG GCTTCCTACC GATACACTGG AGTCCCTTCT CGCTTCTCTG
     TAACCACAGC GGACCATAGT TGTCTTTGGT CCTTTTCGAG GCTTTGATGA CTAAATGAGC CGAAGGATGG CTATGTGACC TCAGGGAAGA GCGAAGAGAC

4401 GATCCGGTTC TGGGACGGAT TTCACTCTGA CCATCAGCAG TCTGCAGCCA GAAGACTTCG CAACTTATTA CTGTCAACAA TATTATATTT ATCCTTACAC
     CTAGGCCAAG ACCCTGCCTA AAGTGAGACT GGTAGTCGTC AGACGTCGGT CTTCTGAAGC GTTGAATAAT GACAGTTGTT ATAATATAAA TAGGAATGTG

4501 GTTTGGACAG GGTACCAAGG TGGAGATCAA ACGAACTGTG GCTGCACCAT CTGTCTTCAT CTTCCCGCCA TCTGATGAGC AGTTGAAATC TGGAACTGCT
     CAAACCTGTC CCATGGTTCC ACCTCTAGTT TGCTTGACAC CGACGTGGTA GACAGAAGTA GAAGGGCGGT AGACTACTCG TCAACTTTAG ACCTTGACGA

4601 TCTGTTGTGT GCCTGCTGAA TAACTTCTAT CCCAGAGAGG CCAAAGTACA GTGGAAGGTG GATAACGCCC TCCAATCGGG TAACTCCCAG GAGAGTGTCA
     AGACAACACA CGGACGACTT ATTGAAGATA GGGTCTCTCC GGTTTCATGT CACCTTCCAC CTATTGCGGG AGGTTAGCCC ATTGAGGGTC CTCTCACAGT

4701 CAGAGCAGGA CAGCAAGGAC AGCACCTACA GCCTCAGCAG CACCCTGACG CTGAGCAAAG CAGACTACGA GAAACACAAA GTCTACGCCT GCGAAGTCAC
     GTCTCGTCCT GTCGTTCCTG TCGTGGATGT CGGAGTCGTC GTGGGACTGC GACTCGTTTC GTCTGATGCT CTTTGTGTTT CAGATGCGGA CGCTTCAGTG

4801 CCATCAGGGC CTGAGCTCGC CCGTCACAAA GAGCTTCAAC AGGGGAGAGT GTTAAGCTTC GATGGCCGCC ATGGCCCAAC TTGTTTATTG CAGCTTATAA
     GGTAGTCCCG GACTCGAGCG GGCAGTGTTT CTCGAAGTTG TCCCCTCTCA CAATTCGAAG CTACCGGCGG TACCGGGTTG AACAAATAAC GTCGAATATT

4901 TGGTTACAAA TAAAGCAATA GCATCACAAA TTTCACAAAT AAAGCATTTT TTTCACTGCA TTCTAGTTGT GGTTTGTCCA AACTCATCAA TGTATCTTAT
     ACCAATGTTT ATTTCGTTAT CGTAGTGTTT AAAGTGTTTA TTTCGTAAAA AAAGTGACGT AAGATCAACA CCAAACAGGT TTGAGTAGTT ACATAGAATA

5001 CATGTCTGGA TCGGGAATTA ATTCGGCGCA GCACCATGGC CTGAAATAAG TTTAAACCCT CTGAAAGAGG AACTTGGTTA GGTACCGACT AGTAGCAAGG
     GTACAGACCT AGCCCTTAAT TAAGCCGCGT CGTGGTACCG GACTTTATTC AAATTTGGGA GACTTTCTCC TTGAACCAAT CCATGGCTGA TCATCGTTCC
```

Figure 7-3

```
5101 TCGCCACGCA CAAGATCAAT ATTAACAATC AGTCATCTCT CTTTAGCAAT AAAAAGGTGA AAAATTACAT TTTAAAAATG ACACCATAGA CGATGTATGA
     AGCGGTGCGT GTTCTAGTTA TAATTGTTAG TCAGTAGAGA GAAATCGTTA TTTTTCCACT TTTTAATGTA AAATTTTTAC TGTGGTATCT GCTACATACT

5201 AAATAATCTA CTTGGAAATA AATCTAGGCA AAGAAGTGCA AGACTGTTAC CCAGAAAACT TACAAATTGT AAATGAGAGG TTAGTGAAGA TTTAAATGAA
     TTTATTAGAT GAACCTTTAT TTAGATCCGT TTCTTCACGT TCTGACAATG GGTCTTTTGA ATGTTTAACA TTTACTCTCC AATCACTTCT AAATTTACTT

5301 TGAAGATCTA AATAAACTTA TAAATTGTGA GAGAAATTAA TGAATGTCTA AGTTAATGCA GAAACGGAGA GACATACTAT ATTCATGAAC TAAAAGACTT
     ACTTCTAGAT TTATTTGAAT ATTTAACACT CTCTTTAATT ACTTACAGAT TCAATTACGT CTTTGCCTCT CTGTATGATA TAAGTACTTG ATTTTCTGAA

5401 AATATTGTGA AGGTATACTT TCTTTTCACA TAAATTTGTA GTCAATATGT TCACCCCAAA AAAGCTGTTT GTTAACTTGT CAACCTCATT TCAAAATGTA
     TTATAACACT TCCATATGAA AGAAAAGTGT ATTTAAACAT CAGTTATACA AGTGGGGTTT TTTCGACAAA CAATTGAACA GTTGGAGTAA AGTTTTACAT

5501 TATAGAAAGC CCAAAGACAA TAACAAAAAT ATTCTTGTAG AACAAAATGG GAAAGAATGT TCCACTAAAT ATCAAGATTT AGAGCAAAGC ATGAGATGTG
     ATATCTTTCG GGTTTCTGTT ATTGTTTTTA TAAGAACATC TTGTTTTACC CTTTCTTACA AGGTGATTTA TAGTTCTAAA TCTCGTTTCG TACTCTACAC

5601 TGGGGATAGA CAGTGAGGCT GATAAAATAG AGTAGAGCTC AGAAACAGAC CCATTGATAT ATGTAAGTGA CCTATGAAAA AAATATGGCA TTTTACAATG
     ACCCCTATCT GTCACTCCGA CTATTTTATC TCATCTCGAG TCTTTGTCTG GGTAACTATA TACATTCACT GGATACTTTT TTTATACCGT AAAATGTTAC

5701 GGAAAATGAT GATCTTTTTC TTTTTTAGAA AAACAGGGAA ATATATTTAT ATGTAAAAAA TAAAAGGGAA CCCATATGTC ATACCATACA CACAAAAAAA
     CCTTTTACTA CTAGAAAAAG AAAAAATCTT TTTGTCCCTT TATATAAATA TACATTTTTT ATTTTCCCTT GGGTATACAG TATGGTATGT GTGTTTTTTT

5801 TTCCAGTGAA TTATAAGTCT AAATGGAGAA GGCAAAACTT TAAATCTTTT AGAAAATAAT ATAGAAGCAT GCCATCATGA CTTCAGTGTA GAGAAAAATT
     AAGGTCACTT AATATTCAGA TTTACCTCTT CCGTTTTGAA ATTTAGAAAA TCTTTTATTA TATCTTCGTA CGGTAGTACT GAAGTCACAT CTCTTTTTAA

5901 TCTTATGACT CAAAGTCCTA ACCACAAAGA AAAGATTGTT AATTAGATTG CATGAATATT AAGACTTATT TTTAAAATTA AAAAACCATT AAGAAAAGTC
     AGAATACTGA GTTTCAGGAT TGGTGTTTCT TTTCTAACAA TTAATCTAAC GTACTTATAA TTCTGAATAA AAATTTTAAT TTTTTGGTAA TTCTTTTCAG

6001 AGGCCATAGA ATGACAGAAA ATATTTGCAA CACCCCAGTA AAGAGAATTG TAATATGCAG ATTATAAAAA GAAGTCTTAC AAATCAGTAA AAAATAAAAC
     TCCGGTATCT TACTGTCTTT TATAAACGTT GTGGGGTCAT TTCTCTTAAC ATTATACGTC TAATATTTTT CTTCAGAATG TTTAGTCATT TTTTATTTTG

6101 TAGACAAAAA TTTGAACAGA TGAAAGAGAA ACTCTAAATA ATCATTACAC ATGAGAAACT CAATCTCAGA AATCAGAGAA CTATCATTGC ATATACACTA
     ATCTGTTTTT AAACTTGTCT ACTTTCTCTT TGAGATTTAT TAGTAATGTG TACTCTTTGA GTTAGAGTCT TTAGTCTCTT GATAGTAACG TATATGTGAT

6201 AATTAGAGAA ATATTAAAAG GCTAAGTAAC ATCTGTGGCA ATATTGATGG TATATAACCT TGATATGATG TGATGAGAAC AGTACTTTAC CCCATGGGCT
     TTAATCTCTT TATAATTTTC CGATTCATTG TAGACACCGT TATAACTACC ATATATTGGA ACTATACTAC ACTACTCTTG TCATGAAATG GGGTACCCGA

6301 TCCTCCCCAA ACCCTTACCC CAGTATAAAT CATGACAAAT ATACTTTAAA AACCATTACC CTATATCTAA CCAGTACTCC TCAAAACTGT CAAGGTCATC
     AGGAGGGGTT TGGGAATGGG GTCATATTTA GTACTGTTTA TATGAAATTT TTGGTAATGG GATATAGATT GGTCATGAGG AGTTTTGACA GTTCCAGTAG

6401 AAAAATAAGA AAAGTCTGAG GAACTGTCAA AACTAAGAGG AACCCAAGGA GACATGAGAA TTATATGTAA TGTGGCATTC TGAATGAGAT CCCAGAACAG
     TTTTTATTCT TTTCAGACTC CTTGACAGTT TTGATTCTCC TTGGGTTCCT CTGTACTCTT AATATACATT ACACCGTAAG ACTTACTCTA GGGTCTTGTC

6501 AAAAAGAACA GTAGCTAAAA AACTAATGAA ATATAAATAA AGTTTGAACT TTAGTTTTTT TTAAAAAAGA GTAGCATTAA CACGGCAAAG TCATTTTCAT
     TTTTTCTTGT CATCGATTTT TTGATTACTT TATATTTATT TCAAACTTGA AATCAAAAAA AATTTTTTCT CATCGTAATT GTGCCGTTTC AGTAAAAGTA

6601 ATTTTTCTTG AACATTAAGT ACAAGTCTAT AATTAAAAAT TTTTTAAATG TAGTCTGGAA CATTGCCAGA AACAGAAGTA CAGCAGCTAT CTGTGCTGTC
     TAAAAAGAAC TTGTAATTCA TGTTCAGATA TTAATTTTTA AAAAATTTAC ATCAGACCTT GTAACGGTCT TTGTCTTCAT GTCGTCGATA GACACGACAG

6701 GCCTAACTAT CCATAGCTGA TTGGTCTAAA ATGAGATACA TCAACGCTCC TCCATGTTTT TTGTTTTCTT TTTAAATGAA AAACTTTATT TTTTAAGAGG
     CGGATTGATA GGTATCGACT AACCAGATTT TACTCTATGT AGTTGCGAGG AGGTACAAAA AACAAAAGAA AAATTTACTT TTTGAAATAA AAAATTCTCC

6801 AGTTTCAGGT TCATAGCAAA ATTGAGAGGA AGGTACATTC AAGCTGAGGA AGTTTTCCTC TATTCCTAGT TTACTGAGAG ATTGCATCAT GAATGGGTGT
```

Figure 7-4

```
     TCAAAGTCCA AGTATCGTTT TAACTCTCCT TCCATGTAAG TTCGACTCCT TCAAAAGGAG ATAAGGATCA AATGACTCTC TAACGTAGTA CTTACCCACA

6901 TAAATTTTGT CAAATGCTTT TTCTGTGTCT ATCAATATGA CCATGTGATT TTCTTCTTTA ACCTGTTGAT GGGACAAATT ACGTTAATTG ATTTTCAAAC
     ATTTAAAACA GTTTACGAAA AAGACACAGA TAGTTATACT GGTACACTAA AAGAAGAAAT TGGACAACTA CCCTGTTTAA TGCAATTAAC TAAAAGTTTG

7001 GTTGAACCAC CCTTACATAT CTGGAATAAA TTCTACTTGG TTGTGGTGTA TATTTTTTGA TACATTCTTG GATTCTTTTT GCTAATATTT TGTTGAAAAT
     CAACTTGGTG GGAATGTATA GACCTTATTT AAGATGAACC AACACCACAT ATAAAAAACT ATGTAAGAAC CTAAGAAAAA CGATTATAAA ACAACTTTTA

7101 GTTTGTATCT TTGTTCATGA GAGATATTGG TCTGTTGTTT TCTTTTCTTG TAATGTCATT TTCTAGTTCC GGTATTAAGG TAATGCTGGC CTAGTTGAAT
     CAAACATAGA AACAAGTACT CTCTATAACC AGACAACAAA AGAAAAGAAC ATTACAGTAA AAGATCAAGG CCATAATTCC ATTACGACCG GATCAACTTA

7201 GATTTAGGAA GTATTCCCTC TGCTTCTGTC TTCTGAGGTA CCGCGGCCGC CCGTCGTTTT ACAACGTCGT GACTGGGAAA ACCCTGGCGT TACCGAACTT
     CTAAATCCTT CATAAGGGAG ACGAAGACAG AAGACTCCAT GGCGCCGGCG GGCAGCAAAA TGTTGCAGCA CTGACCCTTT TGGGACCGCA ATGGGTTGAA

7301 AATCGCCTTG CAGCACATCC CCCTTTCGCC AGCTGGCGTA ATAGCGAAGA GGCCCGCACC GATCGCCCTT CCCAACAGTT GCGCAGCCTG AATGGCGAAT
     TTAGCGGAAC GTCGTGTAGG GGGAAAGCGG TCGACCGCAT TATCGCTTCT CCGGGCGTGG CTAGCGGGAA GGGTTGTCAA CGCGTCGGAC TTACCGCTTA

7401 GGCGCCTGAT GCGGTATTTT CTCCTTACGC ATCTGTGCGG TATTTCACAC CGCATACGTC AAAGCAACCA TAGTACGCGC CCTGTAGCGG CGCATTAAGC
     CCGCGGACTA CGCCATAAAA GAGGAATGCG TAGACACGCC ATAAAGTGTG GCGTATGCAG TTTCGTTGGT ATCATGCGCG GGACATCGCC GCGTAATTCG

7501 GCGGCGGGTG TGGTGGTTAC GCGCAGCGTG ACCGCTACAC TTGCCAGCGC CCTAGCGCCC GCTCCTTTCG CTTTCTTCCC TTCCTTTCTC GCCACGTTCG
     CGCCGCCCAC ACCACCAATG CGCGTCGCAC TGGCGATGTG AACGGTCGCG GGATCGCGGG CGAGGAAAGC GAAAGAAGGG AAGGAAAGAG CGGTGCAAGC

7601 CCGGCTTTCC CCGTCAAGCT CTAAATCGGG GGCTCCCTTT AGGGTTCCGA TTTAGTGCTT TACGGCACCT CGACCCCAAA AAACTTGATT TGGGTGATGG
     GGCCGAAAGG GGCAGTTCGA GATTTAGCCC CCGAGGGAAA TCCCAAGGCT AAATCACGAA ATGCCGTGGA GCTGGGGTTT TTTGAACTAA ACCCACTACC

7701 TTCACGTAGT GGGCCATCGC CCTGATAGAC GGTTTTTCGC CCTTTGACGT TGGAGTCCAC GTTCTTTAAT AGTGGACTCT TGTTCCAAAC TGGAACAACA
     AAGTGCATCA CCCGGTAGCG GGACTATCTG CCAAAAAGCG GGAAACTGCA ACCTCAGGTG CAAGAAATTA TCACCTGAGA ACAAGGTTTG ACCTTGTTGT

7801 CTCAACCCTA TCTCGGGCTA TTCTTTTGAT TTATAAGGGA TTTTGCCGAT TTCGGCCTAT TGGTTAAAAA ATGAGCTGAT TTAACAAAAA TTTAACGCGA
     GAGTTGGGAT AGAGCCCGAT AAGAAAACTA AATATTCCCT AAAACGGCTA AAGCCGGATA ACCAATTTTT TACTCGACTA AATTGTTTTT AAATTGCGCT

7901 ATTTTAACAA AATATTAACG TTTACAATTT TATGGTGCAC TCTCAGTACA ATCTGCTCTG ATGCCGCATA GTTAAGCCAG CCCCGACACC CGCCAACACC
     TAAAATTGTT TTATAATTGC AAATGTTAAA ATACCACGTG AGAGTCATGT TAGACGAGAC TACGGCGTAT CAATTCGGTC GGGGCTGTGG GCGGTTGTGG

8001 CGCTGACGCG CCCTGACGGG CTTGTCTGCT CCCGGCATCC GCTTACAGAC AAGCTGTGAC CGTCTCCGGG AGCTGCATGT GTCAGAGGTT TTCACCGTCA
     GCGACTGCGC GGGACTGCCC GAACAGACGA GGGCCGTAGG CGAATGTCTG TTCGACACTG GCAGAGGCCC TCGACGTACA CAGTCTCCAA AAGTGGCAGT

8101 TCACCGAAAC GCGCGAGAGA CGAAAGGGCC TCGTGATACG CCTATTTTTA TAGGTTAATG TCATGATAAT AATGGTTTCT TAGACGTCAG GTGGCACTTT
     AGTGGCTTTG CGCGCTCTCT GCTTTCCCGG AGCACTATGC GGATAAAAAT ATCCAATTAC AGTACTATTA TTACCAAAGA ATCTGCAGTC CACCGTGAAA

8201 TCGGGGAAAT GTGCGCGGAA CCCCTATTTG TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT GCTTCAATAA
     AGCCCCTTTA CACGCGCCTT GGGGATAAAC AAATAAAAAG ATTTATGTAA GTTTATACAT AGGCGAGTAC TCTGTTATTG GGACTATTTA CGAAGTTATT

8301 TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCCGTG TCGCCCTTAT TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC
     ATAACTTTTT CCTTCTCATA CTCATAAGTT GTAAAGGCAC AGCGGGAATA AGGGAAAAAA CGCCGTAAAA CGGAAGGACA AAAACGAGTG GGTCTTTGCG

8401 TGGTGAAAGT AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTTAC ATCGAACTGG ATCTCAACAG CGGTAAGATC CTTGAGAGTT TTCGCCCCGA
     ACCACTTTCA TTTTCTACGA CTTCTAGTCA ACCCACGTGC TCACCCAATG TAGCTTGACC TAGAGTTGTC GCCATTCTAG GAACTCTCAA AAGCGGGGCT

8501 AGAACGTTTT CCAATGATGA GCACTTTTAA AGTTCTGCTA TGTGGCGCGG TATTATCCCG TATTGACGCC GGGCAAGAGC AACTCGGTCG CCGCATACAC
     TCTTGCAAAA GGTTACTACT CGTGAAAATT TCAAGACGAT ACACCGCGCC ATAATAGGGC ATAACTGCGG CCCGTTCTCG TTGAGCCAGC GGCGTATGTG
```

Figure 7-5

```
8601 TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA
     ATAAGAGTCT TACTGAACCA ACTCATGAGT GGTCAGTGTC TTTTCGTAGA ATGCCTACCG TACTGTCATT CTCTTAATAC GTCACGACGG TATTGGTACT

8701 GTGATAACAC TGCGGCCAAC TTACTTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA CAACATGGGG GATCATGTAA CTCGCCTTGA
     CACTATTGTG ACGCCGGTTG AATGAAGACT GTTGCTAGCC TCCTGGCTTC CTCGATTGGC GAAAAAACGT GTTGTACCCC CTAGTACATT GAGCGGAACT

8801 TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT ACCAAACGAC GAGCGTGACA CCACGATGCC TGTAGCAATG GCAACAACGT TGCGCAAACT ATTAACTGGC
     AGCAACCCTT GGCCTCGACT TACTTCGGTA TGGTTTGCTG CTCGCACTGT GGTGCTACGG ACATCGTTAC CGTTGTTGCA ACGCGTTTGA TAATTGACCG

8901 GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGCCCTTCCG GCTGGCTGGT
     CTTGATGAAT GAGATCGAAG GGCCGTTGTT AATTATCTGA CCTACCTCCG CCTATTTCAA CGTCCTGGTG AAGACGCGAG CCGGGAAGGC CGACCGACCA

9001 TTATTGCTGA TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG TAAGCCCTCC CGTATCGTAG TTATCTACAC
     AATAACGACT ATTTAGACCT CGGCCACTCG CACCCAGAGC GCCATAGTAA CGTCGTGACC CCGGTCTACC ATTCGGGAGG GCATAGCATC AATAGATGTG

9101 GACGGGGAGT CAGGCAACTA TGGATGAACG AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAAG CATTGGTAAC TGTCAGACCA AGTTTACTCA
     CTGCCCCTCA GTCCGTTGAT ACCTACTTGC TTTATCTGTC TAGCGACTCT ATCCACGGAG TGACTAATTC GTAACCATTG ACAGTCTGGT TCAAATGAGT

9201 TATATACTTT AGATTGATTT AAAACTTCAT TTTTAATTTA AAAGGATCTA GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT
     ATATATGAAA TCTAACTAAA TTTTGAAGTA AAAATTAAAT TTTCCTAGAT CCACTTCTAG GAAAAACTAT TAGAGTACTG GTTTTAGGGA ATTGCACTCA

9301 TTTCGTTCCA CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTTCTGCG CGTAATCTGC TGCTTGCAAA CAAAAAAACC
     AAAGCAAGGT GACTCGCAGT CTGGGGCATC TTTTCTAGTT TCCTAGAAGA ACTCTAGGAA AAAAAGACGC GCATTAGACG ACGAACGTTT GTTTTTTTGG

9401 ACCGCTACCA GCGGTGGTTT GTTTGCCGGA TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA TACTGTTCTT
     TGGCGATGGT CGCCACCAAA CAAACGGCCT AGTTCTCGAT GGTTGAGAAA AAGGCTTCCA TTGACCGAAG TCGTCTCGCG TCTATGGTTT ATGACAAGAA

9501 CTAGTGTAGC CGTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACCGCC TACATACCTC GCTCTGCTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG
     GATCACATCG GCATCAATCC GGTGGTGAAG TTCTTGAGAC ATCGTGGCGG ATGTATGGAG CGAGACGATT AGGACAATGG TCACCGACGA CGGTCACCGC

9601 ATAAGTCGTG TCTTACCGGG TTGGACTCAA GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC GGGGGGTTCG TGCACACAGC CCAGCTTGGA
     TATTCAGCAC AGAATGGCCC AACCTGAGTT CTGCTATCAA TGGCCTATTC CGCGTCGCCA GCCCGACTTG CCCCCCAAGC ACGTGTGTCG GGTCGAACCT

9701 GCGAACGACC TACACCGAAC TGAGATACCT ACAGCGTGAG CTATGAGAAA GCGCCACGCT TCCCGAAGGG AGAAAGGCGG ACAGGTATCC GGTAAGCGGC
     CGCTTGCTGG ATGTGGCTTG ACTCTATGGA TGTCGCACTC GATACTCTTT CGCGGTGCGA AGGGCTTCCC TCTTTCCGCC TGTCCATAGG CCATTCGCCG

9801 AGGGTCGGAA CAGGAGAGCG CACGAGGGAG CTTCCAGGGG GAAACGCCTG GTATCTTTAT AGTCCTGTCG GGTTTCGCCA CCTCTGACTT GAGCGTCGAT
     TCCCAGCCTT GTCCTCTCGC GTGCTCCCTC GAAGGTCCCC CTTTGCGGAC CATAGAAATA TCAGGACAGC CCAAAGCGGT GGAGACTGAA CTCGCAGCTA

9901 TTTTGTGATG CTCGTCAGGG GGGCGGAGCC TATGGAAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT GGCCTTTTGC TGGCCTTTTG CTCACATGTT
     AAAACACTAC GAGCAGTCCC CCCGCCTCGG ATACCTTTTT GCGGTCGTTG CGCCGGAAAA ATGCCAAGGA CCGGAAAACG ACCGGAAAAC GAGTGTACAA

10001 CTTTCCTGCG TTATCCCCTG ATTCTGTGGA TAACCGTATT ACCGCCTTTG AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG CAGCGAGTCA
      GAAAGGACGC AATAGGGGAC TAAGACACCT ATTGGCATAA TGGCGGAAAC TCACTCGACT ATGGCGAGCG GCGTCGGCTT GCTGGCTCGC GTCGCTCAGT

10101 GTGAGCGAGG AAGCGGAAGA GCCCGCGGGC AAGGTCGCCA CGCACAAGAT CAATATTAAC AATCAGTCAT CTCTCTTTAG CAATAAAAAG GTGAAAAATT
      CACTCGCTCC TTCGCCTTCT CGGGCGCCCG TTCCAGCGGT GCGTGTTCTA GTTATAATTG TTAGTCAGTA GAGAGAAATC GTTATTTTTC CACTTTTTAA

10201 ACATTTTAAA AATGACACCA TAGACGATGT ATGAAAATAA TCTACTTGGA AATAAATCTA GGCAAAGAAG TGCAAGACTG TTACCCAGAA AACTTACAAA
      TGTAAAATTT TTACTGTGGT ATCTGCTACA TACTTTTATT AGATGAACCT TTATTTAGAT CCGTTTCTTC ACGTTCTGAC AATGGGTCTT TTGAATGTTT

10301 TTGTAAATGA GAGGTTAGTG AAGATTTAAA TGAATGAAGA TCTAAATAAA CTTATAAATT GTGAGAGAAA TTAATGAATG TCTAAGTTAA TGCAGAAACG
      AACATTTACT CTCCAATCAC TTCTAAATTT ACTTACTTCT AGATTTATTT GAATATTTAA CACTCTCTTT AATTACTTAC AGATTCAATT ACGTCTTTGC
```

Figure 7-6

```
10401 GAGAGACATA CTATATTCAT GAACTAAAAG ACTTAATATT GTGAAGGTAT ACTTTCTTTT CACATAAATT TGTAGTCAAT ATGTTCACCC CAAAAAAGCT
      CTCTCTGTAT GATATAAGTA CTTGATTTTC TGAATTATAA CACTTCCATA TGAAAGAAAA GTGTATTTAA ACATCAGTTA TACAAGTGGG GTTTTTTCGA

10501 GTTTGTTAAC TTGTCAACCT CATTTCAAAA TGTATATAGA AAGCCCAAAG ACAATAACAA AAATATTCTT GTAGAACAAA ATGGGAAAGA ATGTTCCACT
      CAAACAATTG AACAGTTGGA GTAAAGTTTT ACATATATCT TTCGGGTTTC TGTTATTGTT TTTATAAGAA CATCTTGTTT TACCCTTTCT TACAAGGTGA

10601 AAATATCAAG ATTTAGAGCA AAGCATGAGA TGTGTGGGGA TAGACAGTGA GGCTGATAAA ATAGAGTAGA GCTCAGAAAC AGACCCATTG ATATATGTAA
      TTTATAGTTC TAAATCTCGT TTCGTACTCT ACACACCCCT ATCTGTCACT CCGACTATTT TATCTCATCT CGAGTCTTTG TCTGGGTAAC TATATACATT

10701 GTGACCTATG AAAAAAATAT GGCATTTTAC AATGGGAAAA TGATGATCTT TTTCTTTTTT AGAAAAACAG GGAAATATAT TTATATGTAA AAAATAAAAG
      CACTGGATAC TTTTTTTATA CCGTAAAATG TTACCCTTTT ACTACTAGAA AAAGAAAAAA TCTTTTTGTC CCTTTATATA AATATACATT TTTTATTTTC

10801 GGAAGCCATA TGTCATACCA TACACACAAA AAAATTCCAG TGAATTATAA GTCTAAATGG AGAAGGCAAA ACTTTAAATC TTTTAGAAAA TAATATAGAA
      CCTTGGGTAT ACAGTATGGT ATGTGTGTTT TTTTAAGGTC ACTTAATATT CAGATTTACC TCTTCCGTTT TGAAATTTAG AAAATCTTTT ATTATATCTT

10901 GCATGCCATC ATGACTTCAG TGTAGAGAAA AATTTCTTAT GACTCAAAGT CCTAACCACA AAGAAAAGAT TGTTAATTAG ATTGCATGAA TATTAAGACT
      CGTACGGTAG TACTGAAGTC ACATCTCTTT TTAAAGAATA CTGAGTTTCA GGATTGGTGT TTCTTTTCTA ACAATTAATC TAACGTACTT ATAATTCTGA

11001 TATTTTTAAA ATTAAAAAAC CATTAAGAAA AGTCAGGCCA TAGAATGACA GAAAATATTT GCAACACCCC AGTAAAGAGA ATTGTAATAT GCAGATTATA
      ATAAAAATTT TAATTTTTTG GTAATTCTTT TCAGTCCGGT ATCTTACTGT CTTTTATAAA CGTTGTGGGG TCATTTCTCT TAACATTATA CGTCTAATAT

11101 AAAAGAAGTC TTACAAATCA GTAAAAAATA AAACTAGACA AAAATTTGAA CAGATGAAAG AGAAACTCTA AATAATCATT ACACATGAGA AACTCAATCT
      TTTTCTTCAG AATGTTTAGT CATTTTTTAT TTTGATCTGT TTTTAAACTT GTCTACTTTC TCTTTGAGAT TTATTAGTAA TGTGTACTCT TTGAGTTAGA

11201 CAGAAATCAG AGAACTATCA TTGCATATAC ACTAAATTAG AGAAATATTA AAAGGCTAAG TAACATCTGT GGCAATATTG ATGGTATATA ACCTTGATAT
      GTCTTTAGTC TCTTGATAGT AACGTATATG TGATTTAATC TCTTTATAAT TTTCCGATTC ATTGTAGACA CCGTTATAAC TACCATATAT TGGAACTATA

11301 GATGTGATGA GAACAGTACT TTACCCCATG GGCTTCCTCC CCAAACCCTT ACCCCAGTAT AAATCATGAC AAATATACTT TAAAAACCAT TACCCTATAT
      CTACACTACT CTTGTCATGA AATGGGGTAC CCGAAGGAGG GGTTTGGGAA TGGGGTCATA TTTAGTACTG TTTATATGAA ATTTTTGGTA ATGGGATATA

11401 CTAACCAGTA CTCCTCAAAA CTGTCAAGGT CATCAAAAAT AAGAAAAGTC TGAGGAACTG TCAAAACTAA GAGGAACCCA AGGAGACATG AGAATTATAT
      GATTGGTCAT GAGGAGTTTT GACAGTTCCA GTAGTTTTTA TTCTTTTCAG ACTCCTTGAC AGTTTTGATT CTCCTTGGGT TCCTCTGTAC TCTTAATATA

11501 GTAATGTGGC ATTCTGAATG AGATCCCAGA ACAGAAAAAG AACAGTAGCT AAAAAACTAA TGAAATATAA ATAAAGTTTG AACTTTAGTT TTTTTTAAAA
      CATTACACCG TAAGACTTAC TCTAGGGTCT TGTCTTTTTC TTGTCATCGA TTTTTTGATT ACTTTATATT TATTTCAAAC TTGAAATCAA AAAAAATTTT

11601 AAGAGTAGCA TTAACACGGC AAAGTCATTT TCATATTTTT CTTGAACATT AAGTACAAGT CTATAATTAA AAATTTTTTA AATGTAGTCT GGAACATTGC
      TTCTCATCGT AATTGTGCCG TTTCAGTAAA AGTATAAAAA GAACTTGTAA TTCATGTTCA GATATTAATT TTTAAAAAAT TTACATCAGA CCTTGTAACG

11701 CAGAAACAGA AGTACAGCAG CTATCTGTGC TGTCGCCTAA CTATCCATAG CTGATTGGTC TAAAATGAGA TACATCAACG CTCCTCCATG TTTTTTGTTT
      GTCTTTGTCT TCATGTCGTC GATAGACACG ACAGCGGATT GATAGGTATC GACTAACCAG ATTTTACTCT ATGTAGTTGC GAGGAGGTAC AAAAAACAAA

11801 TCTTTTTAAA TGAAAAACTT TATTTTTTAA GAGGAGTTTC AGGTTCATAG CAAAATTGAG AGGAAGGTAC ATTCAAGCTG AGGAAGTTTT CCTCTATTCC
      AGAAAAAATTT ACTTTTTGAA ATAAAAAATT CTCCTCAAAG TCCAAGTATC GTTTTAACTC TCCTTCCATG TAAGTTCGAC TCCTTCAAAA GGAGATAAGG

11901 TAGTTTACTG AGAGATTGCA TCATGAATGG GTGTTAAATT TTGTCAAATG CTTTTTCTGT GTCTATCAAT ATGACCATGT GATTTTCTTC TTTAACCTGT
      ATCAAATGAC TCTCTAACGT AGTACTTACC CACAATTTAA AACAGTTTAC GAAAAAGACA CAGATAGTTA TACTGGTACA CTAAAAGAAG AAATTGGACA

12001 TGATGGGACA AATTACGTTA ATTGATTTTC AAACGTTGAA CCACCCTTAC ATATCTGGAA TAAATTCTAC TTGGTTGTGG TGTATATTTT TTGATACATT
      ACTACCCTGT TTAATGCAAT TAACTAAAAG TTTGCAACTT GGTGGGAATG TATAGACCTT ATTTAAGATG AACCAACACC ACATATAAAA AACTATGTAA

12101 CTTGGATTCT TTTTGCTAAT ATTTTGTTGA AAATGTTTGT ATCTTTGTTC ATGAGAGATA TTGGTCTGTT GTTTTCTTTT CTTGTAATGT CATTTTCTAG
```

Figure 7-7

```
      GAACCTAAGA AAAACGATTA TAAAACAACT TTTACAAACA TAGAAACAAG TACTCTCTAT AACCAGACAA CAAAAGAAAA GAACATTACA GTAAAAGATC

12201 TTCCGGTATT AAGGTAATGC TGGCCTAGTT GAATGATTTA GGAAGTATTC CCTCTGCTTC TGTCTTCTGA AGCGGAAGAG CGCCCAATAC GCAAACCGCC
      AAGGCCATAA TTCCATTACG ACCGGATCAA CTTACTAAAT CCTTCATAAG GGAGACGAAG ACAGAAGACT TCGCCTTCTC GCGGGTTATG CGTTTGGCGG

12301 TCTCCCCGCG CGTTGGCCGA TTCATTAATG CAGCTGGCAC GACAGGTTTC CCGACTGGAA AGCGGGCAGT GAGCGCAACG CAATTAATGT GAGTTAGCTC
      AGAGGGGCGC GCAACCGGCT AAGTAATTAC GTCGACCGTG CTGTCCAAAG GGCTGACCTT TCGCCCGTCA CTCGCGTTGC GTTAATTACA CTCAATCGAG

12401 ACTCATTAGG CACCCCAGGC TTTACACTTT ATGCTTCCGG CTCGTATGTT GTGTGGAATT GTGAGCGGAT AACAATTTCA CACAGGAAAC AGCTATGACA
      TGAGTAATCC GTGGGGTCCG AAATGTGAAA TACGAAGGCC GAGCATACAA CACACCTTAA CACTCGCCTA TTGTTAAAGT GTGTCCTTTG TCGATACTGT

12501 TGATTACGAA TTAA
      ACTAATGCTT AATT

>length: 12514
```

Figure 7-8



% GFP	% Viability (PI Staining)
70.9	59.2
68.7	60.9
1.6	69.7
1.2	94

Figure 8. FACS analysis of transiently transfected CHO cells with a GFP plasmid in 250 ml spinner transfection.



Figure 9. Expression level of clones from traditional 10 nM MTX selection.



Figure 10-1



Figure 10-2

Figures 10.1 and 10.2. Expression level of clones from 25 and 50 nM MTX direct selections of SV40-based constructs derived from spinner transfection, respectively.



Figure 11. Expression level of clones from 25 nM MTX direct selection of CMV construct derived from spinner transfection.



Figure 12. Titer Evaluation in Miniferm.

Figure 13. Plasmid pCMV.IPD.Heterologous Polypeptide

5 <400>

60 TTCGAGCTCG CCCGACATTG ATTATTGACT AGAGTCGATC ACCGGTAGTA ATCAATTACG

120 GGGTCATTAG TTCATAGCCC ATATATGGAG TTCCGCGTTA CATAACTTAC GGTAAATGGC

180 CCGCCTGGCT GACCGCCCAA CGACCCCCGC CCATTGACGT CAATAATGAC GTATGTTCCC

240 ATAGTAACGC CAATAGGGAC TTTCCATTGA CGTCAATGGG TGGAGTATTT ACGGTAAACT

300 GCCCACTTGG CAGTACATCA AGTGTATCAT ATGCCAAGTA CGCCCCCTAT TGACGTCAAT

360 GACGGTAAAT GGCCCGCCTG GCATTATGCC CAGTACATGA CCTTATGGGA CTTTCCTACT

420 TGGCAGTACA TCTACGTATT AGTCATCGCT ATTACCATGG TGATGCGGTT TTGGCAGTAC

480 ATCAATGGGC GTGGATAGCG GTTTGACTCA CGGGGATTTC CAAGTCTCCA CCCCATTGAC

540 GTCAATGGGA GTTTGTTTTG GCACCAAAAT CAACGGGACT TTCCAAAATG TCGTAACAAC

600 TCCGCCCCAT TGACGCAAAT GGGCGGTAGG CGTGTACGGT GGGAGGTCTA TATAAGCAGA

660 GCTCGTTTAG TGAACCGTCA GATCGCCTGG AGACGCCATC CACGCTGTTT TGACCTGGGC

720 CCGGCCGAGG CCGCCTCGGC CTCTGAGCTA TTCCAGAAGT AGTGAGGAGG CTTTTTTGGA

780 GGCCTAGGCT TTTGCAAAAA GCTAGCTTAT CCGGCCGGGA ACGGTGCATT GGAACGCGGA

840 TTCCCCGTGC CAAGAGTGAC GTAAGTACCG CCTATAGAGC GACTAGTCCA CCATGACCGA

900 GTACAAGCCC ACGGTGCGCC TCGCCACCCG CGACGACGTC CCGCGGGCCG TACGCACCCT

Figure 13.1

```
960   CGCCGCCGCG TTCGCCGACT ACCCCGCCAC GCGCCACACC GTAGACCCGG ACCGCCACAT
1020  CGAGCGGGTC ACCGAGCTGC AAGAACTCTT CCTCACGCGC GTCGGGCTCG ACATCGGCAA
1080  GGTGTGGGTC GCGGACGACG GCGCCGCGGT GGCGGTCTGG ACCACGCCGG AGAGCGTCGA
1140  AGCGGGGGCG GTGTTCGCCG AGATCGGCCC GCGCATGGCC GAGTTGAGCG GTTCCCGGCT
1200  GGCCGCGCAG CAACAGATGG AAGGCCTCCT GGCGCCGCAC CGGCCCAAGG AGCCCGCGTG
1260  GTTCCTGGCC ACCGTCGGCG TCTCGCCCGA CCACCAGGGC AAGGGTCTGG GCAGCGCCGT
1320  CGTGCTCCCC GGAGTGGAGG CGGCCGAGCG CGCCGGGGTG CCCGCCTTCC TGGAGACCTC
1380  CGCGCCCCGC AACCTCCCCT TCTACGAGCG GCTCGGCTTC ACCGTCACCG CCGACGTCGA
1440  GGTGCCCGAA GGACCGCGCA CCTGGTGCAT GACCCGCAAG CCCGGTGCCA ACATGGTTCG
1500  ACCATTGAAC TGCATCGTCG CCGTGTCCCA AAATATGGGG ATTGGCAAGA ACGGAGACCT
1560  ACCCTGGCCT CCGCTCAGGA ACGCGTTCAA GTACTTCCAA AGAATGACCA CAACCTCTTC
1620  AGTGGAAGGT AAACAGAATC TGGTGATTAT GGGTAGGAAA ACCTGGTTCT CCATTCCTGA
1680  GAAGAATCGA CCTTTAAAGG ACAGAATTAA TATAGTTCTC AGTAGAGAAC TCAAAGAACC
1740  ACCACGAGGA GCTCATTTTC TTGCCAAAAG TTTGGATGAT GCCTTAAGAC TTATTGAACA
1800  ACCGGAATTG GCAAGTAAAG TAGACATGGT TTGGATAGTC GGAGGCAGTT CTGTTTACCA
1860  GGAAGCCATG AATCAACCAG GCCACCTCAG ACTCTTTGTG ACAAGGATCA TGCAGGAATT
1920  TGAAAGTGAC ACGTTTTTCC CAGAAATTGA TTTGGGGAAA TATAAACCTC TCCCAGAATA
1980  CCCAGGCGTC CTCTCTGAGG TCCAGGAGGA AAAAGGCATC AAGTATAAGT TTGAAGTCTA
```

Figure 13.2

2040 CGAGAAGAAA GACTAACGTT AACTGCTCCC CTCCTAAAGC TATGCATTTT TATAAGACCA

2100 TGAGACTTTT GCTGGCTTTA GATCCCCTTG GCTTCGTTAG AACGCAGCTA CAATTAATAC

2160 ATAACCTTAT GTATCATACA CATACGATTT AGGTGACACT ATAGAATAAC ATCCACTTTG

2220 CCTTTCTCTC CACAGGTGTC CACTCCCAGG TCCAACTGCA CCTCGGTTCT ATCGATTGAA

TTCCACC **--Insert Sequence of Interest--**

CGA TGGCCGCCAT GGCCCAACTT GTTTATTGCA GCTTATAATG

GTTACAAATA AAGCAATAGC ATCACAAATT TCACAAATAA AGCATTTTTT TCACTGCATT

CTAGTTGTGG TTTGTCCAAA CTCATCAATG TATCTTATCA TGTCTGGATC GGGAATTAAT

TCGGCGCAGC ACCATGGCCT GAAATAACCT CTGAAAGAGG AACTTGGTTA GGTACCTATT

AATAGTAATC AATTACGGGG TCATTAGTTC ATAGCCCATA TATGGAGTTC CGCGTTACAT

AACTTACGGT AAATGGCCCG CCTGGCTGAC CGCCCAACGA CCCCCGCCCA TTGACGTCAA

TAATGACGTA TGTTCCCATA GTAACGCCAA TAGGGACTTT CCATTGACGT CAATGGGTGG

AGTATTTACG GTAAACTGCC CACTTGGCAG TACATCAAGT GTATCATATG CCAAGTACGC

CCCCTATTGA CGTCAATGAC GGTAAATGGC CCGCCTGGCA TTATGCCCAG TACATGACCT

TATGGGACTT TCCTACTTGG CAGTACATCT ACGTATTAGT CATCGCTATT ACCATGGTGA

TGCGGTTTTG GCAGTACATC AATGGGCGTG GATAGCGGTT TGACTCACGG GGATTTCCAA

GTCTCCACCC CATTGACGTC AATGGGAGTT TGTTTTGGCA CCAAAATCAA CGGGACTTTC

CAAAATGTCG TAACAACTCC GCCCCATTGA CGCAAATGGG CGGTAGGCGT GTACGGTGGG

Figure 13.3

AGGTCTATAT AAGCAGAGCT CGTTTAGTGA ACCGTCAGAT CGCCTGGAGA CGCCATCCAC

GCTGTTTTGA CCTGCTAGCT TATCCGGCCG GGAACGGTGC ATTGGAACGC GGATTCCCCG

TGCCAAGAGT CAGGTAAGTA CCGCCTATAG AGTCTATAGG CCCACCCCCT TGGCTTCGTT

AGAACGCGGC TACAATTAAT ACATAACCTT TTGGATCGAT CCTACTGACA CTGACATCCA

CTTTTTCTTT TTCTCCACAG GTGTCCACTC CCAGGTCCAA CTGCACCTCG GTTCGCGAAG

CTCGCTTGGG CTGCATCGAT TGAATTCCAC C **--Insert Sequence of Interest--**

CGATGG CCGCCATGGC CCAACTTGTT TATTGCAGCT TATAATGGTT

ACAAATAAAG CAATAGCATC ACAAATTTCA CAAATAAAGC ATTTTTTTCA CTGCATTCTA

GTTGTGGTTT GTCCAAACTC ATCAATGTAT CTTATCATGT CTGGATCGGG AATTAATTCG

GCGCAGCACC ATGGCCTGAA ATAAGTTTAA ACCCTCTGAA AGAGGAACTT GGTTAGGTAC

CGACTAGTCT TTTGCAAAAA GCTGTTACCT CGAGCGGCCG CTTAATTAAG GCGCGCCATT

TAAATCCTGC AGGTAACAGC TTGGCACTGG CCGTCGTTTT ACAACGTCGT GACTGGGAAA

ACCCTGGCGT TACCCAACTT AATCGCCTTG CAGCACATCC CCCTTTCGCC AGCTGGCGTA

ATAGCGAAGA GGCCCGCACC GATCGCCCTT CCCAACAGTT GCGCAGCCTG AATGGCGAAT

GGCGCCTGAT GCGGTATTTT CTCCTTACGC ATCTGTGCGG TATTTCACAC CGCATACGTC

AAAGCAACCA TAGTACGCGC CCTGTAGCGG CGCATTAAGC GCGGCGGGTG TGGTGGTTAC

GCGCAGCGTG ACCGCTACAC TTGCCAGCGC CCTAGCGCCC GCTCCTTTCG CTTTCTTCCC

TTCCTTTCTC GCCACGTTCG CCGGCTTTCC CCGTCAAGCT CTAAATCGGG GGCTCCCTTT

Figure 13.4

AGGGTTCCGA TTTAGTGCTT TACGGCACCT CGACCCCAAA AAACTTGATT TGGGTGATGG

TTCACGTAGT GGGCCATCGC CCTGATAGAC GGTTTTTCGC CCTTTGACGT TGGAGTCCAC

GTTCTTTAAT AGTGGACTCT TGTTCCAAAC TGGAACAACA CTCAACCCTA TCTCGGGCTA

TTCTTTTGAT TTATAAGGGA TTTTGCCGAT TTCGGCCTAT TGGTTAAAAA ATGAGCTGAT

TTAACAAAAA TTTAACGCGA ATTTTAACAA AATATTAACG TTTACAATTT TATGGTGCAC

TCTCAGTACA ATCTGCTCTG ATGCCGCATA GTTAAGCCAG CCCCGACACC GCCCCGACAC

CCGCCAACAC CCGCTGACGC GCCCTGACGG GCTTGTCTGC TCCCGGCATC CGCTTACAGA

CAAGCTGTGA CCGTCTCCGG GAGCTGCATG TGTCAGAGGT TTTCACCGTC ATCACCGAAA

CGCGCGAGAG ACGAAAGGGC CTCGTGATAC GCCTATTTTT ATAGGTTAAT GTCATGATAA

TAATGGTTTC TTAGACGTCA GGTGGCACTT TTCGGGGAAA TGTGCGCGGA ACCCCTATTT

GTTTATTTTT CTAAATACAT TCAAATATGT ATCCGCTCAT GAGACAATAA CCCTGATAAA

TGCTTCAATA ATATTGAAAA AGGAAGAGTA TGAGTATTCA ACATTTCCGT GTCGCCCTTA

TTCCCTTTTT TGCGGCATTT TGCCTTCCTG TTTTTGCTCA CCCAGAAACG CTGGTGAAAG

TAAAAGATGC TGAAGATCAG TTGGGTGCAC GAGTGGGTTA CATCGAACTG GATCTCAACA

GCGGTAAGAT CCTTGAGAGT TTTCGCCCCG AAGAACGTTT TCCAATGATG AGCACTTTTA

AAGTTCTGCT ATGTGGCGCG GTATTATCCC GTATTGACGC CGGGCAAGAG CAACTCGGTC

GCCGCATACA CTATTCTCAG AATGACTTGG TTGAGTACTC ACCAGTCACA GAAAAGCATC

TTACGGATGG CATGACAGTA AGAGAATTAT GCAGTGCTGC CATAACCATG AGTGATAACA

Figure 13.5

CTGCGGCCAA CTTACTTCTG ACAACGATCG GAGGACCGAA GGAGCTAACC GCTTTTTTGC

ACAACATGGG GGATCATGTA ACTCGCCTTG ATCGTTGGGA ACCGGAGCTG AATGAAGCCA

TACCAAACGA CGAGCGTGAC ACCACGATGC CTGTAGCAAT GGCAACAACG TTGCGCAAAC

TATTAACTGG CGAACTACTT ACTCTAGCTT CCCGGCAACA ATTAATAGAC TGGATGGAGG

CGGATAAAGT TGCAGGACCA CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG TTTATTGCTG

ATAAATCTGG AGCCGGTGAG CGTGGGTCTC GCGGTATCAT TGCAGCACTG GGGCCAGATG

GTAAGCCCTC CCGTATCGTA GTTATCTACA CGACGGGGAG TCAGGCAACT ATGGATGAAC

GAAATAGACA GATCGCTGAG ATAGGTGCCT CACTGATTAA GCATTGGTAA CTGTCAGACC

AAGTTTACTC ATATATACTT TAGATTGATT TAAAACTTCA TTTTTAATTT AAAAGGATCT

AGGTGAAGAT CCTTTTTGAT AATCTCATGA CCAAAATCCC TTAACGTGAG TTTTCGTTCC

ACTGAGCGTC AGACCCCGTA GAAAAGATCA AAGGATCTTC TTGAGATCCT TTTTTTCTGC

GCGTAATCTG CTGCTTGCAA ACAAAAAAAC CACCGCTACC AGCGGTGGTT TGTTTGCCGG

ATCAAGAGCT ACCAACTCTT TTTCCGAAGG TAACTGGCTT CAGCAGAGCG CAGATACCAA

ATACTGTTCT TCTAGTGTAG CCGTAGTTAG GCCACCACTT CAAGAACTCT GTAGCACCGC

CTACATACCT CGCTCTGCTA ATCCTGTTAC CAGTGGCTGC TGCCAGTGGC GATAAGTCGT

GTCTTACCGG GTTGGACTCA AGACGATAGT TACCGGATAA GGCGCAGCGG TCGGGCTGAA

CGGGGGGTTC GTGCACACAG CCCAGCTTGG AGCGAACGAC CTACACCGAA CTGAGATACC

TACAGCGTGA GCTATGAGAA AGCGCCACGC TTCCCGAAGG GAGAAAGGCG GACAGGTATC

Figure 13.6

CGGTAAGCGG CAGGGTCGGA ACAGGAGAGC GCACGAGGGA GCTTCCAGGG GGAAACGCCT

GGTATCTTTA TAGTCCTGTC GGGTTTCGCC ACCTCTGACT TGAGCGTCGA TTTTTGTGAT

GCTCGTCAGG GGGGCGGAGC CTATGGAAAA ACGCCAGCAA CGCGGCCTTT TTACGGTTCC

TGGCCTTTTG CTGGCCTTTT GCTCACATGT TCTTTCCTGC GTTATCCCCT GATTCTGTGG

ATAACCGTAT TACCGCCTTT GAGTGAGCTG ATACCGCTCG CCGCAGCCGA ACGACCGAGC

GCAGCGAGTC AGTGAGCGAG GAAGCGGAAG AGCGCCCAAT ACGCAAACCG CCTCTCCCCG

CGCGTTGGCC GATTCATTAA TGCAGCTGGC ACGACAGGTT TCCCGACTGG AAAGCGGGCA

GTGAGCGCAA CGCAATTAAT GTGAGTTAGC TCACTCATTA GGCACCCCAG GCTTTACACT

TTATGCTTCC GGCTCGTATG TTGTGTGGAA TTGTGAGCGG ATAACAATTT CACACAGGAA

ACAGCTATGA CATGATTACG AATTAA

Figure 13.7

Figure 14. Plasmid SV40.IPD.Heterologous Polypeptide

```
6     <400>
60    TTCGAGCTCG CCCGACATTG ATTATTGACT AGAGTCGATC GACAGCTGTG GAATGTGTGT
120   CAGTTAGGGT GTGGAAAGTC CCCAGGCTCC CCAGCAGGCA GAAGTATGCA AAGCATGCAT
180   CTCAATTAGT CAGCAACCAG GTGTGGAAAG TCCCCAGGCT CCCCAGCAGG CAGAAGTATG
240   CAAAGCATGC ATCTCAATTA GTCAGCAACC ATAGTCCCGC CCCTAACTCC GCCCATCCCG
300   CCCCTAACTC CGCCCAGTTC CGCCCATTCT CCGCCCCATG GCTGACTAAT TTTTTTTATT
360   TATGCAGAGG CCGAGGCCGC CTCGGCCTCT GAGCTATTCC AGAAGTAGTG AGGAGGCTTT
420   TTTGGAGGCC TAGGCTTTTG CAAAAAGCTA GCTTATCCGG CCGGGAACGG TGCATTGGAA
480   CGCGGATTCC CCGTGCCAAG AGTGACGTAA GTACCGCCTA TAGAGCGACT AGTCCACCAT
540   GACCGAGTAC AAGCCCACGG TGCGCCTCGC CACCCGCGAC GACGTCCCGC GGGCCGTACG
600   CACCCTCGCC GCCGCGTTCG CCGACTACCC CGCCACGCGC CACACCGTAG ACCCGGACCG
660   CCACATCGAG CGGGTCACCG AGCTGCAAGA ACTCTTCCTC ACGCGCGTCG GGCTCGACAT
720   CGGCAAGGTG TGGGTCGCGG ACGACGGCGC CGCGGTGGCG GTCTGGACCA CGCCGGAGAG
780   CGTCGAAGCG GGGGCGGTGT TCGCCGAGAT CGGCCCGCGC ATGGCCGAGT TGAGCGGTTC
840   CCGGCTGGCC GCGCAGCAAC AGATGGAAGG CCTCCTGGCG CCGCACCGGC CCAAGGAGCC
900   CGCGTGGTTC CTGGCCACCG TCGGCGTCTC GCCCGACCAC CAGGGCAAGG GTCTGGGCAG
```

Figure 14.1

960 CGCCGTCGTG CTCCCCGGAG TGGAGGCGGC CGAGCGCGCC GGGGTGCCCG CCTTCCTGGA

1020 GACCTCCGCG CCCCGCAACC TCCCCTTCTA CGAGCGGCTC GGCTTCACCG TCACCGCCGA

1080 CGTCGAGTGC CCGAAGGACC GCGCGACCTG GTGCATGACC CGCAAGCCCG GTGCCAACAT

1140 GGTTCGACCA TTGAACTGCA TCGTCGCCGT GTCCCAAAAT ATGGGGATTG GCAAGAACGG

1200 AGACCTACCC TGCCCTCCGC TCAGGAACGC GTTCAAGTAC TTCCAAAGAA TGACCACAAC

1260 CTCTTCAGTG GAAGGTAAAC AGAATCTGGT GATTATGGGT AGGAAAACCT GGTTCTCCAT

1320 TCCTGAGAAG AATCGACCTT TAAAGGACAG AATTAATATA GTTCTCAGTA GAGAACTCAA

1380 AGAACCACCA CGAGGAGCTC ATTTTCTTGC CAAAAGTTTG GATGATGCCT TAAGACTTAT

1440 TGAACAACCG GAATTGGCAA GTAAAGTAGA CATGGTTTGG ATAGTCGGAG GCAGTTCTGT

1500 TTACCAGGAA GCCATGAATC AACCAGGCCA CCTTAGACTC TTTGTGACAA GGATCATGCA

1560 GGAATTTGAA AGTGACACGT TTTTCCCAGA AATTGATTTG GGGAAATATA AACCTCTCCC

1620 AGAATACCCA GGCGTCCTCT CTGAGGTCCA GGAGGAAAAA GGCATCAAGT ATAAGTTTGA

1680 AGTCTACGAG AAGAAAGACT AACGTTAACT GCTCCCCTCC TAAAGCTATG CATTTTTATA

1740 AGACCATGGG ACTTTTGCTG GCTTTAGATC CCCTTGGCTT CGTTAGAACG CAGCTACAAT

1800 TAATACATAA CCTTATGTAT CATACACATA CGATTTAGGT GACACTATAG ATAACATCCA

1860 CTTTGCCTTT CTCTCCACAG GTGTCCACTC CCAGGTCCAA CTGCACCTCG GTTCTATCGA

1920 TTGAATTCCA CC **-Insert Sequence of Interest-**

CGATGGCC GCCATGGCCC AACTTGTTTA TTGCAGCTTA

Figure 14.2

TAATGGTTAC AAATAAAGCA ATAGCATCAC AAATTTCACA AATAAAGCAT TTTTTTCACT

GCATTCTAGT TGTGGTTTGT CCAAACTCAT CAATGTATCT TATCATGTCT GGATCGGGAA

TTAATTCGGC GCAGCACCAT GGCCTGAAAT AACCTCTGAA AGAGGAACTT GGTTAGGTAC

CTTCTGAGGC GGAAAGAACC AGCTGTGGAA TGTGTGTCAG TTAGGGTGTG GAAAGTCCCC

AGGCTCCCCA GCAGGCAGAA GTATGCAAAG CATGCATCTC AATTAGTCAG CAACCAGGTG

TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG AAGTATGCAA AGCATGCATC TCAATTAGTC

AGCAACCATA GTCCCGCCCC TAACTCCGCC CATCCCGCCC CTAACTCCGC CCAGTTCCGC

CCATTCTCCG CCCCATGGCT GACTAATTTT TTTTATTTAT GCAGAGGCCG AGGCCGCCTC

GGCCTCTGAG CTATTCCAGA AGTAGTGAGG AGGCTTTTTT GGAGGAGCTT TTGCAAAAAG

CTAGCTTATC CGGCCGGGAA CGGTGCATTG GAACGCGGAT TCCCCGTGCC AAGAGTCAGG

TAAGTACCGC CTATAGAGTC TATAGGCCCA CCCCCTTGGC TTCGTTAGAA CGCGGCTACA

ATTAATACAT AACCTTTTGG ATCGATCCTA CTGACACTGA CATCCACTTT TTCTTTTTCT

CCACAGGTGT CCACTCCCAG GTCCAACTGC ACCTCGGTTC GCGAAGCTAG CTTGGGCTGC

ATCGATTGAA TTCCACC **-Insert Sequence of Interest-**

CGATGGCCGC CATGGCCCAA CTTGTTTATT GCAGCTTATA ATGGTTACAA ATAAAGCAAT

AGCATCACAA ATTTCACAAA TAAAGCATTT TTTTCACTGC ATTCTAGTTG TGGTTTGTCC

AAACTCATCA ATGTATCTTA TCATGTCTGG ATCGGGAATT AATTCGGCGC AGCACCATGG

CCTGAAATAA GTTTAAACCC TCTGAAAGAG GAACTTGGTT AGGTACCGAC TAGTCTTTTG

Figure 14.3

CAAAAAGCTG TTACCTCGAG CGGCCGCTTA ATTAAGGCGC GCCATTTAAA TCCTGCAGGT

AACAGCTTGG CACTGGCCGT CGTTTTACAA CGTCGTGACT GGGAAAACCC TGGCGTTACC

CAACTTAATC GCCTTGCAGC ACATCCCCCT TTCGCCAGCT GGCGTAATAG CGAAGAGGCC

CGCACCGATC GCCCTTCCCA ACAGTTGCGC AGCCTGAATG GCGAATGGCG CCTGATGCGG

TATTTTCTCC TTACGCATCT GTGCGGTATT TCACACCGCA TACGTCAAAG CAACCATAGT

ACGCGCCCTG TAGCGGCGCA TTAAGCGCGG CGGGTGTGGT GGTTACGCGC AGCGTGACCG

CTACACTTGC CAGCGCCCTA GCGCCCGCTC CTTTCGCTTT CTTCCCTTCC TTTCTCGCCA

CGTTCGCCGG CTTTCCCCGT CAAGCTCTAA ATCGGGGGCT CCCTTTAGGG TTCCGATTTA

GTGCTTTACG GCACCTCGAC CCCAAAAAAC TTGATTTGGG TGATGGTTCA CGTAGTGGGC

CATCGCCCTG ATAGACGGTT TTTCGCCCTT TGACGTTGGA GTCCACGTTC TTTAATAGTG

GACTCTTGTT CCAAACTGGA ACAACACTCA ACCCTATCTC GGGCTATTCT TTTGATTTAT

AAGGGATTTT GCCGATTTCG GCCTATTGGT TAAAAAATGA GCTGATTTAA CAAAAATTTA

ACGCGAATTT TAACAAAATA TTAACGTTTA CAATTTTATG GTGCACTCTC AGTACAATCT

GCTCTGATGC CGCATAGTTA AGCCAGCCCC GACACCCGCC AACACCCGCT GACGCGCCCT

GACGGGCTTG TCTGCTCCCG GCATCCGCTT ACAGACAAGC TGTGACCGTC TCCGGGAGCT

GCATGTGTCA GAGGTTTTCA CCGTCATCAC CGAAACGCGC GACGAAAGGG CCTCGTGATA

CGCCTATTTT TATAGGTTAA TGTCATGATA ATAATGGTTT CTTAGACGTC AGGTGGCACT

TTTCGGGGAA ATGTGCGCGG AACCCCTATT TGTTTATTTT TCTAAATACA TTCAAATATG

Figure 14.4

TATCCGCTCA TGAGACAATA ACCCTGATAA ATGCTTCAAT AATATTGAAA AAGGAAGAGT

ATGAGTATTC AACATTTCCG TGTCGCCCTT ATTCCCTTTT TTGCGGCATT TTGCCTTCCT

GTTTTTGCTC ACCCAGAAAC GCTGGTGAAA GTAAAAGATG CTGAAGATCA GTTGGGTGCA

CGAGTGGGTT ACATCGAACT GGATCTCAAC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC

GAAGAACGTT TTCCAATGAT GAGCACTTTT AAAGTTCTGC TATGTGGCGC GGTATTATCC

CGTATTGACG CCGGGCAAGA GCAACTCGGT CGCCGCATAC ACTATTCTCA GAATGACTTG

GTTGAGTACT CACCAGTCAC AGAAAAGCAT CTTACGGATG GCATGACAGT AAGAGAATTA

TGCAGTGCTG CCATAACCAT GAGTGATAAC ACTGCGGCCA ACTTACTTCT GACAACGATC

GGAGGACCGA AGGAGCTAAC CGCTTTTTTG CACAACATGG GGGATCATGT AACTCGCCTT

GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA CACCACGATG

CCTGTAGCAA TGGCAACAAC GTTGCGCAAA CTATTAACTG GCGAACTACT TACTCTAGCT

TCCCGGCAAC AATTAATAGA CTGGATGGAG GCGGATAAAG TTGCAGGACC ACTTCTGCGC

TCGGCCCTTC CGGCTGGCTG GTTTATTGCT GATAAATCTG GAGCCGGTGA GCGTGGGTCT

CGCGGTATCA TTGCAGCACT GGGGCCAGAT GGTAAGCCCT CCCGTATCGT AGTTATCTAC

ACGACGGGGA GTCAGGCAAC TATGGATGAA CGAAATAGAC AGATCGCTGA GATAGGTGCC

TCACTGATTA AGCATTGGTA ACTGTCAGAC CAAGTTTACT CATATATACT TTAGATTGAT

TTAAAACTTC ATTTTTAATT TAAAAGGATC TAGGTGAAGA TCCTTTTTGA TAATCTCATG

ACCAAAATCC CTTAACGTGA GTTTTCGTTC CACTGAGCGT CAGACCCCGT AGAAAAGATC

Figure 14.5

AAAGGATCTT CTTGAGATCC TTTTTTTCTG CGCGTAATCT GCTGCTTGCA AACAAAAAAA

CCACCGCTAC CAGCGGTGGT TTGTTTGCCG GATCAAGAGC TACCAACTCT TTTTCCGAAG

GTAACTGGCT TCAGCAGAGC GCAGATACCA AATACTGTCC TTCTAGTGTA GCCGTAGTTA

GGCCACCACT TCAAGAACTC TGTAGCACCG CCTACATACC TCGCTCTGCT AATCCTGTTA

CCAGTGGCTG CTGCCAGTGG CGATAAGTCG TGTCTTACCG GGTTGGACTC AAGACGATAG

TTACCGGATA AGGCGCAGCG GTCGGGCTGA ACGGGGGGTT CGTGCACACA GCCCAGCTTG

GAGCGAACGA CCTACACCGA ACTGAGATAC CTACAGCGTG AGCTATGAGA AAGCGCCACG

CTTCCCGAAG GGAGAAAGGC GGACAGGTAT CCGGTAAGCG GCAGGGTCGG AACAGGAGAG

CGCACGAGGG AGCTTCCAGG GGGAAACGCC TGGTATCTTT ATAGTCCTGT CGGGTTTCGC

CACCTCTGAC TTGAGCGTCG ATTTTTGTGA TGCTCGTCAG GGGGGCGGAG CCTATGGAAA

AACGCCAGCA ACGCGGCCTT TTTACGGTTC CTGGCCTTTT GCTGGCCTTT TGCTCACATG

TTCTTTCCTG CGTTATCCCC TGATTCTGTG GATAACCGTA TTACCGCCTT TGAGTGAGCT

GATACCGCTC GCCGCAGCCG AACGACCGAG CGCAGCGAGT CAGTGAGCGA GGAAGCGGAA

GAGCGCCCAA TACGCAAACC GCCTCTCCCC GCGCGTTGGC CGATTCATTA ATGCAGCTGG

CACGACAGGT TTCCCGACTG GAAAGCGGGC AGTGAGCGCA ACGCAATTAA TGTGAGTTAG

CTCACTCATT AGGCACCCCA GGCTTTACAC TTTATGCTTC CGGCTCGTAT GTTGTGTGGA

ATTGTGAGCG GATAACAATT TCACACAGGA AACAGCTATG ACATGATTAC GAATTAA

Figure 14.6



Figure 15. pCMV.IPD.HP



Figure 16. Timeline and Titer Comparison.

SEQUENCE LISTING

<110> Krummen, Lynne
Shen, Amy
Chisum, Venessa

<120> INTRON FUSION CONSTRUCT AND METHOD OF USING FOR SELECTING HIGH-EXPRESSING
PRODUCTION CELL LINES

<130> 22338/00101

<150> US 60/426,095
<151> 2002-11-14

<160> 4

<170> PatentIn version 3.1

<210> 1
<211> 5147
<212> DNA
<213> Artificial

<220>
<223> plasmid pSV.IPUR circular ds-DNA

<400> 1
ttcgagctcg cccgacattg attattgact agagtcgatc gacagctgtg gaatgtgtgt 60

cagttagggt gtggaaagtc cccaggctcc ccagcaggca gaagtatgca aagcatgcat 120

ctcaattagt cagcaaccag gtgtggaaag tccccaggct ccccagcagg cagaagtatg 180

caaagcatgc atctcaatta gtcagcaacc atagtcccgc ccctaactcc gcccatcccg 240

cccctaactc cgcccagttc cgcccattct ccgccccatg gctgactaat ttttttatt 300

tatgcagagg ccgaggccgc ctcggcctct gagctattcc agaagtagtg aggaggcttt 360

tttggaggcc taggcttttg caaaaagcta gcttatccgg ccgggaacgg tgcattggaa 420

cgcggattcc ccgtgccaag agtgacgtaa gtaccgccta tagagcgact agtccaccat 480

gaccgagtac aagcccacgg tgcgcctcgc cacccgcgac gacgtccccc gggccgtacg 540

caccctcgcc gccgcgttcg ccgactaccc cgccacgcgc cacaccgtcg acccggaccg 600

ccacatcgag cgggtcaccg agctgcaaga actcttcctc acgcgcgtcg ggctcgacat 660

cggcaaggtg tgggtcgcgg acgacggcgc cgcggtggcg gtctggacca cgccggagag 720

cgtcgaagcg ggggcggtgt tcgccgagat cggcccgcgc atggccgagt tgagcggttc 780

ccggctggcc gcgcagcaac agatggaagg cctcctggcg ccgcaccggc ccaaggagcc 840

cgcgtggttc ctggccaccg tcggcgtctc gcccgaccac cagggcaagg gtctgggcag 900

cgccgtcgtg ctccccggag tggaggcggc cgagcgcgcc ggggtgcccg ccttcctgga 960

gacctccgcg ccccgcaacc tccccttcta cgagcggctc ggcttcaccg tcaccgccga 1020

cgtcgagtgc ccgaaggacc gcgcgacctg gtgcatgacc cgcaagcccg gtgcctgagt 1080

taactgctcc cctcctaaag ctatgcattt ttataagacc atgggacttt tgctggcttt 1140

agatcccctt ggcttcgtta gaacgcagct acaattaata cataacctta tgtatcatac 1200

acatacgatt taggtgacac tatagataac atccactttg cctttctctc cacaggtgtc 1260

cactcccagg tccaactgca cctcggttct atcgattgaa ttccccgggg atcctctaga 1320

gtcgacctgc agaagcttcg atggccgcca tggcccaact tgtttattgc agcttataat 1380

ggttacaaat aaagcaatag catcacaaat ttcacaaata aagcattttt ttcactgcat 1440

tctagttgtg gtttgtccaa actcatcaat gtatcttatc atgtctggat cgatcgggaa 1500

ttaattcggc gcagcaccat ggcctgaaat aacctctgaa agaggaactt ggttaggtac 1560

cttctgaggc ggaaagaacc agctgtggaa tgtgtgtcag ttagggtgtg gaaagtcccc 1620

aggctcccca gcaggcagaa gtatgcaaag catgcatctc aattagtcag caaccaggtg 1680

tggaaagtcc ccaggctccc cagcaggcag aagtatgcaa agcatgcatc tcaattagtc 1740

agcaaccata gtcccgcccc taactccgcc catcccgccc ctaactccgc ccagttccgc 1800

ccattctccg ccccatggct gactaatttt ttttatttat gcagaggccg aggccgcctc 1860

ggcctctgag ctattccaga agtagtgagg aggcttttt ggaggcctag gcttttgcaa 1920

aaagctgtta cctcgagcgg ccgcttaatt aaggcgcgcc atttaaatcc tgcaggtaac 1980

agcttggcac tggccgtcgt tttacaacgt cgtgactggg aaaaccctgg cgttacccaa 2040

cttaatcgcc ttgcagcaca tccccccttc gccagctggc gtaatagcga agaggcccgc 2100

accgatcgcc cttcccaaca gttgcgtagc ctgaatggcg aatggcgcct gatgcggtat 2160

tttctcctta cgcatctgtg cggtatttca caccgcatac gtcaaagcaa ccatagtacg 2220

cgccctgtag cggcgcatta agcgcggcgg gtgtggtggt tacgcgcagc gtgaccgcta 2280

cacttgccag cgccctagcg cccgctcctt tcgctttctt cccttccttt ctcgccacgt 2340

tcgccggctt tccccgtcaa gctctaaatc gggggctccc tttagggttc cgatttagtg 2400

ctttacggca cctcgacccc aaaaaacttg atttgggtga tggttcacgt agtgggccat 2460

cgccctgata gacggttttt cgcccctttga cgttggagtc cacgttcttt aatagtggac 2520

tcttgttcca aactggaaca acactcaacc ctatctcggg ctattctttt gatttataag 2580

ggattttgcc gatttcggcc tattggttaa aaaatgagct gatttaacaa aaatttaacg 2640

cgaattttaa caaaatatta acgtttacaa ttttatggtg cactctcagt acaatctgct 2700

ctgatgccgc atagttaagc caactccgct atcgctacgt gactgggtca tggctgcgcc 2760

ccgacacccg ccaacacccg ctgacgcgcc ctgacgggct tgtctgctcc cggcatccgc 2820

ttacagacaa gctgtgaccg tctccgggag ctgcatgtgt cagaggtttt caccgtcatc 2880

accgaaacgc gcgaggcagt attcttgaag acgaaagggc ctcgtgatac gcctattttt 2940

ataggttaat gtcatgataa taatggtttc ttagacgtca ggtggcactt ttcggggaaa 3000

tgtgcgcgga acccctattt gtttattttt ctaaatacat tcaaatatgt atccgctcat 3060

gagacaataa ccctgataaa tgcttcaata atattgaaaa aggaagagta tgagtattca 3120

acatttccgt gtcgccctta ttccctttt tgcggcattt tgccttcctg tttttgctca 3180

cccagaaacg ctggtgaaag taaaagatgc tgaagatcag ttgggtgcac gagtgggtta 3240

catcgaactg gatctcaaca gcggtaagat ccttgagagt tttcgccccg aagaacgttt 3300

tccaatgatg agcactttta aagttctgct atgtggcgcg gtattatccc gtgatgacgc 3360

cgggcaagag caactcggtc gccgcataca ctattctcag aatgacttgg ttgagtactc 3420

accagtcaca gaaaagcatc ttacggatgg catgacagta agagaattat gcagtgctgc 3480

cataaccatg agtgataaca ctgcggccaa cttacttctg acaacgatcg gaggaccgaa 3540

ggagctaacc gcttttttgc acaacatggg ggatcatgta actcgccttg atcgttggga 3600

accggagctg aatgaagcca taccaaacga cgagcgtgac accacgatgc cagcagcaat 3660

ggcaacaacg ttgcgcaaac tattaactgg cgaactactt actctagctt cccggcaaca 3720

attaatagac tggatggagg cggataaagt tgcaggacca cttctgcgct cggcccttcc 3780

ggctggctgg tttattgctg ataaatctgg agccggtgag cgtgggtctc gcggtatcat 3840

tgcagcactg gggccagatg gtaagccctc ccgtatcgta gttatctaca cgacggggag 3900

tcaggcaact atggatgaac gaaatagaca gatcgctgag ataggtgcct cactgattaa 3960

gcattggtaa ctgtcagacc aagtttactc atatatactt tagattgatt taaaacttca 4020

tttttaattt aaaaggatct aggtgaagat cctttttgat aatctcatga ccaaaatccc 4080

ttaacgtgag ttttcgttcc actgagcgtc agaccccgta gaaaagatca aaggatcttc 4140

ttgagatcct ttttttctgc gcgtaatctg ctgcttgcaa acaaaaaaac caccgctacc 4200

agcggtggtt tgtttgccgg atcaagagct accaactctt tttccgaagg taactggctt 4260

cagcagagcg cagataccaa atactgtcct tctagtgtag ccgtagttag gccaccactt 4320

caagaactct gtagcaccgc ctacatacct cgctctgcta atcctgttac cagtggctgc 4380

tgccagtggc gataagtcgt gtcttaccgg gttggactca agacgatagt taccggataa 4440

ggcgcagcgg tcgggctgaa cgggggggttc gtgcacacag cccagcttgg agcgaacgac 4500

ctacaccgaa ctgagatacc tacagcgtga gcattgagaa agcgccacgc ttcccgaagg 4560

gagaaaggcg gacaggtatc cggtaagcgg cagggtcgga acaggagagc gcacgaggga 4620

gcttccaggg ggaaacgcct ggtatcttta tagtcctgtc gggtttcgcc acctctgact 4680

tgagcgtcga tttttgtgat gctcgtcagg ggggcggagc ctatggaaaa acgccagcaa 4740

cgcggccttt ttacggttcc tggccttttg ctggcctttt gctcacatgt tctttcctgc 4800

gttatcccct gattctgtgg ataaccgtat taccgccttt gagtgagctg ataccgctcg 4860

ccgcagccga acgaccgagc gcagcgagtc agtgagcgag gaagcggaag agcgcccaat 4920

acgcaaaccg cctctccccg cgcgttggcc gattcattaa tccagctggc acgacaggtt 4980

tcccgactgg aaagcgggca gtgagcgcaa cgcaattaat gtgagttacc tcactcatta 5040

ggcaccccag gctttacact ttatgcttcc ggctcgtatg ttgtgtggaa ttgtgagcgg 5100

tattgttaaa gtgtgtcctt tgtcgatact ggtactaatg cttaatt 5147

<210> 2
<211> 5171
<212> DNA
<213> Artificial

<220>
<223> plasmid pSV.ID circular ds-DNA

<220>
<221> misc_feature
<222> (444)..(444)
<223> splice donor

<220>
<221> misc_feature
<222> (1946)..(1946)
<223> start pUC118

<220>
<221> misc_feature
<222> (1954)..(1954)
<223> linearization linker inserted into Hpal site

<220>

<221> misc_feature
<222> (529)..(1090)
<223> DHFR coding region

<220>
<221> misc_feature
<222> (1522)..(1522)
<223> sv40 origin

<400> 2
ttcgagctcg cccgacattg attattgact agagtcgatc gacagctgtg gaatgtgtgt 60

cagttagggt gtggaaagtc cccaggctcc ccagcaggca gaagtatgca aagcatgcat 120

ctcaattagt cagcaaccag gtgtggaaag tccccaggct ccccagcagg cagaagtatg 180

caaagcatgc atctcaatta gtcagcaacc atagtcccgc ccctaactcc gcccatcccg 240

cccctaactc cgcccagttc cgcccattct ccgccccatg gctgactaat ttttttatt 300

tatgcagagg ccgaggccgc ctcggcctct gagctattcc agaagtagtg aggaggcttt 360

tttggaggcc taggcttttg caaaaagcta gcttatccgg ccgggaacgg tgcattggaa 420

cgcggattcc ccgtgccaag agtgacgtaa gtaccgccta tagagtctat aggcccaccc 480

cttggctcta gagagatata agcctaggat tttatccccg gtgccatcat ggttcgacca 540

ttgaactgca tcgtcgccgt gtcccaaaat atggggattg gcaagaacgg agacctaccc 600

tgccctccgc tcaggaacgc gttcaagtac ttccaaagaa tgaccacaac ctcttcagtg 660

gaaggtaaac agaatctggt gattatgggt aggaaaacct ggttctccat tcctgagaag 720

aatcgacctt taaaggacag aattaatata gttctcagta gagaactcaa agaaccacca 780

cgaggagctc attttcttgc caaaagtttg gatgatgcct taagacttat tgaacaaccg 840

gaattggcaa gtaaagtaga catggtttgg atagtcggag gcagttctgt ttaccaggaa 900

gccatgaatc aaccaggcca ccttagactc tttgtgacaa ggatcatgca ggaatttgaa 960

agtgacacgt ttttcccaga aattgatttg gggaaatata aacctctccc agaataccca 1020

ggcgtcctct ctgaggtcca ggaggaaaaa ggcatcaagt ataagtttga agtctacgag 1080

aagaaagact aacaggaaga tgctttcaag ttctctgctc ccctcctaaa gctatgcatt 1140

tttataagac catgggactt ttgctggctt tagacccccc tggcttcgtt agaacgcggc 1200

tacaattaat acataacctt atgtatcata cacatagatt taggtgacac tatagaataa 1260

catccacttt gcctttctct ccacaggtgt cactccaggt caactgcacc tcggttctat 1320

cgattgaatt ccccggggat cctctagagt cgacctgcag aagcttggcc gccatggccc 1380

aacttgttta ttgcagctta taatggttac aaataaagca atagcatcac aaatttcaca 1440

aataaagcat ttttttcact gcattctagt tgtggtttgt ccaaactcat caatgtatct 1500

tatcatgtct ggatcgatcg ggaattaatt cggcgcagca ccatggcctg aaataacctc 1560

tgaaagagga acttggttag gtaccttctg aggcggaaag aaccagctgt ggaatgtgtg 1620

tcagttaggg tgtggaaagt ccccaggctc cccagcaggc agaagtatgc aaagcatgca 1680

tctcaattag tcagcaacca ggtgtggaaa gtccccaggc tccccagcag gcagaagtat 1740

gcaaagcatg catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc 1800

gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 1860

ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 1920

ttttggaggc ctaggctttt gcaaaaagct gttacctcga gcggccgctt aattaaggcg 1980

cgccatttaa atcctgcagg taacagcttg gcactggccg tcgttttaca acgtcgtgac 2040

tgggaaaacc ctggcgttac ccaacttaat cgccttgcag cacatccccc cttcgccagc 2100

tggcgtaata gcgaagaggc ccgcaccgat cgcccttccc aacagttgcg tagcctgaat 2160

ggcgaatggc gcctgatgcg gtattttctc cttacgcatc tgtgcggtat ttcacaccgc 2220

atacgtcaaa gcaaccatag tacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg 2280

tggttacgcg cagcgtgacc gctacacttg ccagcgccct agcgcccgct cctttcgctt 2340

tcttcccttc ctttctcgcc acgttcgccg gctttccccg tcaagctcta aatcgggggc 2400

tcccctttagg gttccgattt agtgctttac ggcacctcga ccccaaaaaa cttgatttgg 2460

gtgatggttc acgtagtggg ccatcgccct gatagacggt ttttcgccct ttgacgttgg 2520

agtccacgtt ctttaatagt ggactcttgt tccaaactgg aacaacactc aaccctatct 2580

cgggctattc ttttgattta taagggattt tgccgatttc ggcctattgg ttaaaaaatg 2640

agctgattta acaaaaattt aacgcgaatt ttaacaaaat attaacgttt acaattttat 2700

ggtgcactct cagtacaatc tgctctgatg ccgcatagtt aagccaactc cgctatcgct 2760

acgtgactgg gtcatggctg cgccccgaca cccgccaaca cccgctgacg cgccctgacg 2820

ggcttgtctg ctcccggcat ccgcttacag acaagctgtg accgtctccg ggagctgcat 2880

gtgtcagagg ttttcaccgt catcaccgaa acgcgcgagg cagtattctt gaagacgaaa 2940

gggcctcgtg atacgcctat ttttataggt taatgtcatg ataataatgg tttcttagac 3000

gtcaggtggc acttttcggg gaaatgtgcg cggaacccct atttgtttat ttttctaaat 3060

acattcaaat atgtatccgc tcatgagaca ataaccctga taaatgcttc aataatattg 3120

aaaaaggaag agtatgagta ttcaacattt ccgtgtcgcc cttattccct tttttgcggc 3180

attttgcctt cctgtttttg ctcacccaga aacgctggtg aaagtaaaag atgctgaaga 3240

tcagttgggt gcacgagtgg gttacatcga actggatctc aacagcggta agatccttga 3300

gagttttcgc cccgaagaac gttttccaat gatgagcact tttaaagttc tgctatgtgg 3360

cgcggtatta tcccgtgatg acgccgggca agagcaactc ggtcgccgca tacactattc 3420

tcagaatgac ttggttgagt actcaccagt cacagaaaag catcttacgg atggcatgac 3480

agtaagagaa ttatgcagtg ctgccataac catgagtgat aacactgcgg ccaacttact 3540

tctgacaacg atcggaggac cgaaggagct aaccgctttt ttgcacaaca tgggggatca 3600

tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa gccataccaa acgacgagcg 3660

tgacaccacg atgccagcag caatggcaac aacgttgcgc aaactattaa ctggcgaact 3720

acttactcta gcttcccggc aacaattaat agactggatg gaggcggata aagttgcagg 3780

accacttctg cgctcggccc ttccggctgg ctggtttatt gctgataaat ctggagccgg 3840

tgagcgtggg tctcgcggta tcattgcagc actggggcca gatggtaagc cctcccgtat 3900

cgtagttatc tacacgacgg ggagtcaggc aactatggat gaacgaaata gacagatcgc 3960

tgagataggt gcctcactga ttaagcattg gtaactgtca gaccaagttt actcatatat 4020

actttagatt gatttaaaac ttcattttta atttaaaagg atctaggtga agatcctttt 4080

tgataatctc atgaccaaaa tcccttaacg tgagttttcg ttccactgag cgtcagaccc 4140

cgtagaaaag atcaaaggat cttcttgaga tccttttttt ctgcgcgtaa tctgctgctt 4200

gcaaacaaaa aaaccaccgc taccagcggt ggtttgtttg ccggatcaag agctaccaac 4260

tctttttccg aaggtaactg gcttcagcag agcgcagata ccaaatactg tccttctagt 4320

gtagccgtag ttaggccacc acttcaagaa ctctgtagca ccgcctacat acctcgctct 4380

gctaatcctg ttaccagtgg ctgctgccag tggcgataag tcgtgtctta ccgggttgga 4440

ctcaagacga tagttaccgg ataaggcgca gcggtcgggc tgaacggggg gttcgtgcac 4500

acagcccagc ttggagcgaa cgacctacac cgaactgaga tacctacagc gtgagcattg 4560

agaaagcgcc acgcttcccg aagggagaaa ggcggacagg tatccggtaa gcggcagggt 4620

cggaacagga gagcgcacga gggagcttcc agggggaaac gcctggtatc tttatagtcc 4680

tgtcgggttt cgccacctct gacttgagcg tcgatttttg tgatgctcgt caggggggcg 4740

gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg ttcctggcct tttgctggcc 4800

ttttgctcac atgttctttc ctgcgttatc ccctgattct gtggataacc gtattaccgc 4860

ctttgagtga gctgataccg ctcgccgcag ccgaacgacc gagcgcagcg agtcagtgag 4920

cgaggaagcg gaagagcgcc caatacgcaa accgcctctc cccgcgcgtt ggccgattca 4980

ttaatccagc tggcacgaca ggtttcccga ctggaaagcg ggcagtgagc gcaacgcaat 5040

taatgtgagt tacctcactc attaggcacc ccaggcttta cactttatgc ttccggctcg 5100

tatgttgtgt ggaattgtga gcggataaca atttcacaca ggaaacagct atgaccatga 5160

ttacgaatta a 5171

<210> 3
<211> 5712
<212> DNA
<213> Artificial

<220>
<223> plasmid pSV.IPD circular ds-DNA

<220>
<221> misc_feature
<222> (444)..(444)
<223> splice donor

<220>
<221> misc_feature
<222> (479)..(479)
<223> start PUR coding

<220>
<221> misc_feature
<222> (1079)..(1643)
<223> DHFR coding region

<400> 3
ttcgagctcg cccgacattg attattgact agagtcgatc gacagctgtg gaatgtgtgt 60

cagttagggt gtggaaagtc cccaggctcc ccagcaggca gaagtatgca aagcatgcat 120

ctcaattagt cagcaaccag gtgtggaaag tccccaggct ccccagcagg cagaagtatg 180

caaagcatgc atctcaatta gtcagcaacc atagtcccgc ccctaactcc gcccatcccg 240

cccctaactc cgcccagttc cgcccattct ccgccccatg gctgactaat ttttttatt 300

tatgcagagg ccgaggccgc ctcggcctct gagctattcc agaagtagtg aggaggcttt 360

tttggaggcc taggcttttg caaaaagcta gcttatccgg ccgggaacgg tgcattggaa 420

cgcggattcc ccgtgccaag agtgacgtaa gtaccgccta tagagcgact agtccaccat 480

gaccgagtac aagcccacgg tgcgcctcgc cacccgcgac gacgtcccgc gggccgtacg 540

caccctcgcc gccgcgttcg ccgactaccc cgccacgcgc cacaccgtag acccggaccg 600

ccacatcgag cgggtcaccg agctgcaaga actcttcctc acgcgcgtcg ggctcgacat 660

cggcaaggtg tgggtcgcgg acgacggcgc cgcggtggcg gtctggacca cgccggagag 720

cgtcgaagcg ggggcggtgt tcgccgagat cggcccgcgc atggccgagt tgagcggttc 780

ccggctggcc gcgcagcaac agatggaagg cctcctggcg ccgcaccggc ccaaggagcc 840

cgcgtggttc ctggccaccg tcggcgtctc gcccgaccac cagggcaagg gtctgggcag 900

cgccgtcgtg ctccccggag tggaggcggc cgagcgcgcc ggggtgcccg ccttcctgga 960

gacctccgcg ccccgcaacc tccccttcta cgagcggctc ggcttcaccg tcaccgccga 1020

cgtcgagtgc ccgaaggacc gcgcgacctg gtgcatgacc cgcaagcccg gtgccaacat 1080

ggttcgacca ttgaactgca tcgtcgccgt gtcccaaaat atggggattg gcaagaacgg 1140

agacctaccc tgccctccgc tcaggaacgc gttcaagtac ttccaaagaa tgaccacaac 1200

ctcttcagtg gaaggtaaac agaatctggt gattatgggt aggaaaacct ggttctccat 1260

tcctgagaag aatcgacctt taaaggacag aattaatata gttctcagta gagaactcaa 1320

agaaccacca cgaggagctc attttcttgc caaaagtttg gatgatgcct taagacttat 1380

tgaacaaccg gaattggcaa gtaaagtaga catggtttgg atagtcggag gcagttctgt 1440

ttaccaggaa gccatgaatc aaccaggcca ccttagactc tttgtgacaa ggatcatgca 1500

ggaatttgaa agtgacacgt ttttcccaga aattgatttg gggaaatata aacctctccc 1560

agaataccca ggcgtcctct ctgaggtcca ggaggaaaaa ggcatcaagt ataagtttga 1620

agtctacgag aagaaagact aacgttaact gctcccctcc taaagctatg catttttata 1680

agaccatggg acttttgctg gctttagatc cccttggctt cgttagaacg cagctacaat 1740

taatacataa ccttatgtat catacacata cgatttaggt gacactatag ataacatcca 1800

ctttgccttt ctctccacag gtgtccactc ccaggtccaa ctgcacctcg gttctatcga 1860

ttgaattccc cggggatcct ctagagtcga cctgcagaag cttcgatggc cgccatggcc 1920

caacttgttt attgcagctt ataatggtta caaataaagc aatagcatca caaatttcac 1980

aaataaagca ttttttttcac tgcattctag ttgtggtttg tccaaactca tcaatgtatc 2040

ttatcatgtc tggatcgatc gggaattaat tcggcgcagc accatggcct gaaataacct 2100

ctgaaagagg aacttggtta ggtaccttct gaggcggaaa gaaccagctg tggaatgtgt 2160

gtcagttagg gtgtggaaag tccccaggct ccccagcagg cagaagtatg caaagcatgc 2220

atctcaatta gtcagcaacc aggtgtggaa agtccccagg ctccccagca ggcagaagta 2280

tgcaaagcat gcatctcaat tagtcagcaa ccatagtccc gcccctaact ccgcccatcc 2340

cgcccctaac tccgcccagt tccgcccatt ctccgcccca tggctgacta attttttta 2400

tttatgcaga ggccgaggcc gcctcggcct ctgagctatt ccagaagtag tgaggaggct 2460

tttttggagg cctaggcttt tgcaaaaagc tgttacctcg agcggccgct taattaaggc 2520

gcgccattta aatcctgcag gtaacagctt ggcactggcc gtcgttttac aacgtcgtga 2580

ctgggaaaac cctggcgtta cccaacttaa tcgccttgca gcacatcccc ccttcgccag 2640

ctggcgtaat agcgaagagg cccgcaccga tcgcccttcc caacagttgc gtagcctgaa 2700

tggcgaatgg cgcctgatgc ggtattttct ccttacgcat ctgtgcggta tttcacaccg 2760

catacgtcaa agcaaccata gtacgcgccc tgtagcggcg cattaagcgc ggcgggtgtg 2820

gtggttacgc gcagcgtgac cgctacactt gccagcgccc tagcgcccgc tcctttcgct 2880

ttcttccctt cctttctcgc cacgttcgcc ggctttcccc gtcaagctct aaatcggggg 2940

ctcccttag ggttccgatt tagtgcttta cggcacctcg accccaaaaa acttgatttg 3000

ggtgatggtt cacgtagtgg gccatcgccc tgatagacgg tttttcgccc tttgacgttg 3060

gagtccacgt tctttaatag tggactcttg ttccaaactg gaacaacact caaccctatc 3120

tcgggctatt cttttgattt ataagggatt ttgccgattt cggcctattg gttaaaaaat 3180

gagctgattt aacaaaaatt taacgcgaat tttaacaaaa tattaacgtt tacaatttta 3240

tggtgcactc tcagtacaat ctgctctgat gccgcatagt taagccaact ccgctatcgc 3300

tacgtgactg ggtcatggct gcgccccgac acccgccaac acccgctgac gcgccctgac 3360

gggcttgtct gctcccggca tccgcttaca gacaagctgt gaccgtctcc gggagctgca 3420

tgtgtcagag gttttcaccg tcatcaccga aacgcgcgag gcagtattct tgaagacgaa 3480

agggcctcgt gatacgccta tttttatagg ttaatgtcat gataataatg gtttcttaga 3540

cgtcaggtgg cacttttcgg ggaaatgtgc gcggaacccc tatttgttta tttttctaaa 3600

tacattcaaa tatgtatccg ctcatgagac aataaccctg ataaatgctt caataatatt 3660

gaaaaaggaa gagtatgagt attcaacatt tccgtgtcgc ccttattccc ttttttgcgg 3720

cattttgcct tcctgttttt gctcacccag aaacgctggt gaaagtaaaa gatgctgaag 3780

atcagttggg tgcacgagtg ggttacatcg aactggatct caacagcggt aagatccttg 3840

agagttttcg ccccgaagaa cgttttccaa tgatgagcac ttttaaagtt ctgctatgtg 3900

gcgcggtatt atcccgtgat gacgccgggc aagagcaact cggtcgccgc atacactatt 3960

ctcagaatga cttggttgag tactcaccag tcacagaaaa gcatcttacg gatggcatga 4020

cagtaagaga attatgcagt gctgccataa ccatgagtga taacactgcg gccaacttac 4080

ttctgacaac gatcggagga ccgaaggagc taaccgcttt tttgcacaac atgggggatc 4140

atgtaactcg ccttgatcgt tgggaaccgg agctgaatga agccatacca aacgacgagc 4200

gtgacaccac gatgccagca gcaatggcaa caacgttgcg caaactatta actggcgaac 4260

tacttactct agcttcccgg caacaattaa tagactggat ggaggcggat aaagttgcag 4320

gaccacttct gcgctcggcc cttccggctg gctggtttat tgctgataaa tctggagccg 4380

gtgagcgtgg gtctcgcggt atcattgcag cactggggcc agatggtaag ccctcccgta 4440

tcgtagttat ctacacgacg gggagtcagg caactatgga tgaacgaaat agacagatcg 4500

ctgagatagg tgcctcactg attaagcatt ggtaactgtc agaccaagtt tactcatata 4560

tactttagat tgatttaaaa cttcattttt aatttaaaag gatctaggtg aagatccttt 4620

ttgataatct catgaccaaa atcccttaac gtgagttttc gttccactga gcgtcagacc 4680

ccgtagaaaa gatcaaagga tcttcttgag atccttttttt tctgcgcgta atctgctgct 4740

tgcaaacaaa aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa gagctaccaa 4800

ctcttttttcc gaaggtaact ggcttcagca gagcgcagat accaaatact gtccttctag 4860

tgtagccgta gttaggccac cacttcaaga actctgtagc accgcctaca tacctcgctc 4920

tgctaatcct gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt accgggttgg 4980

actcaagacg atagttaccg gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca 5040

cacagcccag cttggagcga acgacctaca ccgaactgag atacctacag cgtgagcatt 5100

gagaaagcgc cacgcttccc gaagggagaa aggcggacag gtatccggta agcggcaggg 5160

tcggaacagg agagcgcacg agggagcttc caggggggaaa cgcctggtat ctttatagtc 5220

ctgtcgggtt tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc 5280

ggagcctatg gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc ttttgctggc 5340

cttttgctca catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg 5400

cctttgagtg agctgatacc gctcgccgca gccgaacgac cgagcgcagc gagtcagtga 5460

gcgaggaagc ggaagagcgc ccaatacgca aaccgcctct ccccgcgcgt tggccgattc 5520

attaatccag ctggcacgac aggtttcccg actggaaagc gggcagtgag cgcaacgcaa 5580

ttaatgtgag ttacctcact cattaggcac cccaggcttt acactttatg cttccggctc 5640

gtatgttgtg tggaattgtg agcggataac aatttcacac aggaaacagc tatgaccatg 5700

attacgaatt aa 5712

<210> 4
<211> 12514
<212> DNA
<213> Artificial

<220>
<223> plasmid pSV.IPD.2C4 circular ds-DNA

<220>
<221> misc_feature
<222> (444)..(444)
<223> splice donor

<220>
<221> misc_feature
<222> (479)..(479)
<223> start PUR coding

<220>
<221> misc_feature
<222> (1079)..(1643)
<223> DHFR coding region

<220>
<221> misc_feature
<222> (1883)..(1883)
<223> start 2C4 HC coding

<220>
<221> misc_feature
<222> (4154)..(4154)
<223> start LC coding

<400> 4
ttcgagctcg cccgacattg attattgact agagtcgatc gacagctgtg gaatgtgtgt 60

cagttagggt gtggaaagtc cccaggctcc ccagcaggca gaagtatgca aagcatgcat 120

ctcaattagt cagcaaccag gtgtggaaag tccccaggct ccccagcagg cagaagtatg 180

caaagcatgc atctcaatta gtcagcaacc atagtcccgc ccctaactcc gcccatcccg 240

cccctaactc cgcccagttc cgcccattct ccgccccatg gctgactaat ttttttatt 300

tatgcagagg ccgaggccgc ctcggcctct gagctattcc agaagtagtg aggaggcttt 360

tttggaggcc taggcttttg caaaaagcta gcttatccgg ccgggaacgg tgcattggaa 420

cgcggattcc ccgtgccaag agtgacgtaa gtaccgccta tagagcgact agtccaccat 480

gaccgagtac aagcccacgg tgcgcctcgc cacccgcgac gacgtcccgc gggccgtacg 540

caccctcgcc gccgcgttcg ccgactaccc cgccacgcgc cacaccgtag acccggaccg 600

ccacatcgag cgggtcaccg agctgcaaga actcttcctc acgcgcgtcg ggctcgacat 660

cggcaaggtg tgggtcgcgg acgacggcgc cgcggtggcg gtctggacca cgccggagag 720

cgtcgaagcg ggggcggtgt tcgccgagat cggcccgcgc atggccgagt tgagcggttc 780

ccggctggcc gcgcagcaac agatggaagg.cctcctggcg ccgcaccggc ccaaggagcc 840

cgcgtggttc ctggccaccg tcggcgtctc gcccgaccac cagggcaagg gtctgggcag 900

cgccgtcgtg ctccccggag tggaggcggc cgagcgcgcc ggggtgcccg ccttcctgga 960

gacctccgcg ccccgcaacc tcccccttcta cgagcggctc ggcttcaccg tcaccgccga 1020

cgtcgagtgc ccgaaggacc gcgcgacctg gtgcatgacc cgcaagcccg gtgccaacat 1080

ggttcgacca ttgaactgca tcgtcgccgt gtcccaaaat atggggattg gcaagaacgg 1140

agacctaccc tgccctccgc tcaggaacgc gttcaagtac ttccaaagaa tgaccacaac 1200

ctcttcagtg gaaggtaaac agaatctggt gattatgggt aggaaaacct ggttctccat 1260

tcctgagaag aatcgacctt taaaggacag aattaatata gttctcagta gagaactcaa 1320

agaaccacca cgaggagctc attttcttgc caaaagtttg gatgatgcct taagacttat 1380

tgaacaaccg gaattggcaa gtaaagtaga catggtttgg atagtcggag gcagttctgt 1440

ttaccaggaa gccatgaatc aaccaggcca ccttagactc tttgtgacaa ggatcatgca 1500

ggaatttgaa agtgacacgt ttttcccaga aattgatttg gggaaatata aacctctccc 1560

agaataccca ggcgtcctct ctgaggtcca ggaggaaaaa ggcatcaagt ataagtttga 1620

agtctacgag aagaaagact aacgttaact gctcccctcc taaagctatg catttttata 1680

agaccatggg acttttgctg gctttagatc cccttggctt cgttagaacg cagctacaat 1740

taatacataa ccttatgtat catacacata cgatttaggt gacactatag aataacatcc 1800

actttgcctt tctctccaca ggtgtccact cccaggtcca actgcacctc ggttctatcg 1860

attgaattcc accatgggat ggtcatgtat catccttttt ctagtagcaa ctgcaactgg 1920

agtacattca gaagttcagc tggtggagtc tggcggtggc ctggtgcagc cagggggctc 1980

actccgtttg tcctgtgcag cttctggctt caccttcacc gactatacca tggactgggt 2040

ccgtcaggcc ccgggtaagg gcctggaatg ggttgcagat gttaatccta acagtggcgg 2100

ctctatctat aaccagcgct tcaagggccg tttcactctg agtgttgaca gatctaaaaa 2160

cacattatac ctgcagatga acagcctgcg tgctgaggac actgccgtct attattgtgc 2220

tcgtaacctg ggaccctctt tctactttga ctactggggt caaggaaccc tggtcaccgt 2280

ctcctcggcc tccaccaagg gcccatcggt cttccccctg gcaccctcct ccaagagcac 2340

ctctgggggc acagcggccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac 2400

ggtgtcgtgg aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca 2460

gtcctcagga ctctactccc tcagcagcgt ggtgactgtg ccctctagca gcttgggcac 2520

ccagacctac atctgcaacg tgaatcacaa gcccagcaac accaaggtgg acaagaaagt 2580

tgagcccaaa tcttgtgaca aaactcacac atgcccaccg tgcccagcac ctgaactcct 2640

gggggggaccg tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg 2700

gacccctgag gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt 2760

caactggtac gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca 2820

gtacaacagc acgtaccggg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa 2880

tggcaaggag tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac 2940

catctccaaa gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg 3000

ggaagagatg accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag 3060

cgacatcgcc gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc 3120

tcccgtgctg gactccgacg gctccttctt cctctacagc aagctcaccg tggacaagag 3180

caggtggcag caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca 3240

ctacacgcag aagagcctct ccctgtctcc gggtaaatga gtgcgacggc cctagagtcg 3300

acctgcagaa gcttcgatgg ccgccatggc ccaacttgtt tattgcagct tataatggtt 3360

acaaataaag caatagcatc acaaatttca caaataaagc attttttttca ctgcattcta 3420

gttgtggttt gtccaaactc atcaatgtat cttatcatgt ctggatcggg aattaattcg 3480

gcgcagcacc atggcctgaa ataacctctg aaagaggaac ttggttaggt accttctgag 3540

gcggaaagaa ccagctgtgg aatgtgtgtc agttagggtg tggaaagtcc ccaggctccc 3600

cagcaggcag aagtatgcaa agcatgcatc tcaattagtc agcaaccagg tgtggaaagt 3660

ccccaggctc cccagcaggc agaagtatgc aaagcatgca tctcaattag tcagcaacca 3720

tagtcccgcc cctaactccg cccatcccgc ccctaactcc gcccagttcc gcccattctc 3780

cgccccatgg ctgactaatt ttttttattt atgcagaggc cgaggccgcc tcggcctctg 3840

agctattcca gaagtagtga ggaggctttt ttggaggact aggcttttgc aaaaagctag 3900

cttatccggc cgggaacggt gcattggaac gcggattccc cgtgccaaga gtcaggtaag 3960

taccgcctat agagtctata ggcccacccc cttggcttcg ttagaacgcg gctacaatta 4020

atacataacc ttttggatcg atcctactga cactgacatc cacttttttct ttttctccac 4080

aggtgtccac tcccaggtcc aactgcacct cggttcgcga agctagcttg ggctgcatcg 4140

attgaattcc accatgggat ggtcatgtat catccttttt ctagtagcaa ctgcaactgg 4200

agtacattca gatatccaga tgacccagtc cccgagctcc ctgtccgcct ctgtgggcga 4260

tagggtcacc atcacctgca aggccagtca ggatgtgtct attggtgtcg cctggtatca 4320

acagaaacca ggaaaagctc cgaaactact gatttactcg gcttcctacc gatacactgg 4380

agtcccttct cgcttctctg gatccggttc tgggacggat ttcactctga ccatcagcag 4440

tctgcagcca gaagacttcg caacttatta ctgtcaacaa tattatattt atccttacac 4500

gtttggacag ggtaccaagg tggagatcaa acgaactgtg gctgcaccat ctgtcttcat 4560

cttcccgcca tctgatgagc agttgaaatc tggaactgct tctgttgtgt gcctgctgaa 4620

taacttctat cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg 4680

taactcccag gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag 4740

caccctgacg ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac 4800

ccatcagggc ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttaagcttc 4860

gatggccgcc atggcccaac ttgtttattg cagcttataa tggttacaaa taaagcaata 4920

gcatcacaaa tttcacaaat aaagcatttt tttcactgca ttctagttgt ggtttgtcca 4980

aactcatcaa tgtatcttat catgtctgga tcgggaatta attcggcgca gcaccatggc 5040

ctgaaataag tttaaaccct ctgaaagagg aacttggtta ggtaccgact agtagcaagg 5100

tcgccacgca caagatcaat attaacaatc agtcatctct ctttagcaat aaaaaggtga 5160

aaaattacat tttaaaaatg acaccataga cgatgtatga aaataatcta cttggaaata 5220

aatctaggca aagaagtgca agactgttac ccagaaaact tacaaattgt aaatgagagg 5280

ttagtgaaga tttaaatgaa tgaagatcta aataaactta taaattgtga gagaaattaa 5340

tgaatgtcta agttaatgca gaaacggaga gacatactat attcatgaac taaaagactt 5400

aatattgtga aggtatactt tcttttcaca taaatttgta gtcaatatgt tcaccccaaa 5460

aaagctgttt gttaacttgt caacctcatt tcaaaatgta tatagaaagc ccaaagacaa 5520

taacaaaaat attcttgtag aacaaaatgg gaaagaatgt tccactaaat atcaagattt 5580

agagcaaagc atgagatgtg tggggataga cagtgaggct gataaaatag agtagagctc 5640

agaaacagac ccattgatat atgtaagtga cctatgaaaa aaatatggca ttttacaatg 5700

ggaaaatgat gatctttttc ttttttagaa aaacagggaa atatatttat atgtaaaaaa 5760

taaaagggaa cccatatgtc ataccataca cacaaaaaaa ttccagtgaa ttataagtct 5820

aaatggagaa ggcaaaactt taaatctttt agaaaataat atagaagcat gccatcatga 5880

cttcagtgta gagaaaaatt tcttatgact caaagtccta accacaaaga aaagattgtt 5940

aattagattg catgaatatt aagacttatt tttaaaatta aaaaaccatt aagaaaagtc 6000

aggccataga atgacagaaa atatttgcaa caccccagta aagagaattg taatatgcag 6060

attataaaaa gaagtcttac aaatcagtaa aaaataaaac tagacaaaaa tttgaacaga 6120

tgaaagagaa actctaaata atcattacac atgagaaact caatctcaga aatcagagaa 6180

ctatcattgc atatacacta aattagagaa atattaaaag gctaagtaac atctgtggca 6240

atattgatgg tatataacct tgatatgatg tgatgagaac agtactttac cccatgggct 6300

tcctccccaa acccttaccc cagtataaat catgacaaat atactttaaa aaccattacc 6360

ctatatctaa ccagtactcc tcaaaactgt caaggtcatc aaaaataaga aaagtctgag 6420

gaactgtcaa aactaagagg aacccaagga gacatgagaa ttatatgtaa tgtggcattc 6480

tgaatgagat cccagaacag aaaaagaaca gtagctaaaa aactaatgaa atataaataa 6540

agtttgaact ttagtttttt ttaaaaaaga gtagcattaa cacggcaaag tcattttcat 6600

atttttcttg aacattaagt acaagtctat aattaaaaat tttttaaatg tagtctggaa 6660

cattgccaga aacagaagta cagcagctat ctgtgctgtc gcctaactat ccatagctga 6720

ttggtctaaa atgagataca tcaacgctcc tccatgtttt ttgttttctt tttaaatgaa 6780

aaactttatt ttttaagagg agtttcaggt tcatagcaaa attgagagga aggtacattc 6840

aagctgagga agttttcctc tattcctagt ttactgagag attgcatcat gaatgggtgt 6900

taaattttgt caaatgcttt ttctgtgtct atcaatatga ccatgtgatt ttcttcttta 6960

acctgttgat gggacaaatt acgttaattg attttcaaac gttgaaccac ccttacatat 7020

ctggaataaa ttctacttgg ttgtggtgta tatttttga tacattcttg gattcttttt 7080

gctaatattt tgttgaaaat gtttgtatct ttgttcatga gagatattgg tctgttgttt 7140

tcttttcttg taatgtcatt ttctagttcc ggtattaagg taatgctggc ctagttgaat 7200

gatttaggaa gtattccctc tgcttctgtc ttctgaggta ccgcggccgc ccgtcgtttt 7260

acaacgtcgt gactgggaaa accctggcgt tacccaactt aatcgccttg cagcacatcc 7320

ccctttcgcc agctggcgta atagcgaaga ggcccgcacc gatcgccctt cccaacagtt 7380

gcgcagcctg aatggcgaat ggcgcctgat gcggtatttt ctccttacgc atctgtgcgg 7440

tatttcacac cgcatacgtc aaagcaacca tagtacgcgc cctgtagcgg cgcattaagc 7500

gcggcgggtg tggtggttac gcgcagcgtg accgctacac ttgccagcgc cctagcgccc 7560

gctcctttcg ctttcttccc ttcctttctc gccacgttcg ccggctttcc ccgtcaagct 7620

ctaaatcggg ggctcccttt agggttccga tttagtgctt tacggcacct cgaccccaaa 7680

aaacttgatt tgggtgatgg ttcacgtagt gggccatcgc cctgatagac ggtttttcgc 7740

cctttgacgt tggagtccac gttctttaat agtggactct tgttccaaac tggaacaaca 7800

ctcaacccta tctcgggcta ttcttttgat ttataaggga ttttgccgat ttcggcctat 7860

tggttaaaaa atgagctgat ttaacaaaaa tttaacgcga attttaacaa aatattaacg 7920

tttacaattt tatggtgcac tctcagtaca atctgctctg atgccgcata gttaagccag 7980

ccccgacacc cgccaacacc cgctgacgcg ccctgacggg cttgtctgct cccggcatcc 8040

gcttacagac aagctgtgac cgtctccggg agctgcatgt gtcagaggtt ttcaccgtca 8100

tcaccgaaac gcgcgagaga cgaaagggcc tcgtgatacg cctatttta taggttaatg 8160

tcatgataat aatggtttct tagacgtcag gtggcacttt tcggggaaat gtgcgcggaa 8220

cccctatttg tttatttttc taaatacatt caaatatgta tccgctcatg agacaataac 8280

cctgataaat gcttcaataa tattgaaaaa ggaagagtat gagtattcaa catttccgtg 8340

tcgcccttat tccctttttt gcggcatttt gccttcctgt ttttgctcac ccagaaacgc 8400

tggtgaaagt aaaagatgct gaagatcagt tgggtgcacg agtgggttac atcgaactgg 8460

atctcaacag cggtaagatc cttgagagtt ttcgccccga agaacgtttt ccaatgatga 8520

gcacttttaa agttctgcta tgtggcgcgg tattatcccg tattgacgcc gggcaagagc 8580

aactcggtcg ccgcatacac tattctcaga atgacttggt tgagtactca ccagtcacag 8640

aaaagcatct tacggatggc atgacagtaa gagaattatg cagtgctgcc ataaccatga 8700

gtgataacac tgcggccaac ttacttctga caacgatcgg aggaccgaag gagctaaccg 8760

ctttttgca caacatgggg gatcatgtaa ctcgccttga tcgttgggaa ccggagctga 8820

atgaagccat accaaacgac gagcgtgaca ccacgatgcc tgtagcaatg gcaacaacgt 8880

tgcgcaaact attaactggc gaactactta ctctagcttc ccggcaacaa ttaatagact 8940

ggatggaggc ggataaagtt gcaggaccac ttctgcgctc ggcccttccg gctggctggt 9000

ttattgctga taaatctgga gccggtgagc gtgggtctcg cggtatcatt gcagcactgg 9060

ggccagatgg taagccctcc cgtatcgtag ttatctacac gacggggagt caggcaacta 9120

tggatgaacg aaatagacag atcgctgaga taggtgcctc actgattaag cattggtaac 9180

tgtcagacca agtttactca tatatacttt agattgattt aaaacttcat ttttaattta 9240

aaaggatcta ggtgaagatc ctttttgata atctcatgac caaaatccct taacgtgagt 9300

tttcgttcca ctgagcgtca gaccccgtag aaaagatcaa aggatcttct tgagatcctt 9360

tttttctgcg cgtaatctgc tgcttgcaaa caaaaaaacc accgctacca gcggtggttt 9420

gtttgccgga tcaagagcta ccaactcttt ttccgaaggt aactggcttc agcagagcgc 9480

agataccaaa tactgttctt ctagtgtagc cgtagttagg ccaccacttc aagaactctg 9540

tagcaccgcc tacatacctc gctctgctaa tcctgttacc agtggctgct gccagtggcg 9600

ataagtcgtg tcttaccggg ttggactcaa gacgatagtt accggataag gcgcagcggt 9660

cgggctgaac gggggggttcg tgcacacagc ccagcttgga gcgaacgacc tacaccgaac 9720

tgagatacct acagcgtgag ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg 9780

acaggtatcc ggtaagcggc agggtcggaa caggagagcg cacgagggag cttccagggg 9840

gaaacgcctg gtatctttat agtcctgtcg ggtttcgcca cctctgactt gagcgtcgat 9900

ttttgtgatg ctcgtcaggg gggcggagcc tatggaaaaa cgccagcaac gcggcctttt 9960

tacggttcct ggccttttgc tggccttttg ctcacatgtt ctttcctgcg ttatcccctg 10020

attctgtgga taaccgtatt accgcctttg agtgagctga taccgctcgc cgcagccgaa 10080

cgaccgagcg cagcgagtca gtgagcgagg aagcggaaga gcccgcgggc aaggtcgcca 10140

cgcacaagat caatattaac aatcagtcat ctctctttag caataaaaag gtgaaaaatt 10200

acattttaaa aatgacacca tagacgatgt atgaaaataa tctacttgga aataaatcta 10260

ggcaaagaag tgcaagactg ttacccagaa aacttacaaa ttgtaaatga gaggttagtg 10320

aagatttaaa tgaatgaaga tctaaataaa cttataaatt gtgagagaaa ttaatgaatg 10380

tctaagttaa tgcagaaacg gagagacata ctatattcat gaactaaaag acttaatatt 10440

gtgaaggtat actttctttt cacataaatt tgtagtcaat atgttcaccc caaaaaagct 10500

gtttgttaac ttgtcaacct catttcaaaa tgtatataga aagcccaaag acaataacaa 10560

aaatattctt gtagaacaaa atgggaaaga atgttccact aaatatcaag atttagagca 10620

aagcatgaga tgtgtgggga tagacagtga ggctgataaa atagagtaga gctcagaaac 10680

agacccattg atatatgtaa gtgacctatg aaaaaaatat ggcattttac aatgggaaaa 10740

tgatgatctt tttctttttt agaaaaacag ggaaatatat ttatatgtaa aaaataaaag 10800

ggaacccata tgtcatacca tacacacaaa aaaattccag tgaattataa gtctaaatgg 10860

agaaggcaaa actttaaatc ttttagaaaa taatatagaa gcatgccatc atgacttcag 10920

tgtagagaaa aatttcttat gactcaaagt cctaaccaca aagaaaagat tgttaattag 10980

attgcatgaa tattaagact tatttttaaa attaaaaaac cattaagaaa agtcaggcca 11040

tagaatgaca gaaaatattt gcaacacccc agtaaagaga attgtaatat gcagattata 11100

aaaagaagtc ttacaaatca gtaaaaaata aaactagaca aaaatttgaa cagatgaaag 11160

agaaactcta aataatcatt acacatgaga aactcaatct cagaaatcag agaactatca 11220

ttgcatatac actaaattag agaaatatta aaaggctaag taacatctgt ggcaatattg 11280

atggtatata accttgatat gatgtgatga gaacagtact ttaccccatg ggcttcctcc 11340

ccaaaccctt accccagtat aaatcatgac aaatatactt taaaaaccat taccctatat 11400

ctaaccagta ctcctcaaaa ctgtcaaggt catcaaaaat aagaaaagtc tgaggaactg 11460

tcaaaactaa gaggaaccca aggagacatg agaattatat gtaatgtggc attctgaatg 11520

agatcccaga acagaaaaag aacagtagct aaaaaactaa tgaaatataa ataaagtttg 11580

aactttagtt ttttttaaaa aagagtagca ttaacacggc aaagtcattt tcatattttt 11640

cttgaacatt aagtacaagt ctataattaa aaatttttta aatgtagtct ggaacattgc 11700

cagaaacaga agtacagcag ctatctgtgc tgtcgcctaa ctatccatag ctgattggtc 11760

taaaatgaga tacatcaacg ctcctccatg ttttttgttt tctttttaaa tgaaaaactt 11820

tatttttaa gaggagtttc aggttcatag caaaattgag aggaaggtac attcaagctg 11880

aggaagtttt cctctattcc tagtttactg agagattgca tcatgaatgg gtgttaaatt 11940

ttgtcaaatg ctttttctgt gtctatcaat atgaccatgt gattttcttc tttaacctgt 12000

tgatgggaca aattacgtta attgattttc aaacgttgaa ccacccttac atatctggaa 12060

taaattctac ttggttgtgg tgtatatttt ttgatacatt cttggattct ttttgctaat 12120

attttgttga aaatgtttgt atctttgttc atgagagata ttggtctgtt gttttctttt 12180

cttgtaatgt cattttctag ttccggtatt aaggtaatgc tggcctagtt gaatgattta 12240

ggaagtattc cctctgcttc tgtcttctga agcggaagag cgcccaatac gcaaaccgcc 12300

tctccccgcg cgttggccga ttcattaatg cagctggcac gacaggtttc ccgactggaa 12360

agcgggcagt gagcgcaacg caattaatgt gagttagctc actcattagg caccccaggc 12420

tttacacttt atgcttccgg ctcgtatgtt gtgtggaatt gtgagcggat aacaatttca 12480

cacaggaaac agctatgaca tgattacgaa ttaa 12514